Come Back to Firefox: Mozilla launches its most ambitious campaign yet to bring people back to the independent alternative to big tech browsers 2026-10-25 · PR Newswire · AI, Internet & apps https://www.prnewswire.com/news-releases/come-back-to-firefox-mozilla-launches-its-most-ambitious-campaign-yet-to-bring-people-back-to-the-independent-alternative-to-big-tech-browsers-302918568.html As tracking and unwanted AI reshape the web, Firefox reunites the internet's original viral icons to make the case for a browser that puts people back in control. SAN FRANCISCO, Oct. 25, 2026 -- In its new campaign, Come Back to Firefox, the independent browser by Mozilla... ———————————————————————————————————————————————————————————— DirectCaseReview.com Launches an Online Platform to Help Car Accident Victims Learn What Their Case May Be Worth 2026-10-25 · EIN Presswire · SaaS, Automotive, Legal, Internet & apps https://www.einpresswire.com/article/951551194/directcasereview-com-launches-an-online-platform-to-help-car-accident-victims-learn-what-their-case-may-be-worth Direct Case Review Matches Clients with Attorneys A free platform connecting people injured in motor vehicle accidents with local personal injury attorneys for a no-cost, no-obligation case review. SCOTTSDALE, AZ, UNITED STATES, October 25, 2026 / EINPresswire.com / -- Today, DirectCaseReview.com announced the launch of its online platform that connects people injured in motor vehicle accidents with experienced local ———————————————————————————————————————————————————————————— Freddy Will Named Content Creator of the Year at the Influencer Magazine Awards 2026 2026-10-25 · EIN Presswire · Media, Marketing & advertising, Internet & apps, Entertainment https://www.einpresswire.com/article/950184948/freddy-will-named-content-creator-of-the-year-at-the-influencer-magazine-awards-2026 Grammy-nominated Sierra Leonean American author, emcee and publisher honoured for two decades of independent storytelling across books, music and continents LONDON, UNITED KINGDOM, October 25, 2026 / EINPresswire.com / -- Wilfred “Freddy Will” Kanu Jr. , the Sierra Leonean American author, emcee and independent publisher, has been named Content Creator of the Year at the Influencer Magazine Awards 2026 (Edition 3). T ———————————————————————————————————————————————————————————— Mobulous Technologies Named AI-Assisted Mobile App Development Company of the Year 2026 2026-10-25 · PR.com · AI, Software & IT, Internet & apps https://www.pr.com/press-release/982640 Mobulous Technologies Pvt. Ltd. has been recognized as the “AI-Assisted Mobile App Development Company of the Year 2026” at the Elite Leadership Awards and Summit 2026 in Goa, India. The recognition is also featured in the October 2026 edition of Insights Success, highlighting Mobulous's expertise in AI-assisted software development, mobile applications, and digital innovation. [PR.com] ———————————————————————————————————————————————————————————— Chris Gibson Announces 1M YouTube Milestone 2026-10-25 · MarketersMEDIA · Internet & apps, Consumer goods https://news.marketersmedia.com/chris-gibson-announces-1m-youtube-milestone/89207261 Chris Gibson Live passes 1 million YouTube subscribers as the licensed esthetician expands skincare and wellness brands. -- Chris Gibson, licensed esthetician, author, and digital skincare educator known to audiences as America’s Holistic Esthetician, has announced that his YouTube channel, Chris Gibson Live , has surpassed 1 million subscribers. The milestone follows a period of rapid audience growth, including more ———————————————————————————————————————————————————————————— Baidu, Inc. Class Action Reminder – Robbins LLP Encourages BIDU Investors to Contact the Firm for Information About Their Rights 2026-10-24 · GlobeNewswire · AI, Legal, Marketing & advertising, Internet & apps https://www.globenewswire.com/news-release/2026/10/24/3387707/32719/en/baidu-inc-class-action-reminder-robbins-llp-encourages-bidu-investors-to-contact-the-firm-for-information-about-their-rights.html Baidu, Inc. (BIDU) faces allegations it overstated the ability of its AI business to mitigate rapid declines in its legacy online marketing business. ———————————————————————————————————————————————————————————— Internet of Things (IOT) Trainer: YALONG Showcases Industrial Mechatronics Simulators at Worldskills 2026-10-24 · EIN Presswire · Energy, Education, Industrial, Software & IT, Internet & apps https://www.einpresswire.com/article/951993244/internet-of-things-iot-trainer-yalong-showcases-industrial-mechatronics-simulators-at-worldskills WENZHOU, ZHEJIANG, CHINA, October 25, 2026 / EINPresswire.com / -- The rapid digital transformation across industrial automation, smart building infrastructure, and commercial energy management has made interconnected edge intelligence an essential pillar of modern technical and vocational education. Developing standardized didactic platforms that faithfully mirror industrial IoT topologies requires deep industrial f ———————————————————————————————————————————————————————————— SocialBlaze Launches API for Connected Social Media Workflows 2026-10-24 · PR.com · SaaS, Marketing & advertising, Internet & apps https://www.pr.com/press-release/982091 New developer access helps businesses connect SocialBlaze with the tools they use to manage their marketing. [PR.com] ———————————————————————————————————————————————————————————— SocialBlaze Launches MCP Connection for AI Social Media Workflows 2026-10-24 · PR.com · AI, Media, Internet & apps https://www.pr.com/press-release/982092 Compatible AI applications can connect with SocialBlaze, bringing content preparation and supported social media actions closer together. [PR.com] ———————————————————————————————————————————————————————————— New to The Street Announces "The Backbone," a Monthly Series on the Companies Powering the Digital Economy 2026-10-24 · ACCESS Newswire · Cloud & data centers, Internet & apps, Consumer electronics https://finance.yahoo.com/media-advertising/articles/street-announces-backbone-monthly-series-150000086.html Each featured company receives a three-part series with an on-site visit, Bloomberg Television coverage across four continents, social media and Times Square billboard exposure. Premieres January 2027. NEW YORK CITY, NY / October 24, 2026 / New to The Street today announced "The Backbone," a monthly series featuring the companies that build, power, cool and connect America's data centers. The series ———————————————————————————————————————————————————————————— CNS Issues Report To Promote International Ceramic Expo Held in China's Porcelain Capital Jingdezhen 2026-10-24 · ACCESS Newswire · Internet & apps https://finance.yahoo.com/technology/articles/cns-issues-report-promote-international-145000703.html JINGDEZHEN, CHINA / October 24, 2026 / China News Service (CNS) issued a media report on Friday to promote the 2026 China Jingdezhen International Ceramic Expo held recently in the porcelain-making city of central China's Jiangxi Province. 2026 Jingdezhen Forum. Photo: Dai Yue youtube.com/watch?v=9bPv2ErGJ0w Over more than 1,000 years of porcelain-making, Jingdezhen has become virtually synonymous w ———————————————————————————————————————————————————————————— Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026 2026-10-24 · Business Wire · Finance, AI, Telecom, Semiconductors, Cloud & data centers, Internet & apps https://finance.yahoo.com/technology/articles/semtech-brings-5g-network-slicing-120000374.html AirLink 5G Solutions Keep First Responders Connected During Peak Network Demand CAMARILLO, Calif., October 24, 2026--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things ("IoT") devices ———————————————————————————————————————————————————————————— Ghana: Joyce Bawah Mogtari urges unity as NDC holds constituency elections 2026-10-24 · Africa Publicity · Government & policy, Internet & apps https://africapublicity.com/ghana-joyce-bawah-mogtari-urges-unity-as-ndc-holds-constituency-elections/ Senior Ghanaian Presidential Advisor and Senior Aide to President John Dramani Mahama, Joyce Bawah Mogtari, has urged members of the National Democratic Congress (NDC) to prioritise unity and solidarity as the party holds its constituency elections today, Saturday, October 24. In a Facebook post on Saturday, she extended her best wishes to aspirants, delegates […] ———————————————————————————————————————————————————————————— Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence 2026-10-24 · Bayer · Finance, Healthcare, Education, Biotech & pharma, Government & policy, Internet & apps, Chemicals & materials https://www.bayer.com/media/en-us/darolutamide-plus-adt-and-radiation-therapy-reduces-risk-of-metastasis-or-death-by-58-in-prostate-cancer-patients-at-high-risk-of-recurrence/ Berlin, October 24, 2026 – New late-breaking data to be presented today at the European Society for Medical Oncology (ESMO) Congress 2026 will show that adding Bayer’s androgen receptor inhibitor (ARi), darolutamide, to standard-of-care androgen deprivation therapy (ADT) and locoregional radiation therapy (RT), significantly improves metastasis-free survival based on conventional imaging (MFS-CI) in prostate cancer patients with high risk of recurrence compared to placebo. Darolutamide is currently not approved for this treatment setting. These data will be presented at Presidential Symposium I at the ESMO Congress 2026 (LBA4, Saturday 24 October, 16:30 CET). At a median follow-up of 3.8 years, the interim analysis demonstrated a 58% reduction in the risk of metastasis or death with darolutamide plus ADT and RT compared with placebo plus ADT and RT (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001). The 4-year metastasis-free survival rate was 95% for patients receiving darolutamide compared with 88% for those receiving placebo. “Prostate cancer patients at a high risk of relapse face a considerable risk of recurrence and metastatic spread, making early, highly effective intervention vital,” said Dr. Tamim Niazi, Associate Professor of Oncology at McGill University, Radiation Oncologist at the Jewish General Hospital in Montreal, Canada. and Co-Lead Investigator of the study. “The clear improvement in metastasis-free survival seen in interim results from the DASL-HiCaP trial highlights the potential of adding darolutamide to standard androgen deprivation therapy and radiation therapy to help prevent or delay disease progression in patients who are at high risk of progression despite receiving primary curative therapy.” Secondary endpoints also showed consistent positive trends with darolutamide, with a 53% reduction in the risk of prostate-specific antigen progression free survival (PSA-PFS; HR 0.47; 95% CI: 0.33–0.67), and a 4-year PSA-PFS rate of 91% versus 83% with placebo. Prostate cancer-specific survival (PCSS) and overall survival (OS) hazard ratios were 0.58 (95% CI: 0.17–1.97; 99% vs 99% at 4 years) and 0.88 (95% CI: 0.49–1.59; 97% vs 95% at 4 years), respectively, with follow-up ongoing. The safety profile of darolutamide was consistent with its known tolerability, with adverse events being similar to the placebo group. Proportions of patients experiencing Grade ≥2 adverse events of special interest for darolutamide versus placebo were: fatigue/asthenia (14% vs 10%), hypertension (7% vs 9%), fractures (2% vs 3%), and cardiac events (3% vs 3%). Any Grade ≥3 adverse event occurred in 43% of patients in the darolutamide group versus 36% in the placebo group. "These new data highlight the potential of darolutamide to make a meaningful difference for patients earlier in the course of their prostate cancer,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization at Bayer’s Pharmaceuticals Division. “By advancing darolutamide into earlier disease settings, we aim to reach more patients across the prostate cancer care continuum. We are proud to support ANZUP, the Sydney Clinical Trials Centre, CCTG and international partners in research as we work together with the potential to improve outcomes for men living with prostate cancer.” Follow-up of participants is continuing to provide further information on longer-term outcomes, including overall survival. About the DASL-HiCaP trial (ANZUP1801)  The DASL-HiCaP trial is an investigator-initiated, randomized, placebo-controlled, Phase III trial (NCT04136353) evaluating darolutamide added to standard-of-care ADT and locoregional radiation therapy in prostate cancer patients at high risk of recurrence. DASL-HiCaP was conducted in collaboration with the University of Sydney and ANZUP Clinical Trials Group and is the fourth Phase III trial for darolutamide. Following ARAMIS, ARASENS, and ARANOTE, which demonstrated darolutamide’s efficacy and safety in advanced prostate cancer, DASL-HiCaP represents the first Phase III study of darolutamide in early prostate cancer. A total of 1,106 participants across Australia, New Zealand, Canada, the United States, Ireland and the United Kingdom were randomized 1:1 to receive darolutamide (600 mg twice daily) or matching placebo for 96 weeks, combined with an LHRH analog for 96 weeks and RT to the prostate/prostate bed and pelvic lymph nodes. The primary endpoint was metastasis-free survival based on conventional imaging (MFS-CI). Secondary endpoints included prostate-specific antigen progression free survival (PSA-PFS), prostate cancer-specific survival (PCSS), and overall survival (OS). The protocol specified an interim analysis after 87 MFS-CI events; follow-up is ongoing to evaluate long-term overall survival. About the Sydney Clinical Trials Centre The Sydney Clinical Trials Centre is a flagship research centre of the Faculty of Medicine and Health at the University of Sydney that designs and manages clinical trials. This includes responsibility for study coordination, monitoring, data acquisition and management and statistical analysis. The Sydney Clinical Trials Centre has health economics, biostatistics, systematic reviews and biomarker teams that work with trial data and inform healthcare providers about best practice. For further details, please visit its website at https://www.ctc.usyd.edu.au About ANZUP Clinical Trials Group  ANZUP (https://www.anzup.org.au) is the leading cancer-cooperative trials group bringing together all of the professional disciplines and groups involved in researching and treating urogenital cancers to conduct high-quality cancer research. ANZUP’s mission is to improve the lives of people affected by bladder, kidney, testicular, penile, and prostate cancers, towards our vision of living life without fear of cancer. ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the best clinicians and researchers in genitourinary cancer and communicates frequently and effectively with the broader community along the way. ANZUP receives valuable infrastructure support from the Australian Government through Cancer Australia and research funding from Prostate Cancer Foundation of Australia. About Prostate Cancer Prostate cancer is the second most common cancer and the fourth most common cause of cancer death in men worldwide. Over 1.5 million men are diagnosed with prostate cancer each year and almost 420,000 die from the disease worldwide. By 2040, prostate cancer diagnoses are projected to increase to 2.9 million. Standard therapy for prostate cancer patients at high risk of recurrence combines radiation therapy with androgen deprivation therapy (ADT). However, despite this approach, a significant proportion of patients experience treatment failure, local recurrence, or distant metastases. Intensifying therapy early with an advanced androgen receptor inhibitor aims to improve long-term disease control and delay metastatic progression. About darolutamide (Nubeqa™) Darolutamide is an oral ARi with a distinct chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans support darolutamide's low potential for blood-brain barrier penetration and low potential for clinically relevant drug-drug interactions. Darolutamide, under the brand name Nubeqa™ plus androgen deprivation therapy (ADT), is already approved in more than 85 markets around the world, including the US, EU and China. It is approved for the treatment of adult patients with mHSPC without docetaxel in 75 markets and with docetaxel in more than 85 countries, and for adult patients with nmCRPC at high risk of developing metastatic disease in more than 85 countries. Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. Darolutamide demonstrated efficacy and tolerability in pivotal Phase 3 studies, supporting its indications in nmCRPC and mHSPC with and without chemotherapy, with a favorable safety profile that offers an advancement in treatment management for physicians and patients. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. Current ongoing trials include the Phase III ARASTEP trial evaluating the efficacy of darolutamide plus ADT compared to ADT alone in hormone-sensitive prostate cancer (HSPC), in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. About Prostate Cancer at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. Prostate cancer is the second most commonly diagnosed cancer in men and a key area of focus for Bayer. The company’s franchise includes two products on the market (Nubeqa™ and Xofigo™) and several compounds in development. Bayer is focused on addressing the unique needs of patients with prostate cancer, providing treatments that extend their lives throughout the different stages of the disease and allowing them to continue with their everyday activities, so that patients can live longer, better lives. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at www.bayer.com/en/portfolio/pharmaceuticals Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— France's Debt Crisis Sparks Nationwide Protests Amid Eurozone Instability 2026-10-24 · Newsworthy.ai · Finance, AI, SaaS, Automotive, Media, Investing & markets, Government & policy, Marketing & advertising, Internet & apps https://newsworthy.ai/news/202610243070/frances-debt-crisis-sparks-nationwide-protests-amid-eurozone-instability Fredericksburg, TX Friday Oct 23, 2026 @ 10:25 PM Central — Episode 1913 of the No Agenda Show, titled 'Meat Muck' and published October 18, 2026, finds host Adam Curry broadcasting from the Texas Hill Country alongside guest co-host Rob Dew, dubbed Sir Deucifer. Recorded the morning after the fifth annual Fredericksburg meetup, the episode tackles a packed slate of global unrest and domestic strangeness, from burning French city halls to Elon Musk's hopping Roadster. With John C. Dvorak's absence still shaping the program, Curry and Dew deliver the trademark media deconstruction that has defined the show for 19 years. The two-hosts spend the opening segment on the escalating protests across France, where interior minister Laurent Nunez reported crowds swelling to 800,000 and Marine Le Pen's poll numbers continue climbing against a backdrop of debt projected near 120% of GDP. Threads explored include: How protesters are coordinating via Bluetooth mesh apps like BitChat after internet shutdowns AfD leader Alice Weidel's call to end German financing of 'an already lost war' in Ukraine Queen Ursula von der Leyen's new 70 billion euro Ukraine funding gap for 2027 The Nord Stream sabotage trial of Ukrainian suspect Sergei Kuznetsov in Hamburg Curry questions why the International Criminal Court has stayed silent on the Nord Stream prosecution, while Dew notes the political convenience of keeping the accused agent from speaking. The hosts replay a Christopher Hitchens clip framing the broader civilizational stakes: They are not just joking. They really mean to abolish everything you care about, and they want to take away everything you love and to destroy everything you have and to replace it with a Stone Age ideology derived from the desert of Palestine in a very bad time in human history. The segment pivots to a Tom Luongo thesis that European elites are deliberately bankrupting the bloc to roll out the digital euro. Elsewhere, the episode unpacks an AI-driven study flagging roughly 261,000 potentially fabricated cancer research papers, with 36% traced to Chinese institutions and 20% to Iran. Dew brings a deep dive on Turin, Italy, its black magic triangle, ley lines to London and San Francisco, and the 1879 Lucifer statue atop the Frejus tunnel monument. Curry breaks down CoreWeave's 2032 bonds trading at distressed 15% yields, warning the AI buildout could trigger a broader bond market crack. Other threads: Tesla's thruster-equipped Roadster demo, Press Secretary Katie Zachariah's five-day White House tenure, Jalen Hurts' blood clot diagnosis, and viral video evidence that Arby's roast beef now arrives as a bagged paste. About No Agenda Show No Agenda is a long-running, listener-supported podcast hosted by Adam Curry and John C. Dvorak that takes a skeptical, independent look at mainstream media, politics, culture, and the forces shaping the daily news cycle. Known for its sharp commentary, humor, and media deconstruction approach, the show offers an irreverent alternative to conventional news analysis. Episode 1913 is available now wherever podcasts are heard. ———————————————————————————————————————————————————————————— 5 Best Free Competitor Instagram Ad Spy Tools in 2026 Ranked In New Report 2026-10-24 · MarketersMEDIA · Marketing & advertising, Internet & apps https://news.marketersmedia.com/5-best-free-competitor-instagram-ad-spy-tools-in-2026-ranked-in-new-report/89207226 A new report compares five tools for researching Instagram advertising, assessing their free access options, competitor research capabilities and creative features to help marketers choose tools suited to their budgets and campaign workflows. -- A new report examining the best free Instagram ad spy tools in 2026 compares five platforms that help marketers research competitor campaigns, identify creative trends and in ———————————————————————————————————————————————————————————— ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Baidu, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIDU 2026-10-24 · GlobeNewswire · Finance, Legal, Internet & apps https://www.globenewswire.com/news-release/2026/10/24/3387651/673/en/rosen-top-ranked-investor-counsel-encourages-baidu-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-bidu.html NEW YORK, Oct. 23, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baidu, Inc. (NASDAQ: BIDU) between November 18, 2025 and August 17, 2026, inclusive (the “Class Period”), of the important November 13, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Local Directory Listings vs Social Media: Small Business Credibility Compared 2026-10-23 · MarketersMEDIA · Marketing & advertising, Internet & apps https://news.marketersmedia.com/local-directory-listings-vs-social-media-small-business-credibility-compared/89207215 Small business owners often favor social media, but local directories add geographic and category context social profiles alone can't provide. Huntersville Hub illustrates how directory listings and social media serve complementary roles in building local business credibility. -- Small business owners weighing where to invest limited marketing time often default to social media, but local directory listings serve a d ———————————————————————————————————————————————————————————— ZenaTech Unveils its Proprietary AI Software Suite Designed to Accelerate Land Survey Delivery for Drone as a Service Commercial, Municipal and Infrastructure Clients 2026-10-23 · ACN Newswire · Finance, AI, SaaS, Education, Industrial, Aerospace & defense, Logistics, Legal, Government & policy, Software & IT, Internet & apps, Construction & engineering, Agriculture https://www.acnnewswire.com/press-release/english/111043/ Vancouver, BC, Oct 24, 2026 - ZenaTech, Inc. (Nasdaq: ZENA)(FSE: 49Q)(BMV: ZENA)("ZenaTech" or the "Company"), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today unveiled its proprietary artificial intelligence software suite and planned integration across its DaaS land survey operations. By pairing ZenaDrone high-density LiDAR (Light Detection and Ranging) data acquisition with automated feature extraction and point cloud classification, ZenaTech plans to accelerate survey-grade data delivery time from days to as little as minutes across commercial land surveying, municipal and infrastructure projects for DaaS clients across North America and around the world. The combined platform is currently in the development and testing stage. ZenaTech, Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/zenatech-1   “Land survey delivery has traditionally been limited by manual post-processing, which caps how many projects a survey team can complete,” said Shaun Passley, Ph.D., CEO of ZenaTech. “By integrating our AI software directly into ZenaDrone DaaS operations, we aimto automate the heavily manual work of point cloud classification and CAD linework generation, so the same crews and drones can deliver turn-key, actionable intelligence to clients faster and with consistent quality. As we apply our AI suite across our AI tools growing network of DaaS subsidiaries, we believe it can improve operating efficiency and support the scalable, recurring revenue model at the center of our DaaS strategy.” The combined platform is designed to bridge hardware data collection with AI-driven point cloud processing. A ZenaDrone land survey drone equipped with high-density LiDAR captures a site as a point cloud, a dataset that can contain billions of individual 3D measurement points. ZenaAI is then intended to run automated geospatial workflows on that data, classifying each point by what it represents, converting the classified data into terrain models and vector drawings, removing noise, tagging infrastructure assets and exporting the results in formats that survey and engineering teams can use directly. Its key planned capabilities include: Automated Point Cloud Classification: Designed to use deep learning neural networks to rapidly parse billions of 3D LiDAR points, separating ground returns from dense canopy, buildings, utility lines and surface vegetation to generate true Digital Terrain Models (DTM) Automated Feature Extraction and Linework: Computer vision algorithms are intended to detect and vectorize critical planimetric features, including curb lines, pavement edges, retaining walls and structures, and export them directly into CAD and BIM (Building Information Modeling) formats Rapid DaaS Turnaround: By replacing manual point-picking and heuristic scripting, the AI software suite is being designed to reduce post-processing workflows by as much as 80% and shorten survey turnaround time, allowing DaaS survey teams to deliver fully classified datasets within hours of flight completion Smart Noise Filtering and Asset Tagging: Automated artifact suppression is intended to clean airborne noise, multipath errors and scan overlap, while semantic tagging logs discrete infrastructure assets, such as manholes, hydrants and utility poles, with millimeter-level precision Point cloud classification and linework have traditionally required skilled technicians to work through by hand, which can take days and limits how many projects a survey team can complete. ZenaTech believes that automating these steps could raise surveying productivity, allowing the same drones and crews to deliver more projects faster and potentially improving margins over time. As proprietary software, the AI suite is also intended to add a scalable SaaS layer to the Company’s acquisition-led DaaS strategy, applying a consistent processing workflow across the surveying businesses it acquires and supporting its recurring revenue model for commercial, municipal and infrastructure clients that rely on timely data for planning, design and construction.   The AI-powered LiDAR processing is currently in development with testing across DaaS land surveying, infrastructure monitoring and utility inspection projects expected next year. The Company will provide updates on launch and rollout as milestones are achieved. ZenaTech’s Drone as a Service (DaaS) division provides on-demand turnkey drone piloting, data capture, and data processing services to commercial, government, and infrastructure customers, allowing them to access aerial data and automation without owning or operating their own drone fleets. The division is being built through an acquisition-led strategy that combines local low-tech service providers into a global network, creating a scalable platform for delivering recurring-revenue aerial and data services such as surveying, inspections, power washing, and construction progress monitoring. About ZenaTech ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company which specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives. Visit zenatech.com. About ZenaDrone ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system. Contacts Company, Investors and Media:  Linda Montgomery, ZenaTech, 312-241-1415 Investors:  Michael Mason, CORE IR, investors@zenatech.com Safe Harbor This press release and related comments by management of ZenaTech, Inc. include "forward-looking statements" within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management's expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities, including statements about the development, features, availability, pricing, commercialization and market adoption of ZenaAI. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; ZenaTech’s ability to deliver products to the market as currently contemplated, including software platforms such as ZenaAI; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; risks related to the development, testing, accuracy and performance of artificial intelligence and machine learning models; regulatory risks, including regulations governing drone operations; product development, validation and data quality and accuracy risks; customer adoption and recurring revenue opportunities; the competitive conditions of the industry; the ability to complete any contemplated acquisitions; market uncertainty; and applicable laws, regulations, and any amendments affecting the business of ZenaTech. Readers should not place undue reliance on forward-looking statements, which speak only as of the date of this release, and ZenaTech undertakes no obligation to update them except as required by law. Additional Contact: David Shapiro, B2i Digital, Inc., +1 212-579-4844, david@b2idigital.com B2i Digital Social Media: LinkedIn X Facebook Instagram YouTube TikTok Stocktwits Reddit Pinterest Threads To learn more about the B2i Digital Media Network, visit https://b2idigital.com/media-network. ———————————————————————————————————————————————————————————— What Should Baidu, Inc. Investors Know After 12.73% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline 2026-10-23 · PR Newswire · Finance, Legal, Internet & apps https://www.prnewswire.com/news-releases/what-should-baidu-inc-investors-know-after-12-73-stock-drop-the-law-offices-of-frank-r-cruz-outlines-securities-fraud-class-action-lead-plaintiff-deadline-302917665.html Lawsuit alleges Baidu, Inc. made misleading statements to investors from November 18, 2025 to August 17, 2026; lead plaintiff motions are due November 13, 2026 LOS ANGELES, Oct. 23, 2026 -- The Law Offices of Frank R. Cruz today announced a class action lawsuit against Baidu,... ———————————————————————————————————————————————————————————— Staffing firm Medical Virtual Assistants (medicalvirtualassistants.com) launches online hiring platform MedicalVirtual 2026-10-23 · EIN Presswire · SaaS, Healthcare, Jobs & workplace, Internet & apps https://www.einpresswire.com/article/951829027/staffing-firm-medical-virtual-assistants-medicalvirtualassistants-com-launches-online-hiring-platform-medicalvirtual MedicalVirtual Homepage Medical Virtual Assistants matches US practices and providers with experienced healthcare support from Latin America, working your US clinic hours. LOS ANGELES, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- • Medical Virtual Assistants matches US practices and providers with experienced healthcare support from Latin America, working your US clinic hours. • The new online platform ———————————————————————————————————————————————————————————— Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) 2026-10-23 · Roche · Healthcare, Biotech & pharma, Nonprofits, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-23 Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups1 As the first antisense oligonucleotide (ASO) evaluated in IgAN, sefaxersen inhibits complement factor B production and has the potential to slow IgAN disease progression by reducing kidney inflammation2 Investigational sefaxersen is intended to be a once-monthly subcutaneous injection and designed to enable convenient self-administration at home3 Despite recent advances, many people with IgAN remain at risk of disease progression and kidney failure, highlighting the need for additional targeted treatment options for those who do not respond to initial therapy4,5 Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR).1 Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function.6,7 Results presented at the American Society of Nephrology (ASN) Kidney Week 2026 also showed that, among patients with baseline haematuria (blood in urine), a greater proportion of patients achieved haematuria resolution at Week 37 with sefaxersen versus placebo.1 “These phase III results demonstrate the potential for sefaxersen to meaningfully reduce protein in the urine, a key indicator of kidney damage, in people with IgA nephropathy,” said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. “By inhibiting complement factor B in the liver, sefaxersen may offer a novel approach to slow disease progression in IgAN, potentially helping patients delay or avoid long-term dialysis or kidney transplantation.” The treatment effect in all prespecified subgroups was consistent with the clinically meaningful reductions in proteinuria shown in the primary endpoint results.1 Sefaxersen was well tolerated with a safety profile consistent with the previously reported phase II study, exhibiting no new safety signals.1,2 Sefaxersen is an investigational once-monthly subcutaneous injection designed to enable convenient self-administration for people with IgAN.3 The IMAgINATION study will continue as a blinded study to evaluate the change in kidney function over two years, as measured by estimated glomerular filtration rate (eGFR) at week 105. Data will be shared with health authorities, with the goal of bringing this treatment to patients as soon as possible. Typically diagnosed before the age of 40, IgAN affects at least 25 adults per million worldwide each year.8,9 IgAN, also known as Berger’s disease, is a chronic and progressive autoimmune disease that leads to end-stage kidney disease in up to 50% of patients within 20 years of diagnosis.5,10 It is the most common form of primary glomerulonephritis (inflammation of the tiny filters, glomeruli, in the kidneys) and is a major cause of chronic kidney disease as well as kidney failure.8 About sefaxersen Investigational sefaxersen is the first highly specific liver-directed antisense oligonucleotide (ASO) inhibitor of factor B production being evaluated in IgA nephropathy (IgAN).2 Serum complement factor B levels are elevated in people with IgAN. When we reduce these levels, it in turn reduces the level of protein in urine, which is a key indicator of improved kidney function.11,12 Sefaxersen is designed to provide sustained control of the alternative complement pathway, an important pathway in IgAN, enabling once-monthly subcutaneous dosing and is intended for self-administration in people with IgAN.3 In phase I and II trials, sefaxersen was shown to be generally well tolerated in healthy volunteers and people with IgAN who were at high risk of progression, and reduced proteinuria and plasma complement factor B.2,13 Roche licensed sefaxersen from Ionis Pharmaceuticals for the treatment of complement mediated diseases. About the IMAgINATION study IMAgINATION [NCT05797610] is a phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous sefaxersen, an investigational antisense inhibitor of complement factor B, in patients with primary IgA nephropathy at high risk of progression.1,14 The study enrolled 459 people, who are randomised 1:1 to receive sefaxersen or placebo for 105 weeks.1,14 Participants may switch to open-label treatment after week 105 at the investigator's discretion or after the common-close timepoint, whichever occurs first.1,14 The primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio at 37 weeks.1,14 About primary immunoglobulin A nephropathy (IgAN) IgAN, also known as Berger’s disease, is a serious, chronic and progressive autoimmune kidney disease affecting at least 25 adults per million worldwide each year and is typically diagnosed before the age of 40 years.8-10 In IgAN, immune complexes deposit in the kidneys, which activates the complement system’s alternative pathway, leading to inflammation and subsequent kidney damage.15 It is the most common form of primary glomerulonephritis (inflammation of kidney glomeruli) and remains a leading cause of kidney failure, with up to 50% of patients experiencing end-stage kidney disease within 20 years of diagnosis.5,8 Many current therapies aim to reduce protein levels in the urine and control blood pressure to slow progression of the disease.16 Updated KDIGO 2025 guidelines* highlight the need to address both the underlying immune-mediated causes of IgAN and the downstream consequences of kidney damage.4 While new therapies have expanded treatment options, important unmet needs remain, including improved long-term preservation of kidney function and more targeted approaches that address key drivers of disease progression.4,16 About Roche in Immunology For over two decades, Roche has advanced immune system research, creating groundbreaking targeted treatments that have transformed care for people with blood disorders, neurological conditions and autoimmune diseases. With a development pipeline exploring more than 20 medical approaches, we are targeting widespread, complex conditions like chronic lung disease (COPD) and inflammatory bowel disease (IBD), alongside lupus and autoimmune kidney diseases. Our ultimate goal is to lessen the burden of chronic immune disorders on patients, healthcare systems, and society. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. *KDIGO guidelines serve as the foundational framework for healthcare organisations, policymakers, and clinicians worldwide to standardise kidney disease diagnosis, staging, and treatment. References [1] Barratt J., et al. Sefaxersen, a Novel mRNA-Targeted Therapy for IgA Nephropathy: Interim Analysis of the Phase 3 IMAgINATION Trial. Presented at: ASN Kidney Week; 2026 Oct 20-26; Denver, CO, USA. Abstract #FR-OR104. [2] Barbour SJ, et al. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2026;109:592-601. [3] Barratt J, et al. IMAGINATION: a global phase 3 trial of RO7434656, an antisense oligonucleotide inhibitor of complement factor B, in IgA nephropathy. Kidney Int Rep. 2024;9 Suppl. WCN24-912. [4] Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1–S71. [5] Caster DJ, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;8:1792-1800. [6] Longhitano E, et al. Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach. Medicina (Kaunas). 2024 Nov 6;60(11):1821. [7] Qin X, et al. Association Between Urinary Protein-to-Creatinine Ratio and Chronic Kidney Disease Progression: A Secondary Analysis of a Prospective Cohort Study. Front. Med. 2022; 9:854300. [8] Pitcher D, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18:727-738. [9] McGrogan A, Franssen CF and de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430. [10] Cleveland Clinic. IgA Nephropathy [Internet; cited 2026 October 15]. Available from: https://my.clevelandclinic.org/health/diseases/5990-iga-nephropathy. [11] Chiu YL, et al. Alternative complement pathway is activated and associated with galactose-deficient IgA. Front Immunol 2021; 12: 638309. [12] Marques F, et al. Impact of early proteinuria reduction in glomerular disease and decline of kidney function: a retrospective cohort. J Clin Med. 2022;11(19):5968. [13] McCaleb ML, et al. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 2025 Mar;230(2):152876. [14] ClinicalTrials.gov. A Study to Evaluate RO7434656 in Participants With Immunoglobulin A Nephropathy (IgAN) (IMAGINATION) (NCT05797610) [Internet; cited 2026 Oct 15]. Available from: https://clinicaltrials.gov/study/NCT05797610. [15] Wu MY, et al. The emerging role of pathogenesis of IgA nephropathy. J Clin Med. 2018;7:225. [16] Floege J, et al. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43:717-728. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media Investor Release Sefaxersen IMAgINATION ASN ———————————————————————————————————————————————————————————— Global Business Series 2026-10-23 · Pressat · AI, SaaS, Retail, Education, Marketing & advertising, Internet & apps, Entertainment https://pressat.co.uk/releases/global-business-series-58b22063a050f0755a542c38b65dbba6/ Friday 23 October, 2026 The Global Business Series is a collaboration between leading academics at Tsinghua University, China (12th in World University Rankings 2026) and the London School of Economics. In the series. Six distinguished academics tackle four different aspects of doing business internationally – from family businesses to digital platforms to law and marketing. Critical Decisions The authors examine critical issues around succession, continuity and inheritance – issues which every family business will eventually face. Through detailed research the authors provide original insights and lessons. Anyone playing a key role in a family-owned business will benefit from reading this insightful book. The authors: “The reason why the development of family businesses is bumpy and the succession issues are complicated and difficult is that family businesses… involve not only the logic of business and economic operations, but also multiple social and cultural relationships.” Platform Governance In a world where our existence is largely platform-based – from shopping on Amazon to socializing on Facebook – understanding the mechanisms governing these digital habitats is paramount. This authoritative guide takes you from the origins of these platforms to the strategic shift required to move from a traditional product strategy to a winning platform strategy.  It offers vital insights and guidance for understanding and succeeding in today’s digital economy, helping readers navigate the complexities of an increasingly platform-based economy. Think Big Using legal thinking, Han Liu looks at how to analyse situations, balance competing interests and make good decisions – both in business and more broadly in life and everyday situations. This book will empower readers to think critically and strategically. It will help shift mindsets from simply following rules to understanding the deep, strategic logic behind them. It's a journey that will sharpen minds, helping to make better, more informed choices. “If you’re worried about legal jargon, don’t be. This book explains legal thinking in everyday language.” – Han Liu, from the foreword Wellbeing Marketing Examines transformative philosophy to benefit customers and employees. When maximising profit has often become a demon justifying deceptive tactics, exploited workers and unhappy customers, Wellbeing Marketing emerges as a new way of thinking. Through fascinating case studies of global giants like Disneyland and Walmart, alongside unique enterprises like Nakagawa Masashichi Heirloom Store, Fei Li demonstrates that profit and happiness are not mutually exclusive; rather, when an organization aligns its mission with the pursuit of wellbeing, it achieves a sustainable "unity of knowledge and action" that benefits society. About the series authors: Dr Hao Gao is Director of the Research Centre for Global Family Business at Tsinghua University, China. Dr Victor Zheng is Director of the Centre for Social and Political Development Studies at the Chinese University of Hong Kong (CUHK). Yong Wong and Ke Rong, experts in business ecosystems and the digital economy, are Professors and Directors at the Institute of Economics, School of Social Sciences at Tsinghua University (China). Han Liu is an assistant professor and the Vice-Dean of Tsinghua University Law School. He received his master’s degree from Yale University. He is based in China. Fei Li is a prominent professor of marketing at the School of Economics and Management at Tsinghua University. He is based in Beijing. Series editor: Dr Catherine Hua Xiang is an award-winning business author and applied linguist. She launched the International Research Hub on Intercultural Communication, Business & AI at the LSE, where she is also Head of East Asian Languages and Programme Director of the BSc International Relations and Chinese course. ENDS Notes to editors: For all media enquiries contact Simon Wooldridge on: M +44 (0)7879 148420; E: simon.wooldridge@lidbusinessmedia.com LID Publishing is an award-winning business book publishing house. To find out more visit: https://lidpublishing.com/ ———————————————————————————————————————————————————————————— More Than 20,000 Parents Nationwide Call For Consistent Youth Safeguards Online 2026-10-23 · PR Newswire · Internet & apps https://www.prnewswire.com/news-releases/more-than-20-000-parents-nationwide-call-for-consistent-youth-safeguards-online-302918329.html Parents in All 50 States Call for All Social Media Platforms To Adopt Safeguards Implemented as a Result of Agreement Between the States and Meta WASHINGTON, Oct. 23, 2026 -- The Coalition to Empower our Future (CEF), a growing partnership focused on understanding the... ———————————————————————————————————————————————————————————— SAPPE Showcases Product Innovations at SIAL Paris 2026 2026-10-23 · NewMediaWire · Finance, Healthcare, Retail, Food & drink, Sustainability, Investing & markets, Internet & apps https://www.newmediawire.com/news/sappe-showcases-product-innovations-at-sial-paris-2026-7090834 Mogu Mogu Leads a Diverse New Product Lineup on the Global Stage BANGKOK - October 23, 2026 - Sappe Public Company Limited (SAPPE PCL.) is showcasing its innovative product portfolio at SIAL Paris 2026, a global food and beverage trade exhibition held from 17-21 October 2026 at Paris Nord Villepinte Exhibition Centre in Paris, France. The company is presenting new products and flavours that combine fun and creativity while welcoming trade partners, importers and distributors from around the world to exchange ideas and explore business opportunities. Leading SAPPE’s showcase is its flagship brand, Mogu Mogu, with a wide range of new offerings, including Zero Sugar drinks, Jelly, Gummy, Candy and Iced Tea, alongside new flavours in its original drink range. The lineup extends the brand’s signature fun and creativity across diverse product formats, giving trade partners and visitors the opportunity to discover and taste the products firsthand. SAPPE is also presenting products from Sappe Aloe Vera, Sappe Beauti and All Coco, adding variety to its booth and offering new choices for international markets. Trade partners, importers, distributors and other interested visitors can meet the team to discuss the products and explore opportunities for international business development. SIAL Paris is one of the world’s largest food and beverage trade exhibitions, taking place every two years. For its 2026 edition, organisers expect 8,000 exhibitors and approximately 400,000 products across 10 industry sectors, covering 280,000 square metres of exhibition space. Bringing together manufacturers, buyers and distributors from around the world, the event provides SAPPE with another opportunity to showcase the capabilities of Thai brands and its diverse portfolio of innovative products to international trade partners. Visitors can discover and sample SAPPE’s products at Booth 5C F035, Hall 5C, throughout SIAL Paris 2026, from 17-21 October 2026. About SAPPE Sappe PCL (SAPPE) is a leading Thai beverage innovator and the creator of the "Snack Drink" category through its iconic global brand, Mogu Mogu, now exported to over 100 countries across Asia, Europe, the Middle East, and beyond. The company specializes in fruit juice and functional health beverages designed to serve the evolving lifestyle needs of modern consumers around the world. SAPPE's diverse portfolio includes globally recognized brands such as Mogu Mogu, the world's first snackable drink; Sappe Aloe Vera, known for its refreshing taste and natural ingredients; and Sappe Beauti, a functional drink line focused on health, wellness, and women empowerment. Headquartered in Bangkok, Thailand, SAPPE is listed on the Stock Exchange of Thailand (SET) under the symbol SAPPE. Driven by innovation, deep consumer insights, and a strong commitment to sustainability, SAPPE operates with a balanced focus on product innovation, economic performance, social responsibility, and environmental impact. The company believes that building a sustainable future begins with valuing people, embracing diversity, and leading with authenticity, creativity, and the courage to drive positive change. SAPPE's mission is to inspire lives worldwide one meaningful beverage at a time. Sappe official: https://www.sappe.com/en/ Facebook: https://www.facebook.com/sappeplayground Instagram: https://www.instagram.com/mogumogu_global/ Line: https://shop.line.me/@sappeonline Shopee: https://shopee.co.th/sappe.official Email: corpcom@sappe.com Sappe PCL [SET: SAPPE, SAPPE/F, SAPPE-R] https://www.sappe.com/en/ ———————————————————————————————————————————————————————————— 3,814-Acre Kronkosky Natural Area Targets Late Fall 2026 Opening Between Boerne and Bandera 2026-10-23 · Newsworthy.ai · AI, SaaS, Government & policy, Nonprofits, Marketing & advertising, Internet & apps, Construction & engineering https://newsworthy.ai/news/202610233078/3814-acre-kronkosky-natural-area-targets-late-fall-2026-opening-between-boerne-and-bandera Pipe Creek, TX Friday Oct 23, 2026 @ 10:20 AM Central — The Building Texas Show's latest episode, New Texas State Park Near Boerne: Why It Isn't a Park | ABK, hosted by Justin McKenzie and published October 21, 2026, delivers an on-the-ground preview of the Albert & Bessie Kronkosky State Natural Area (ABK), the 3,814-acre site straddling Bandera County and Kendall County along Highway 46 between Boerne and Bandera. New site superintendent Stephanie Kwiatkowski, who stepped into the role in June, explains why Texas Parks and Wildlife is targeting late fall 2026 to open the gates, and why the agency classified ABK as a state natural area rather than a state park. The conversation is a return visit for the show, which previously hosted founding superintendent James Rice while the land was still in survey and planning. Kwiatkowski walks listeners through several specific threads: The legal and operational distinction between a state park and a state natural area under the Texas Admin Code, with comparisons to Government Canyon, Lost Maples, Inks Lake, and McKinney Falls. The 28 miles of multi-use trail open to hikers, mountain bikers, joggers, and strollers. Operational lessons from the July 2026 flooding event, which washed out landscaping, trails, and campsites before any public visitation. Kwiatkowski frames the park-versus-natural-area question as a spectrum between recreation and conservation, and she is candid about the stakes of protecting the ABK viewshed. Standing in a UTV above the canyons during her first weeks on site, she described the moment this way: "The site owns both sides of those canyons. And so that view, that viewshed, it is safeguarded for, um, forever." She also credits the volunteer corps assembled by James Rice, a former biologist, calling the relationships "integral to our success as a site." The episode digs into the ecological specifics that justify ABK's protective designation: bigtooth maples that rival those at Lost Maples State Natural Area, the riparian corridors along Red Bluff Creek and Pipe Creek, and the transition zones between ash juniper woodlands and creek bottoms. Kwiatkowski traces her own path from a childhood of camping in a pop-up trailer, through an environmental science degree with a minor in environmental sociology, GIS and consulting work, a formative seasonal job with the City of New Braunfels parks, the park operations trainee role at the Lost Pines Complex (Bastrop and Buescher State Parks), and an assistant superintendent stint at Pedernales Falls State Park before her June promotion. Construction crews, subcontractors, and a six-person site team are now preparing cabins, screened shelters, tent sites, backcountry camping, and hike-and-bike infrastructure for public access. About The Building Texas Show The Building Texas Show, hosted by Justin McKenzie, spotlights the people, places, and projects shaping Texas communities, from Hill Country conservation to small-business entrepreneurship. New episodes publish weekly across YouTube, Facebook, Instagram, and LinkedIn, with sponsorship support from Chisos Boots. The ABK episode is available now wherever podcasts are heard. ———————————————————————————————————————————————————————————— WHO and ENHYPEN join efforts to inspire young blood donors globally 2026-10-23 · WebWire · Healthcare, Internet & apps, Entertainment https://www.webwire.com/ViewPressRel.asp?aId=363260 World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus met with global K-pop powerhouse ENHYPEN in Seoul on 22 October to celebrate the success of their collaboration for World Blood Donor Day 2026 and recognize the group's role in inspiring young people around the world to donate blood and save lives. - - The collaboration between WHO and ENHYPEN started on World Blood Donor Day on 14 June 2026, bringing together the power of music, social media and the group's glob... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=363260 ———————————————————————————————————————————————————————————— BIDU Investors Have Opportunity to Lead Baidu, Inc. Securities Fraud Lawsuit with SBS Law 2026-10-23 · GlobeNewswire · Legal, Internet & apps https://www.globenewswire.com/news-release/2026/10/23/3387485/0/en/bidu-investors-have-opportunity-to-lead-baidu-inc-securities-fraud-lawsuit-with-sbs-law.html BIDU Investors Have Opportunity to Lead Baidu, Inc. Securities Fraud Lawsuit with SBS Law ———————————————————————————————————————————————————————————— Speaks Your Language, No Internet Needed: VoxNexus Brings On-Device Voice Artificial Intelligence (AI) in 100+ Languages to Affordable Android Devices 2026-10-23 · APO Group · Crypto, AI, SaaS, Energy, Software & IT, Internet & apps https://www.africa-newsroom.com/press/speaks-your-language-no-internet-needed-voxnexus-brings-ondevice-voice-ai-in-100-languages-to-affordable-android-devices?lang=en VoxNexus (www.VoxNexus.ai) released VoxEdge, an on-device voice stack that brings speech recognition, translation and speech synthesis to affordable Android devices, entirely offline. VoxEdge supports speech recognition in 36 languages, translation in 103 languages, and speech synthesis in 45 languages—all running with no connection, no data bundle, and no cloud token bills. AI should work for everyone, not just for speakers of a handful of mainstream languages. Yet across much of Africa, voice AI has been held back by scarce training data and the lack of targeted fine-tuning. Everyday speech also includes code-switching and dialect variation, while cloud-based inference costs can make deployment at scale expensive. VoxNexus’s solutions run entirely on device, and every query is free once the model is installed on the device. Its speech recognition model has as few as 65 million parameters and achieves a lower word error rate than open-source models nearly ten times its size. “Under-resource languages aren’t small languages. Hundreds of millions of people speak them. Until now, AI models just haven’t learned them yet,” said Charles Shi, CEO of VoxNexus. VoxNexus also launched VoxSense, an on-device ambient listening solution that uses only 162 mAh for 12 hours of continuous listening, around 2.5% of a 6,500 mAh phone battery. By keeping all processing on device, VoxSense makes always-on listening practical without draining the battery and without sending any audio to the cloud. Developers and device makers can easily integrate it through a license and a simple SDK. Developers can request a free trial here: www.VoxNexus.ai. VoxSense and VoxEdge were unveiled at the MediaTek Dimensity 9600 launch in Madrid on October 19. Distributed by APO Group on behalf of VoxNexus AI. About VoxNexus: www.VoxNexus.ai. Contact: public@voxnexus.ai ———————————————————————————————————————————————————————————— Royal Plugins Launches Unified WordPress Plugin Suite With AI Management Tools 2026-10-23 · MarketersMEDIA · AI, Internet & apps https://news.marketersmedia.com/royal-plugins-launches-unified-wordpress-plugin-suite-with-ai-management-tools/89207157 -- Royal Plugins has released a suite of WordPress plugins designed to address security, performance, backup, and search engine optimization requirements through individual, purpose-built tools. The company's product line includes GuardPress for security hardening, ForgeCache for caching and speed optimization, SiteVault for automated backups, and SEObolt for search visibility tracking. Each plugin in the Royal Plugi ———————————————————————————————————————————————————————————— PawKick Cuties 2026-10-23 · Games Press · Sports, Internet & apps, Consumer electronics https://www.gamespress.com/PawKick-Cuties-cozy-6-a-side-animal-soccer-is-out-now-on-iPhone-iPad-a 6-a-side soccer between teams of "adorable animal Cuties", free on the App Store now. October 23, 2026 – PawKick Cuties™ is now available free on the App Store for iPhone, iPad and Mac. Players build a team from 23 adorable animal Cuties, each named after something tasty, and play cozy 6-a-side soccer across 13 dreamy fields... ———————————————————————————————————————————————————————————— Your Holiday Business Is Live. How Do You Get Customers 2026-10-23 · ACCESS Newswire · AI, Media, Marketing & advertising, Internet & apps https://finance.yahoo.com/small-business/articles/holiday-business-live-customers-143000501.html NORTHAMPTON, MA / October 23, 2026 / Originally published by GoDaddy What You'll Learn How to create a practical holiday marketing plan that works with a small budget How to use SEO, promotions, email and social media to reach holiday shoppers How AI can help you create marketing content and prepare your ———————————————————————————————————————————————————————————— How Iraqi Storyteller Mohammad Khalid Built a Digital Empire with Over 2.1 Million Subscribers 2026-10-23 · PR Now · Internet & apps https://pressreleasenews.org/pressroom/how-iraqi-storyteller-mohammad-khalid-built-a-digital-empire-with-over-2-1-million-subscribers From an optometry graduate in Najaf to a digital icon, 23-year-old Mohammad Khalid (SaYkO) has captured over 960M million views across social media through his engaging storytelling and authentic humor, and 515K followers on tik tok and 2.1 million subscribers in you tube ———————————————————————————————————————————————————————————— Location of Things (LoT) Market Share and Forecast by 2027 2026-10-23 · PR News Releaser · Internet & apps https://www.prnewsreleaser.com/news/478187 The Location of Things (LoT) refers to the technology that uses location data to connect physical objects, devices, and systems through the Internet of Things. It helps businesses track assets, monitor movements, and improve operational efficiency across different industries. Location ... Read more ———————————————————————————————————————————————————————————— Formula 1 and Consumable Launch the F1 Audio Network, Extending Fandom Beyond Race Day 2026-10-23 · Business Wire · Sports, Internet & apps https://finance.yahoo.com/media-advertising/articles/formula-1-consumable-launch-f1-130600041.html The official audio extension of Formula 1 gives brands a new way to reach racing's premier global fanbase through premium, sound-on experiences across mobile apps and the broader audio ecosystem. NEW YORK, October 23, 2026--Formula 1 and Consumable today announced the launch of the F1 Audio Network, an ———————————————————————————————————————————————————————————— Alternative Rock Artist Michael Dillenger Announces "Crimson Pill" New Single and Debut Music Video on VEVO/YouTube 2026-10-23 · EIN Presswire · Media, Internet & apps, Entertainment https://www.einpresswire.com/article/949125108/alternative-rock-artist-michael-dillenger-announces-crimson-pill-new-single-and-debut-music-video-on-vevo-youtube Dillenger Live Michael Dillenger - Crimson Pill Scene from Crimson Pill Video Alt-rock artist Michael Dillenger explores cyberpsychosis in new song “Crimson Pill,” streaming worldwide October 23, with a music video premiering Halloween. The inspiration of the song was about easy it is lose control of yourself in this insanely technological world. To get so lost... no pill can bring you out of the darkness....” — Mich ———————————————————————————————————————————————————————————— Higgsfield Extends Series B With New Investment From TCV and NVIDIA 2026-10-23 · PR Newswire · AI, Media, Internet & apps, Entertainment https://www.prnewswire.com/news-releases/higgsfield-extends-series-b-with-new-investment-from-tcv-and-nvidia-302918071.html TCV, which has backed Netflix, Spotify, Facebook, Bytedance and Electronic Arts, invested in Higgsfield, reflecting their conviction in AI and generative media. NVIDIA also invested in Higgsfield, as NVIDIA founder and CEO Jensen Huang makes his first visit to Kazakhstan for the country's... ———————————————————————————————————————————————————————————— LocalCableDeals Releases Guide Examining Factors Behind Streaming Service Growth 2026-10-23 · MarketersMEDIA · SaaS, Media, Internet & apps, Entertainment https://news.marketersmedia.com/localcabledeals-releases-guide-examining-factors-behind-streaming-service-growth/89207134 -- LocalCableDeals has released an informational guide examining the platform features and internet connectivity factors behind the growth of streaming services. Titled “The Factors Behind the Growth of Streaming Services,” the guide describes how personalization, device compatibility, interface design, infrastructure, and internet service options contribute to the way audiences access and use streaming entertainment ———————————————————————————————————————————————————————————— Gix Internet Shares to Trade Exclusively on Nasdaq 2026-10-23 · GlobeNewswire · Finance, Investing & markets, Internet & apps https://www.globenewswire.com/news-release/2026/10/23/3387166/0/en/gix-internet-shares-to-trade-exclusively-on-nasdaq.html Voluntary Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing ———————————————————————————————————————————————————————————— Bidease Appoints Former Moloco Revenue Leader Dock Kim as VP of Business Development 2026-10-23 · PR Newswire · Finance, SaaS, Marketing & advertising, Internet & apps https://www.prnewswire.com/news-releases/bidease-appoints-former-moloco-revenue-leader-dock-kim-as-vp-of-business-development-302917418.html Kim joins Bidease following record revenue growth to lead go-to-market across North America, LATAM and EMEA NEW YORK, Oct. 23, 2026 -- Bidease, the performance advertising platform for mobile app growth, has hired former Moloco revenue leader Dock Kim as Vice President of... ———————————————————————————————————————————————————————————— DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network 2026-10-23 · Newswire.com · AI, Healthcare, Retail, Education, Food & drink, Biotech & pharma, Internet & apps https://www.newswire.com/news/datameds-ai-establishes-health-lives-here-community-respiratory-program-for Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026 Program will aim to bring best practices for respiratory season to community pharmacies Nuvaxovid COVID vaccine (protein-based / non-mRNA) prioritized for campaign rollout Improve telehealth availability in the pharmacy through Health Lives Here mobile app Tests to include COVID neutralizing antibodies, antibodies & acute respiratory infections Long COVID-related biomarkers (cardiovascular, incl microclots; immune; metabolic; etc) Immune profiling for other circulating respiratory diseases (influence, RSV, strep, others) Improve access to FDA-approved antivirals Pharmacist education on Tollo Health medical foods and dietary supplements ———————————————————————————————————————————————————————————— Merck Foundation Chief Executive Officer (CEO), Senator Dr. Rasha Kelej and Kenya First Lady H.E. Mrs. Rachel Ruto, E.G.H. Officially Launched their Joint Programs at the Kenya State House 2026-10-23 · APO Group · Finance, Healthcare, Media, Education, Food & drink, Fashion & luxury, Biotech & pharma, Government & policy, Nonprofits, Internet & apps, Entertainment https://merckfoundation.africa-newsroom.com/press/merck-foundation-chief-executive-officer-ceo-senator-dr-rasha-kelej-and-kenya-first-lady-he-mrs-rachel-ruto-egh-officially-launched-their-joint-programs-at-the-kenya-state-house?lang=en Merck Foundation (www.Merck-Foundation.com), the philanthropic arm of Merck KGaA Germany, launched their Educating Linda Program to support girl education at Kenya State House, in partnership with H.E. Mrs. RACHEL RUTO E.G.H, The First Lady of the Republic of Kenya and Ambassador of “Merck Foundation More Than a Mother”. During the visit, the Merck Foundation Kenya Alumni Summit 2026 was also conducted to highlight the impact of their scholarships program with the aim to build healthcare capacity and transform patient care landscape across Kenya nationwide. The program was attended by The First Lady of the Republic of Kenya H.E. Mrs. RACHEL RUTO E.G.H, Chairman of Merck Foundation Board of Trustees, Prof. Dr. Frank Stangenberg-Haverkamp, and CEO of Merck Foundation and President of “More Than a Mother” Campaign, Dr. Rasha Kelej and Kenya Minister of Health, Hon. Aden Duale. Senator Dr. Rasha Kelej (Ret.), CEO of Merck Foundation and President of “More Than a Mother” Campaign emphasized, “It is a great pleasure to meet my dear sister, H.E. Mrs. RACHEL RUTO E.G.H. First Lady of the Republic of Kenya and to recognize her for her tremendous efforts as the Ambassador of “Merck Foundation More Than a Mother”. I am proud that through our long-term partnership we have provided 328 scholarships for young Kenyan healthcare providers in 44 critical and underserved specialties. I am also happy to share that nearly 50% of these scholarships have been awarded to women healthcare providers, reinforcing our commitment to women empowerment. It was also great meeting Kenya Minister of Health, Hon. Aden Duale and our Alumni, who are the future healthcare experts of Kenya.” “We are looking forward to extending our scholarship program to more healthcare providers in partnership with First Lady of Kenya and in collaboration with Medical Societies and Ministry of Health when possible.” She added. H.E. Mrs. Rachel Ruto E.G.H., The First Lady of the Republic of Kenya expressed, “Through our impactful partnership with Merck Foundation, we are not just implementing programs, we are transforming lives. Together, we are strengthening our healthcare capacity, empowering girls through education, breaking infertility stigma, and addressing other critical social and health challenges across Kenya. We are immensely proud that, through our strong partnership, we have been able to provide 328 scholarships for our healthcare providers, not only in the capital city, but across the country. It represents a powerful investment in the future of our healthcare system, a commitment to building expertise where it is needed most, and a significant step towards ensuring equitable access to quality care for all our people. At the same time, we are equally proud to support the education of 47 high-performing yet underprivileged Kenyan schoolgirls, providing them with annual scholarships till they graduate. By empowering these young girls through education, we are not only transforming individual lives, but also shaping stronger families, communities, and a brighter future for our nation.” Prof. Dr. Frank Stangenberg-Haverkamp Chairman of Merck Foundation Board of Trustees added, “Our aim is to improve the overall health and wellbeing of people by building healthcare capacity in Kenya and across developing countries. We are strongly committed to transforming patient care through our scholarships program.” Hon. Aden Duale, Cabinet Secretary, Ministry of Health, Kenya shared, “We sincerely appreciate the Merck Foundation Scholarships Program through which 328 scholarships have been provided till today for our local healthcare providers in many critical underserved specialties, helping us to build and strengthen our healthcare capacity, across the country.” One of the important specialties that Merck Foundation is focusing on in 2025 and 2026 in Kenya is the scholarship of One Year Diploma in Nutrition, to support the program of Feeding and Food Security of Kenya First Lady. More than 90 scholarships are dedicated to this specialty across the 47 provinces of Kenya. This will create a culture shift in leading a healthy lifestyle for the whole population which will contribute to healthier communities and hence social and economic development of the whole country nationwide. The program was also attended by the Kenyan winners of Merck Foundation Media Awards 2024 and 2025. “It was a pleasure meeting and celebrating our Winners, the health and social champions, who are the voice of the voiceless”, added Dr. Rasha Kelej. Out of the total 328 scholarships, Merck Foundation has provided: 121 scholarships for one-year postgraduate diplomas and two-year master’s degrees in Diabetes, Preventative Cardiovascular Medicine, Cardiology, and Endocrinology. These programs enable doctors to establish specialized diabetes clinics across the country. 10 scholarships for Oncology, which is a critical specialty to strengthen cancer care capacity. 49 scholarships for Fertility, Embryology, and Reproductive Medicine under the “More Than a Mother” campaign, bringing hope and support to couples facing infertility challenges. 148 scholarships for other important specialties such as Internal Medicine, Psychiatry, Neurology, Emergency Medicine, Dermatology, and many more, contributing significantly to strengthening Kenya’s healthcare system. Merck Foundation has overall provided more than 2,600 scholarships for healthcare providers in 44 critical and undeserved specialties from over 52 countries. During the Summit, Merck Foundation alumni shared inspiring testimonies on how these scholarships have transformed their professional journeys and improved patient care in their communities. Merck Foundation, in partnership with the First Lady of Kenya, is also launching children’s storybooks — “More Than a Mother”, “Educating Linda”, “Jackline’s Rescue”, “Not Who You Are”, “Ride into the Future”, “Sugar Free Jude” and “Mark’s Pressure” in English and Swahili to raise awareness about critical social and health issues among young children. Thousands of copies will be distributed across schools in Kenya. These storybooks have also been adapted into animated films to further enhance their impact. Moreover, Merck Foundation has conducted 4 Editions of their Online Health Media Training for Kenyan journalists to empower them to raise awareness about sensitive social and health issues such as breaking infertility stigma, supporting girl education, ending child marriage and GBV, and promoting healthy lifestyle practices. Merck Foundation, together with the First Lady of Kenya, also organizes annual awards for media, musicians, filmmakers, and fashion designers to encourage creative talents to raise awareness about important social issues. Merck Foundation in partnership with the First Lady of the Republic of Kenya has also announced the Call for Application for their important annual Awards for Media, Musicians, Fashion Designers, Filmmakers, students, and new potential talents in these fields. Details of the Awards: 1. Merck Foundation Media Recognition Awards 2026 “Diabetes & Hypertension”: Media representatives are invited to showcase their work through strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 2. Merck Foundation Film Awards 2026 “Diabetes & Hypertension”: All Filmmakers, Students of Film Making Training Institutions, or Young Talents are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to promote a healthy lifestyle raise awareness about prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 3. Merck Foundation Fashion Awards 2026 “Diabetes & Hypertension”: All Students and Designers are invited to create and share designs to deliver strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 4. Merck Foundation Song Awards 2025 “Diabetes & Hypertension”: All Singers and Musical Artists are invited to create and share a SONG with the aim to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. Apply here: https://apo-opa.co/4siT2b4 Entries for all the awards are to be submitted via email to: submit@merck-foundation.com Distributed by APO Group on behalf of Merck Foundation. Contact: mehak.handa@external.merckgroup.com Join the conversation on our social media platforms below and let your voice be heard! https://apo-opa.co/4siApEp https://apo-opa.co/4sjDsw3 https://apo-opa.co/48grr0V https://apo-opa.co/4k9Cq3t https://apo-opa.co/4stVHij https://apo-opa.co/4i0xWef www.Merck-Foundation.com https://apo-opa.co/4yD9HHU About Merck Foundation: Merck Foundation works across more than 50 countries with First Ladies, their Foundations, Ministries, and other key stakeholders. Through complementary roles in advocacy, local government coordination, healthcare & media capacity building, girls’ education, and community awareness initiatives. It is this coordinated ecosystem of partnerships—with distinct responsibilities and a shared vision—that enables Merck Foundation to build local capacity, create sustainable impact, and contribute to long-term transformation in healthcare and society. Through their various programs and initiatives, Merck Foundation has provided 2,750+ scholarships for healthcare providers from 52 countries in 44 critical and underserved specialties, awarded 1,570+ scholarships to underprivileged African schoolgirls across 21 countries, trained 4,000+ media professionals, recognized 980 award winners, and reached 9+ million followers across 15 social media channels, driving lasting impact in healthcare, education, and awareness across Africa and Asia. The Merck Foundation is dedicated to improving social and health outcomes for communities in need. While it collaborates with various partners, including governments to achieve its humanitarian goals, the foundation remains strictly neutral in political matters. It does not engage in or support any political activities, elections, or regimes, focusing solely on its mission to elevate humanity and enhance well-being while maintaining a strict non-political stance in all of its endeavors. All Merck Foundation press releases are distributed by e-mail at the same time they become available on the Merck Foundation Website.  Please visit www.Merck-Foundation.com to read more. Follow the social media of Merck Foundation: Facebook (https://apo-opa.co/4siApEp), X (https://apo-opa.co/4sjDsw3),Instagram (https://apo-opa.co/4k9Cq3t), YouTube (https://apo-opa.co/48grr0V), Threads (https://apo-opa.co/4stVHij) and Flickr (https://apo-opa.co/4i0xWef). This content is not intended for US/ Canadian audiences. ———————————————————————————————————————————————————————————— Transfer WhatsApp from Android to iPhone Duo: Tenorshare Offers a Simpler Solution 2026-10-23 · PR Newswire · Internet & apps, Consumer electronics https://www.prnewswire.com/news-releases/transfer-whatsapp-from-android-to-iphone-duo-tenorshare-offers-a-simpler-solution-302917904.html NEW YORK, Oct. 23, 2026 -- Switching from Android to iPhone Duo doesn't have to mean leaving important WhatsApp conversations behind. Tenorshare iCareFone WhatsApp Transfer offers an alternative for users looking to transfer WhatsApp from Android to iPhone Duo, including... ———————————————————————————————————————————————————————————— Transfer WhatsApp from Android to New iPhone Duo: Tenorshare Offers a Simpler Solution 2026-10-23 · Send2Press · Industrial, Software & IT, Internet & apps, Consumer electronics https://www.send2press.com/wire/transfer-whatsapp-from-android-to-new-iphone-duo-tenorshare-offers-a-simpler-solution/ NEW YORK, N.Y., Oct. 23, 2026 -- Switching from Android to iPhone Duo doesn't have to mean leaving important WhatsApp conversations behind. Tenorshare iCareFone WhatsApp Transfer offers an alternative for users looking to transfer WhatsApp from Android to iPhone Duo, including supported chats, photos, videos, and attachments. For users who have already completed their iPhone Duo setup, the software provides a desktop-based transfer option without requiring a factory reset. ———————————————————————————————————————————————————————————— Morgan Burtwistle and Red Bull 2026-10-23 · Games Press · Sports, Internet & apps https://www.gamespress.com/Angry-Ginge-makes-history-as-first-Brit-to-livestream-a-skydive Popular social media entity jumps out of a plane while livestreaming it. 22nd October - Red Bull player Morgan “Angry Ginge” Burtwistle today made UK history, completing the country’s first fully livestreamed skydive, jumping from 13,000 feet alongside Red Bull Athlete Dani Roman... ———————————————————————————————————————————————————————————— Wildcard Wellness Launches Meadow, a Habit Tracker With No Streaks to Break 2026-10-23 · EIN Presswire · Internet & apps https://www.einpresswire.com/article/951192762/wildcard-wellness-launches-meadow-a-habit-tracker-with-no-streaks-to-break Meadow Habit Tracking App Built by a wellness creator who shared his recovery from a herniated disc with 300,000 Instagram followers, Meadow grows a digital flower every day you show up. SACRAMENTO, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- Wildcard Wellness today launched Meadow , a habit and activity tracker built on encouragement rather than pressure. Log a walk or a workout, or finish your daily ———————————————————————————————————————————————————————————— 50 AUSTRALIAN CONTENT CREATORS REINVENT PROSCIUTTO DI CARPEGNA PDO ON SOCIAL MEDIA 2026-10-23 · EIN Presswire · Media, Food & drink, Internet & apps https://www.einpresswire.com/article/951732380/50-australian-content-creators-reinvent-prosciutto-di-carpegna-pdo-on-social-media Prosciutto di Carpegna PDO and melon Pizza with Prosciutto di Carpenga PDO Focaccia with Prosciutto di Carpegna PDO The EU Gem Ham campaign brings European culinary tradition to Australian social media through original video recipes CARPEGNA, ITALY, October 23, 2026 / EINPresswire.com / -- What happens when a European culinary tradition meets the creativity of Australian food lovers? From timeless pairings to unexpec ———————————————————————————————————————————————————————————— Whistleblower Keith Schooley Opens Official Facebook Page for "Merrill Lynch: The Cost Could Be Fatal" 2026-10-23 · 24-7 Press Release · Internet & apps https://www.24-7pressrelease.com/press-release/539865/whistleblower-keith-schooley-opens-official-facebook-page-for-merrill-lynch-the-cost-could-be-fatal The former Merrill Lynch broker from Enid, Oklahoma, whose nine-year fight with the largest firm on Wall Street became a book, has opened an official Facebook page. Readers are asked to follow it and share it. ———————————————————————————————————————————————————————————— Sigma FP2 Mirrorless Camera Evolves the Compact, Hybrid, Full-Frame Formula, Announced; YouTube First Look Video and More Info at B&H 2026-10-23 · GlobeNewswire · Media, Internet & apps, Consumer electronics https://www.globenewswire.com/news-release/2026/10/23/3387063/0/en/sigma-fp2-mirrorless-camera-evolves-the-compact-hybrid-full-frame-formula-announced-youtube-first-look-video-and-more-info-at-b-h.html Sigma FP2 Camera will inherit the “world’s smallest body” from its predecessor, shaving grams and millimeters off a clean, capable, and bricklike body. ———————————————————————————————————————————————————————————— THE NEW CYBERCRIME HUB: BEYOND NATIONAL IDENTITY 2026-10-23 · PR Urgent · Cybersecurity, Internet & apps https://www.prurgent.com/2026-10-23/pressrelease476907.htm Internet scammers are increasingly targeting Americans for fraud ———————————————————————————————————————————————————————————— ClipHaus Campaign for Coinbase and VALORANT Generates 35M+ Organic Views and 15K+ Clips 2026-10-23 · EIN Presswire · Internet & apps https://www.einpresswire.com/article/950992150/cliphaus-campaign-for-coinbase-and-valorant-generates-35m-organic-views-and-15k-clips ClipHaus drove massive visibility for Riot Games’ VALORANT and Coinbase collaboration through a large-scale clipping campaign, amplifying their reach across social media. Creator-led distribution turned Coinbase One Shot tournament moments into more than 15,000 short-form posts, generating 500,000+ likes and 40,000+ shares. The opportunity is not just to sponsor an event, but to turn its moments into thousands of opp ———————————————————————————————————————————————————————————— 15 Minutes Famous Launches Interactive Platform for Community Recognition 2026-10-23 · MarketersMEDIA · SaaS, Internet & apps, Entertainment https://news.marketersmedia.com/15-minutes-famous-launches-interactive-platform-for-community-recognition/89206827 15 Minutes Famous introduces an online platform where users can nominate people for timed spotlights and share personal stories of recognition. -- 15 Minutes Famous, a social entertainment platform created in Los Angeles, has launched a digital experience that allows users to nominate individuals for public recognition through timed spotlights, community engagement, and social sharing. The platform draws on the famil ———————————————————————————————————————————————————————————— MicroVision Begins Commercial Production of MOVIA(TM) Pro for Superior Short-Range Sensing and Onboard Perception, Enabling Physical AI at the Edge 2026-10-23 · ACN Newswire · Finance, AI, SaaS, Real estate, Automotive, Industrial, Logistics, Software & IT, Internet & apps https://www.acnnewswire.com/press-release/english/111019/ ORLANDO, FL, Oct 23, 2026 - MicroVision, Inc. (NASDAQ: MVIS), a leader in advanced perception solutions for industrial, security and defense, intelligent infrastructure, and automotive applications, today announced the much-anticipated commercial production launch of MOVIA™ Pro, shipping sensors to meet customer demand. MOVIA Pro is the company’s next-generation short-range lidar sensor uniquely engineered to deliver differentiated sensing performance and onboard perception capabilities, with flexible integration across intelligent infrastructure, unmanned aerial, industrial robotics, and other emerging autonomous applications.  As the lidar industry transitions toward solid-state architectures that enable cost-effective sensing solutions, MicroVision’s MOVIA Pro is designed to deliver enhanced short-range detection performance for demanding applications. By combining advanced sensing capabilities with onboard perception, MOVIA Pro makes high-performance lidar more accessible across a broader range of autonomous and intelligent systems.   MOVIA Pro joins the company's broader portfolio of short- and long-range lidar technologies, airborne sensing solutions and advanced perception software, providing customers with configurable solutions for a growing range of operating environments. The launch of MOVIA Pro reinforces MicroVision's transformation into a diversified perception technology company focused on delivering commercially ready solutions for industrial, intelligent infrastructure, security and defense, and emerging autonomous applications.   "We’re thrilled to meet pent-up customer demand with this production launch of MOVIA Pro,” said Glen DeVos, CEO of MicroVision. “Customers are ready to progress from evaluation of prototypes to launching commercial programs, and we are pleased to support their progression. Our Orlando-based state-of-the-art production facility is manufacturing MOVIA Pro to meet the increasing demand.  DeVos continued, "With MOVIA Pro, we've combined high-performance sensing with onboard computing, an open software framework and industrial-ready connectivity. This is one device that can sense, perceive, and act, providing customers with a more integrated and adaptable solution."  One Sensor That Sees, Understands, and Enables Solutions at the Edge  MOVIA Pro is MicroVision’s production-ready version of MOVIA S, loaded with high-performance features and a differentiation that extends beyond sensing hardware. Built around an integrated processing architecture, MOVIA Pro enables perception software to run directly on the sensor through MicroVision's Open Software Framework. This allows developers and customers to build, deploy, and update applications on the device, rather than relying exclusively on external computing hardware to interpret point-cloud data. The architecture enables MOVIA Pro to generate sensing information, process that information into actionable perception outputs, and communicate results directly to connected systems.  Key capabilities include:  Onboard perception, edge AI, and open software: Processes point-cloud data directly on the sensor to generate object-level information, supporting AI at the edge and reducing reliance on external computing devices. Multi-echo sensing enhances perception by capturing multiple returns from a single emitted pulse, helping detect objects in challenging conditions. An open, Linux-based software framework enables customers to develop, deploy, and update perception applications.  Flexible connectivity and industrial integration: Supports CAN, Gigabit and 100Mbit Ethernet, and industrial-ready I/O and connectors to simplify integration with industrial equipment, vehicles, and control systems.  Software-defined evolution: Enables capabilities and enhancements through software updates, with a foundation for future-edge computing and AI-ready capabilities.  By combining sensing and perception in a single device, MOVIA Pro is designed to reduce system complexity, cabling and external hardware requirements while supporting more efficient integration, maintenance and future upgrades.   Movia Pro is MicroVision’s next-generation short-range lidar sensor that delivers integrated perception and multi-echo sensing, built for flexible integration across various commercial applications.  Purpose-Built for High-Value Commercial Applications  MOVIA Pro is designed to support a broad range of commercial and defense applications, with MicroVision prioritizing markets where advanced short-range perception can address immediate operational challenges and enable new levels of automation. Its configurable sensing and perception architecture supports applications across:  Aerial Systems – Civil and Defense: Supporting navigation, obstacle awareness, mapping, environmental perception and autonomous operations for unmanned platforms, where compact sensing, onboard processing and reliable perception are critical.  Intelligent Transportation and Smart Infrastructure: Enabling intelligent intersections, traffic monitoring, automated traffic enforcement, infrastructure surveillance and connected transportation systems through high-resolution sensing, broad field of view, and industrial connectivity. Anonymized sensing capabilities can support monitoring applications where privacy is a consideration.   Warehouse and Industrial Automation: Supporting obstacle detection, environmental awareness and automated navigation for autonomous mobile robots (AMRs), automated guided vehicles (AGVs), forklift advanced driver-assistance systems and other intelligent industrial equipment. Continuous near-field coverage, multi-echo capabilities and onboard perception help address dynamic environments where people, equipment and autonomous machines operate in close proximity.  Security, Defense, and Emerging Applications: Supporting infrastructure protection, autonomous ground systems, off-road unmanned ground vehicles, marine systems, commercial vehicles and selected automotive applications, including low-speed autonomy, blind-spot detection and off-road assistance.   Availability and Product Information  MOVIA Pro is now available for customer orders. For additional product information, visit https://microvision.com/sensors/movia-pro. For inquiries, please contact us here.  About MicroVision  MicroVision is defining the next generation of lidar-based perception solutions for industrial, security & defense, infrastructure, and automotive markets. As the industry moves beyond proof of concept toward value, deployment, and commercialization, MicroVision delivers integrated hardware and software solutions designed for real-world performance, automotive-grade reliability, and economic scalability. With engineering centers in the U.S. and Germany, MicroVision leads the industry in depth and breadth of its portfolio, with both short- and long-range lidar solutions, featuring solid-state sensors, advanced sensor architectures, design-to-cost engineering, and open software solutions.  For more information, visit the company's website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc, and LinkedIn at www.linkedin.com/company/microvision/.  MicroVision, MicroVision HALO, IRIS, MOVIA, MOSAIK, and SENTINEL are trademarks of MicroVision, Inc., and SCANTINEL is a trademark of Scantinel GmbH, in the United States and other countries. All other trademarks are the property of their respective owners.  Investor Relations Contact:  Jeff Christensen Darrow Associates Investor Relations MVIS@darrowir.com  Media Contact: Heidi Davidson - For MicroVision heidi@galvanizeworldwide.com (914) 441-6862 ———————————————————————————————————————————————————————————— MicroVision Begins Commercial Production of MOVIA(TM) Pro to Meet Immediate Customer Demand for Superior Short-Range Sensing and Onboard Perception, Enabling Physical AI at the Edge 2026-10-23 · ACN Newswire · Finance, AI, SaaS, Real estate, Automotive, Industrial, Logistics, Software & IT, Internet & apps https://www.acnnewswire.com/press-release/english/111019/ Orlando, Florida, Oct 23, 2026 - MicroVision, Inc. (NASDAQ: MVIS), a leader in advanced perception solutions for industrial, security and defense, intelligent infrastructure, and automotive applications, today announced the much-anticipated commercial production launch of MOVIA™ Pro, shipping sensors to meet customer demand. MOVIA Pro is the company’s next-generation short-range lidar sensor uniquely engineered to deliver differentiated sensing performance and onboard perception capabilities, with flexible integration across intelligent infrastructure, unmanned aerial, industrial robotics, and other emerging autonomous applications.  As the lidar industry transitions toward solid-state architectures that enable cost-effective sensing solutions, MicroVision’s MOVIA Pro is designed to deliver enhanced short-range detection performance for demanding applications. By combining advanced sensing capabilities with onboard perception, MOVIA Pro makes high-performance lidar more accessible across a broader range of autonomous and intelligent systems.   MOVIA Pro joins the company's broader portfolio of short- and long-range lidar technologies, airborne sensing solutions and advanced perception software, providing customers with configurable solutions for a growing range of operating environments. The launch of MOVIA Pro reinforces MicroVision's transformation into a diversified perception technology company focused on delivering commercially ready solutions for industrial, intelligent infrastructure, security and defense, and emerging autonomous applications.   "We’re thrilled to meet pent-up customer demand with this production launch of MOVIA Pro,” said Glen DeVos, CEO of MicroVision. “Customers are ready to progress from evaluation of prototypes to launching commercial programs, and we are pleased to support their progression. Our Orlando-based state-of-the-art production facility is manufacturing MOVIA Pro to meet the increasing demand.  DeVos continued, "With MOVIA Pro, we've combined high-performance sensing with onboard computing, an open software framework and industrial-ready connectivity. This is one device that can sense, perceive, and act, providing customers with a more integrated and adaptable solution."  One Sensor That Sees, Understands, and Enables Solutions at the Edge  MOVIA Pro is MicroVision’s production-ready version of MOVIA S, loaded with high-performance features and a differentiation that extends beyond sensing hardware. Built around an integrated processing architecture, MOVIA Pro enables perception software to run directly on the sensor through MicroVision's Open Software Framework. This allows developers and customers to build, deploy, and update applications on the device, rather than relying exclusively on external computing hardware to interpret point-cloud data. The architecture enables MOVIA Pro to generate sensing information, process that information into actionable perception outputs, and communicate results directly to connected systems.  Key capabilities include:  Onboard perception, edge AI, and open software: Processes point-cloud data directly on the sensor to generate object-level information, supporting AI at the edge and reducing reliance on external computing devices. Multi-echo sensing enhances perception by capturing multiple returns from a single emitted pulse, helping detect objects in challenging conditions. An open, Linux-based software framework enables customers to develop, deploy, and update perception applications.  Flexible connectivity and industrial integration: Supports CAN, Gigabit and 100Mbit Ethernet, and industrial-ready I/O and connectors to simplify integration with industrial equipment, vehicles, and control systems.  Software-defined evolution: Enables capabilities and enhancements through software updates, with a foundation for future-edge computing and AI-ready capabilities.  By combining sensing and perception in a single device, MOVIA Pro is designed to reduce system complexity, cabling and external hardware requirements while supporting more efficient integration, maintenance and future upgrades.   Movia Pro is MicroVision’s next-generation short-range lidar sensor that delivers integrated perception and multi-echo sensing, built for flexible integration across various commercial applications.  Purpose-Built for High-Value Commercial Applications  MOVIA Pro is designed to support a broad range of commercial and defense applications, with MicroVision prioritizing markets where advanced short-range perception can address immediate operational challenges and enable new levels of automation. Its configurable sensing and perception architecture supports applications across:  Aerial Systems – Civil and Defense: Supporting navigation, obstacle awareness, mapping, environmental perception and autonomous operations for unmanned platforms, where compact sensing, onboard processing and reliable perception are critical.  Intelligent Transportation and Smart Infrastructure: Enabling intelligent intersections, traffic monitoring, automated traffic enforcement, infrastructure surveillance and connected transportation systems through high-resolution sensing, broad field of view, and industrial connectivity. Anonymized sensing capabilities can support monitoring applications where privacy is a consideration.   Warehouse and Industrial Automation: Supporting obstacle detection, environmental awareness and automated navigation for autonomous mobile robots (AMRs), automated guided vehicles (AGVs), forklift advanced driver-assistance systems and other intelligent industrial equipment. Continuous near-field coverage, multi-echo capabilities and onboard perception help address dynamic environments where people, equipment and autonomous machines operate in close proximity.  Security, Defense, and Emerging Applications: Supporting infrastructure protection, autonomous ground systems, off-road unmanned ground vehicles, marine systems, commercial vehicles and selected automotive applications, including low-speed autonomy, blind-spot detection and off-road assistance.   Availability and Product Information  MOVIA Pro is now available for customer orders. For additional product information, visit https://microvision.com/sensors/movia-pro. For inquiries, please contact us here.  About MicroVision  MicroVision is defining the next generation of lidar-based perception solutions for industrial, security & defense, infrastructure, and automotive markets. As the industry moves beyond proof of concept toward value, deployment, and commercialization, MicroVision delivers integrated hardware and software solutions designed for real-world performance, automotive-grade reliability, and economic scalability. With engineering centers in the U.S. and Germany, MicroVision leads the industry in depth and breadth of its portfolio, with both short- and long-range lidar solutions, featuring solid-state sensors, advanced sensor architectures, design-to-cost engineering, and open software solutions.  For more information, visit the company's website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc, and LinkedIn at https://www.linkedin.com/company/microvision/.  MicroVision, MicroVision HALO, IRIS, MOVIA, MOSAIK, and SENTINEL are trademarks of MicroVision, Inc., and SCANTINEL is a trademark of Scantinel GmbH, in the United States and other countries. All other trademarks are the property of their respective owners.  Investor Relations Contact:  Jeff Christensen Darrow Associates Investor Relations MVIS@darrowir.com  Media Contact: Heidi Davidson - For MicroVision heidi@galvanizeworldwide.com (914) 441-6862 ———————————————————————————————————————————————————————————— NJ Home Improvement Contractor Local SEO & AEO Marketing Service Expands 2026-10-22 · MarketersMEDIA · Marketing & advertising, Internet & apps https://news.marketersmedia.com/nj-home-improvement-contractor-local-seo-andamp-aeo-marketing-service-expands/89207073 NJ Local Marketing has expanded its local SEO, AEO, and GBP optimization services for home service contractors across New Jersey, helping businesses in roofing, remodeling, and tree service generate more calls from local searches. -- NJ Local Marketing has announced an expansion of its digital marketing services for home service contractors across New Jersey and neighboring states, adding search engine optimization ( ———————————————————————————————————————————————————————————— naoo Completes Kingfluencers Integration and Sets the Stage for Its Next Phase of Growth 2026-10-22 · NewMediaWire · Finance, SaaS, Media, Investing & markets, Marketing & advertising, Internet & apps, Entertainment https://www.newmediawire.com/news/naoo-completes-kingfluencers-integration-and-sets-the-stage-for-its-next-phase-of-growth-7090828 Shared Zurich office, integrated functions and new growth initiatives lay the foundation for the next phase of collaboration ZUG and ZURICH, SWITZERLAND - October 22, 2026 - naoo AG (Dusseldorf: Ticker: NAO; ISIN: CH1323306329), operator of the naoo social media and commerce platform, has completed the integration of Kingfluencers into the naoo Group. The integration process began with the acquisition of Kingfluencers in March 2025 and concludes at the end of October with the move to a shared office in Zurich. Since the acquisition, the two companies have gradually integrated their organizational structures and operations. Shared functions have been established, particularly in Finance, Commercial and People. Most recently, joint growth initiatives have also been launched, combining the naoo platform with Kingfluencers’ creator network, client relationships and commercial capabilities. At the end of October, the operational teams of naoo and Kingfluencers will move into shared offices at Molkenstrasse 15, directly next to Zurich’s historic Helvetiaplatz, close to the Volkshaus and Europaallee. This physical consolidation marks the visible completion of the integration process. naoo AG’s registered headquarters will remain in Zug. With the integration now complete, Gregor Doser has decided to hand over his operational responsibilities to the existing leadership team and step down from the management teams of both naoo AG and Kingfluencers AG. Gregor Doser and naoo are currently discussing a potential future strategic advisory role. Doser joined the Group in May 2025, shortly after the acquisition of Kingfluencers, and has since served as Chief Commercial Officer and Managing Director of Kingfluencers, as well as a member of the Executive Management of naoo AG. In this role, he played a key part in the commercial development of Kingfluencers and, in particular, in integrating the company into the naoo Group. “Gregor has guided the integration process with great care and strategic clarity, making a significant contribution to bringing Kingfluencers and naoo together. We sincerely thank him for his tremendous commitment and the smooth handover to the operational team, and wish him all the best in the next chapter of his career,” says Thomas Wolfensberger, Chairman of the Board of Directors of Kingfluencers AG and Founder & Strategic Advisor of naoo AG. Gregor Doser adds: “With the teams and business areas now successfully integrated, I believe this is the right time to hand over operational leadership to the well-established management team. I am proud of what we have achieved together and look forward to following the Group’s continued development.” Gabriel Höhener will also step down from the Executive Management of naoo AG. As part of the organization’s ongoing development, product responsibilities have been consolidated under Dr. David Liu. Gabriel Höhener has been with naoo since 2022 and most recently served as Chief Product & Technology Officer and a member of Executive Management. In this role, he was responsible for technical product development and made a substantial contribution to building and advancing the naoo platform. During a formative phase of the company’s development, he established important foundations for today’s product and played a key role in shaping its evolution. naoo thanks Gabriel Höhener for his outstanding personal commitment, his important contribution to building the platform and the many years of collaboration. With the integration complete, the naoo Group is increasingly focusing on scaling its joint growth initiatives and strategically expanding the naoo platform. A key priority is the expansion of naoo Play, its entertainment and streaming offering, which aims to attract additional audiences and increase user engagement through new digital entertainment formats, particularly Vertical Short Dramas. In parallel, the existing social media, community and gamification features, as well as naoo Worlds, will continue to be developed. Kingfluencers’ extensive creator network, client relationships and marketing expertise provide valuable synergies to expand the platform’s reach, unlock new monetization opportunities and drive growth across both companies. About naoo naoo AG is building the future of creator-led media, social interaction and local activation in a business model designed to connect digital attention with measurable real-world outcomes. At the core of the Group stands the naoo platform – a next-generation social media and activation ecosystem that connects digital attention with geographic relevance and merchant interaction. The platform delivers a unique user experience through personalized content, gamification, and an innovative points-and-rewards system, while creating unique value through local incentives, measurable activation around physical places and new forms of real-world interaction enabled by naoo business. Business customers can create individualized offers tailored to user needs and incentivize visits to physical locations through naoo points, which can be redeemed for a variety of rewards. Together with Kingfluencers AG - the largest influencer agency in Switzerland and one of the largest in the DACH region - naoo combines platform innovation with industry-leading expertise in creators, campaigns, and brand storytelling, creating new funnel extension opportunities between digital campaigns and real-world interaction. In addition, naoo continues to expand its ecosystem through proprietary creator-driven media formats such as vertical shorts and content hubs that broaden reach, deepen engagement and support a diversified, IP-driven business model. naoo AG is headquartered in Zug, employs 41 people across the group, and is listed on the Düsseldorf Stock Exchange (ticker: NAO, ISIN: CH1323306329). Contact for Media and Investors Karl Fleetwood Chief Operating Officer E-Mail: karl.fleetwood@naoo.com Phone: +41 (0)79 867 10 10 ———————————————————————————————————————————————————————————— DNIB.com Reports Internet Has 411.6 Million Domain Name Registrations at the End of the Third Quarter of 2026 2026-10-22 · Business Wire · Finance, Internet & apps https://finance.yahoo.com/technology/articles/dnib-com-reports-internet-411-211800110.html RESTON, Va., October 22, 2026--VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com , the third quarter of 2026 closed with 411.6 mi ———————————————————————————————————————————————————————————— White Noise Digital Unveils High-Intent Search Framework for Regional Plumbers 2026-10-22 · MarketersMEDIA · SaaS, Marketing & advertising, Software & IT, Internet & apps https://news.marketersmedia.com/white-noise-digital-unveils-high-intent-search-framework-for-regional-plumbers/89202912 White Noise Digital, a leading digital marketing agency in Harrisburg, PA, has launched a specialized High-Intent Search Framework for regional plumbers. The system combines emergency local SEO, targeted pay-per-click advertising, and CRM integration to deliver high-converting service calls to plumbing contractors. -- HARRISBURG, PA — White Noise Digital , a performance-driven internet marketing agency based in Harri ———————————————————————————————————————————————————————————— Centrus to Webcast Conference Call on November 5 at 8:30 a.m. ET 2026-10-22 · PR Newswire · Finance, Energy, Internet & apps https://www.prnewswire.com/news-releases/centrus-to-webcast-conference-call-on-november-5-at-830-am-et-302917455.html BETHESDA, Md., Oct. 22, 2026 -- Centrus Energy Corp. (NYSE: LEU) will broadcast its quarterly conference call with shareholders and the financial community over the Internet on Thursday, November 5, 2026, at 8:30 a.m. ET. The Company will release its third quarter earnings... ———————————————————————————————————————————————————————————— 7SEA Marketing Unifies Shopify Development, CRO and Social Media Management for U.S. D2C Brands 2026-10-22 · EIN Presswire · Retail, Food & drink, Fashion & luxury, Marketing & advertising, Internet & apps https://www.einpresswire.com/article/951560988/7sea-marketing-unifies-shopify-development-cro-and-social-media-management-for-u-s-d2c-brands 7SEA Marketing, Shopify Select Partner Agency for D2C Brands Shopify CRO Results: Before and After Instagram Feeds Managed by 7SEA Marketing for Fashion, Jewelry and Beverage Brands Shopify Select Partner 7SEA Marketing combines store development, CRO and social media management for U.S. D2C brands under one accountable team. Founders don’t need five vendors pointing fingers at each other. They need one team that bui ———————————————————————————————————————————————————————————— Webcast Alert: BorgWarner 2026 Third Quarter Results Conference Call 2026-10-22 · PR Newswire · Finance, Internet & apps https://www.prnewswire.com/news-releases/webcast-alert-borgwarner-2026-third-quarter-results-conference-call-302916916.html AUBURN HILLS, Mich., Oct. 22, 2026 -- BorgWarner Inc. (NYSE: BWA) announces the following Webcast: What: BorgWarner 2026 Third Quarter Results Conference Call When: October 29, 2026 @ 9:30am Eastern Time Where: www.borgwarner.com/investors How: Live over the Internet --... ———————————————————————————————————————————————————————————— DEADLINE ALERT for Innventure, Inc. (INV), XTI Aerospace, Inc. (XTIA), Flotek Industries, Inc. (FTK), and Baidu, Inc. (BIDU): The Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions 2026-10-22 · GlobeNewswire · Aerospace & defense, Legal, Internet & apps https://www.globenewswire.com/news-release/2026/10/22/3386841/3448/en/deadline-alert-for-innventure-inc-inv-xti-aerospace-inc-xtia-flotek-industries-inc-ftk-and-baidu-inc-bidu-the-law-offices-of-howard-g-smith-reminds-investors-of-opportunity-to-lead.html Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Innventure, Inc., XTI Aerospace, Inc., Flotek Industries, Inc., and Baidu, Inc. Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in Innventure, Inc., XTI Aerospace, Inc., Flotek Industries, Inc., and Baidu, Inc. ———————————————————————————————————————————————————————————— Coworking space platform introduces Spacebring Intelligence with autonomous cloud agents 2026-10-22 · EIN Presswire · AI, SaaS, Internet & apps https://www.einpresswire.com/article/951465080/coworking-space-platform-introduces-spacebring-intelligence-with-autonomous-cloud-agents Spacebring Agent for operating coworking spaces Spacebring Agents for autonomous coworking space operation in the cloud Spacebring Agent and a team of AI agents take on the routine work of running a coworking space around the clock, on the web and in the admin mobile app Spacebring went above and beyond with Agents, making life easier for coworking admins with thoughtful, practical features that make a difference. We ———————————————————————————————————————————————————————————— Aviio Launches a Decision Engine for Paid Media, With $5.37M in Ad Spend Already Run Through It 2026-10-22 · EIN Presswire · Marketing & advertising, Internet & apps https://www.einpresswire.com/article/951319741/aviio-launches-a-decision-engine-for-paid-media-with-5-37m-in-ad-spend-already-run-through-it Decision Queue Founded by a former Meta marketing data scientist, Aviio ranks the decisions a paid media team should make next across platforms SAN FRANCISCO, CA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Aviio, Inc. today announced the public launch of Aviio, a decision engine for paid media. Aviio connects to a company's ad accounts across Google, Meta, TikTok and LinkedIn and produces a ranked queue ———————————————————————————————————————————————————————————— Connected Nation study highlights broadband adoption and population health outcomes in the U.S. 2026-10-22 · PR Newswire · Healthcare, Telecom, Internet & apps https://www.prnewswire.com/news-releases/connected-nation-study-highlights-broadband-adoption-and-population-health-outcomes-in-the-us-302917211.html BOWLING GREEN, Ky., Oct. 22, 2026 -- Connected Nation (CN) has released a new report examining the relationship between household computer ownership and internet adoption and health outcomes at the county level across the United States. The report, titled "Broadband Adoption... ———————————————————————————————————————————————————————————— Campaign Reaches 2.2 Million New Yorkers With Free Family Court Help 2026-10-22 · EIN Presswire · Internet & apps https://www.einpresswire.com/article/951531740/campaign-reaches-2-2-million-new-yorkers-with-free-family-court-help Family Legal Care and Wonder Integrated Group (WonderINgroup) partnered on the “You’re Doing Better Than You Think” campaign, reaching 2.2 million New Yorkers with free Family Court help. Social media ads from the “You’re Doing Better Than You Think” campaign, created by WonderINgroup for Family Legal Care, used affirmation-led messages to connect New Yorkers with free Family Court help. Bilingual, plain-language pos ———————————————————————————————————————————————————————————— Derek Hui's Documentary Episode Revisits 400 Weddings: Fistfights, Black Eyes and What the Best Couples Had in Common 2026-10-22 · EIN Presswire · Internet & apps, Entertainment https://www.einpresswire.com/article/946266344/derek-hui-s-documentary-episode-revisits-400-weddings-fistfights-black-eyes-and-what-the-best-couples-had-in-common An episode revisits his 12 years as a wedding photographer and makes the case that "planning a wedding is planning your life." TOKYO, JAPAN, October 22, 2026 / EINPresswire.com / -- Derek Hui, the Canadian entrepreneur and creator documenting his life in Tokyo on YouTube, has taken viewers back to the start of his working life. In an episode published on 7 April, Hui looks back on the more than 400 weddings he says h ———————————————————————————————————————————————————————————— Outdoor Holding Company Increases Aggregate Share Repurchase Authorization to $35 Million and Extends Program Through July 4, 2027 2026-10-22 · GlobeNewswire · Finance, Investing & markets, Internet & apps https://www.globenewswire.com/news-release/2026/10/22/3386472/0/en/outdoor-holding-company-increases-aggregate-share-repurchase-authorization-to-35-million-and-extends-program-through-july-4-2027.html Dallas, Texas, Oct. 22, 2026 -- Outdoor Holding Company (Nasdaq: POWW, POWWP) (“OHC,” “we,” “us,” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace dedicated to firearms, hunting, shooting and related products, today announced that its Board of Directors (the “Board”) approved an amendment to the Company’s share repurchase program that increases the aggregate repurchase authorization from $15 million to $35 million and extends the program by six months, through July 4, 2027. The $35 million authorization includes all repurchases made since the program was launched in January 2026 and represents a $20 million increase over the prior authorization. ———————————————————————————————————————————————————————————— Goodbye, Pushy Salesperson: askpolly Data Signals the Era of Product-Led Sales In-Store 2026-10-22 · ACCESS Newswire · Internet & apps https://finance.yahoo.com/small-business/articles/goodbye-pushy-salesperson-askpolly-data-130000989.html Study of of 223,000+ shopper engagements reported on social media from a randomized, controlled sample finds demos, kiosks and smart store layout are doing the selling, and shoppers barely mention sales staff at all NEW YORK, NY / October 22, 2026 / Shoppers are no longer being sold to in stores, they ar ———————————————————————————————————————————————————————————— 10+ Paid Internships Available for Santa Cruz County Young Adults 2026-10-22 · Newsworthy.ai · AI, SaaS, Real estate, Automotive, Media, Education, Sustainability, Nonprofits, Jobs & workplace, Marketing & advertising, Software & IT, Internet & apps https://newsworthy.ai/news/202610223087/10-paid-internships-available-for-santa-cruz-county-young-adults Santa Cruz, CA Thursday Oct 22, 2026 @ 6:00 AM Pacific — Young adults across Santa Cruz County have a new opportunity to earn money, gain professional experience, and launch their careers. Santa Cruz Works, in partnership with Cabrillo College and the City of Santa Cruz, is offering more than 10 paid internship opportunities with local businesses and nonprofit organizations. The Affordable Housing and Sustainable Communities (AHSC) Internship Opportunity Program is designed for young adults, particularly those living in underserved communities. Participants will gain hands-on experience in fields including technology, marketing, media, sustainability, business operations, and community services. Unlike unpaid internships that can be financially out of reach for many young people, these positions offer wages, flexible schedules, professional mentorship, and valuable career connections. Real Jobs. Real Pay. Real Experience Interns will work approximately 10 to 20 hours per week for up to six months, depending on the position. Each participant will work alongside an experienced supervisor, contribute to meaningful projects, and develop practical skills that can lead to future employment. The program offers several important benefits: Paid employment: Earn wages while gaining valuable professional experience. Flexible schedules: Work 10 to 20 hours per week, allowing time for school and other commitments. Professional mentorship: Receive guidance and feedback from experienced professionals. Career development: Build a resume, develop workplace skills, and establish professional connections. Local opportunities: Work with businesses and organizations throughout Santa Cruz County. All internships must conclude by June 1, 2027. More Than 10 Local Organizations Offering Opportunities Participating organizations represent a diverse range of industries, offering young adults the chance to explore different career paths while contributing to their community. Organizations offering internship opportunities include: Clean Oceans International Coastwoods Real Estate / Legacy Property GeoPulse Solutions Inc. KRML Mission Hill Creamery People First of Santa Cruz Sarah Marschall Strategy Santa Cruz County Animal Shelter Foundation Santa Cruz Children's Museum of Discovery Tannery World Dance and Cultural Center Treeswax United Way of Santa Cruz County Positions and responsibilities vary by organization, providing opportunities for students and young adults with different interests, skills, and career goals. Who Is Eligible? The program is open to young adults 18 years and older who live in underserved communities in Santa Cruz County. Priority is given to residents of neighborhoods including Beach Flats, Lower Ocean, Live Oak, Watsonville, San Lorenzo Valley, and the Pajaro Valley. Applicants do not need extensive professional experience. The program is intended to help young people develop the skills, confidence, and connections necessary to enter the workforce. There is no cost to apply. From Internship to Career The program builds on the success of its first cohort, which placed young adults with local businesses and nonprofits. Previous participants gained experience in software engineering, marketing, communications, video production, and community outreach. Yuliana Morales-Galvan, a software engineering intern at Nurbli, helped improve digital tools supporting Indigenous families. Emily Ramirez developed social media and outreach skills at Clean Oceans International, while Elsa Tamayo gained marketing and communications experience at Siena House. These experiences demonstrate how a paid internship can provide more than a paycheck. Interns build confidence, develop professional relationships, and gain experience that strengthens future job and college applications. How to Apply Young adults interested in exploring available positions are encouraged to apply as soon as possible. To view internships and apply: Visit Santa Cruz Works - Paid Internship Opportunities. Cabrillo College students may also complete the Student Interest Form linked on the program webpage. Parents, teachers, counselors, community organizations, and youth mentors are encouraged to share these opportunities with eligible young adults. About the AHSC Internship Opportunity Program The Affordable Housing and Sustainable Communities Internship Opportunity Program is funded through a grant awarded to the City of Santa Cruz. The City has partnered with Santa Cruz Works to create paid employment opportunities that connect young adults from underserved communities with local employers. Launched in June 2025 in partnership with Digital NEST, the program expanded in its second cohort to include Cabrillo College as a workforce development partner. The initiative supports economic mobility, career readiness, and a stronger local workforce. About Santa Cruz Works Santa Cruz Works is a nonprofit organization dedicated to strengthening the economic vitality of Santa Cruz County and the greater Monterey Bay region. Through entrepreneurship programs, workforce development, industry partnerships, and community events, Santa Cruz Works connects businesses, educators, innovators, and emerging talent to create economic opportunity. Learn more at www.santacruzworks.org. About Cabrillo College Cabrillo College is a leading California community college serving Santa Cruz County and the greater Monterey Bay region. With campuses in Aptos and Watsonville, Cabrillo offers academic programs, career education, associate degrees, certificates, and pathways to four-year universities. As a major transfer pathway to UC Santa Cruz, Cabrillo plays a vital role in developing the region's workforce. Through hands-on learning, internships, and partnerships with local employers, Cabrillo connects education with real-world career opportunities while supporting economic mobility and regional prosperity. Learn more at www.cabrillo.edu. Media Contact Santa Cruz Works Email: Email Contact Website: www.santacruzworks.org ———————————————————————————————————————————————————————————— IBM and Scuderia Ferrari HP Expand AI-Powered Fan Experience Ahead of the United States Grand Prix 2026-10-22 · IBM · Finance, AI, Sports, Software & IT, Internet & apps https://newsroom.ibm.com/2026-10-22-ibm-and-scuderia-ferrari-hp-expand-ai-powered-fan-experience-ahead-of-the-united-states-grand-prix ARMONK, N.Y., October 22, 2026 – As Formula 1 returns to Austin’s Circuit of the Americas for this weekend’s United States Grand Prix, IBM (NYSE: IBM ) and Scuderia Ferrari HP are introducing new AI-powered features to the Scuderia Ferrari mobile app. Built using IBM Bob and IBM Consulting Advantage , the new and enhanced features offer even more ways for fans to engage with each other and the team they love, creatin ———————————————————————————————————————————————————————————— Air Canada App Named Best Airline App at 2026 World Aviation Festival 2026-10-22 · GlobeNewswire · Travel, Aerospace & defense, Internet & apps https://www.globenewswire.com/news-release/2026/10/22/3386424/0/en/air-canada-app-named-best-airline-app-at-2026-world-aviation-festival.html MONTRÉAL, Oct. 22, 2026 -- Air Canada's mobile app has been named Best Airline App at the 2026 World Aviation Festival in Lisbon, winning the Battle of the Airline Apps. A panel of industry judges compared three airline finalists and rated Air Canada's app the best. The judges highlighted the app's ability to bring together the full travel journey in a single experience, helping customers move seamlessly from booking to arrival with personalized, contextual information throughout their trip. ———————————————————————————————————————————————————————————— Cut the Rope Remastered 2026-10-22 · Games Press · Gaming, Internet & apps https://www.gamespress.com/Cut-the-Rope-Remastered-launches-on-December-3-2026-pre-register-now-f Pre-register right now for standalone premium release. The beloved physics-puzzle game is coming to Google Play and the App Store as a standalone premium release. Pre-registration is now open, with a special price of USD2.99 instead of USD3.99 . A classic returns, with a new twist First released in 2010, Cut the Rope became a landmark mobile puzzle game, introducing players to Om Nom, the candy-loving little monster... ———————————————————————————————————————————————————————————— MAGNA-TILES® RELEASES 'MAGNA-TALES,' THE FIRST-EVER ANIMATED CONTENT SERIES BASED ON AMERICA'S #1 MAGNETIC BUILDING SETS BRAND, BRINGING CREATIVITY, MEANINGFUL PLAY, AND ORIGINAL ADVENTURES TO KIDS EVERYWHERE 2026-10-22 · PR Newswire · Energy, Media, Internet & apps https://www.prnewswire.com/news-releases/magna-tiles-releases-magna-tales-the-first-ever-animated-content-series-based-on-americas-1-magnetic-building-sets-brand-bringing-creativity-meaningful-play-and-original-adventures-to-kids-everywhere-302916347.html Launching this October on YouTube, the high-energy animated series transforms beloved physical play into an imaginative, character-driven storytelling world for children and families BOLINGBROOK, Ill., Oct. 22, 2026 -- For nearly 30 years, MAGNA-TILES® has championed... ———————————————————————————————————————————————————————————— Gix Internet: Quantum X Labs Achieved Key Milestones with NVIDIA CUDA-Q Decoder and IBM Quantum Hardware 2026-10-22 · GlobeNewswire · Software & IT, Internet & apps https://www.globenewswire.com/news-release/2026/10/22/3386319/0/en/gix-internet-quantum-x-labs-achieved-key-milestones-with-nvidia-cuda-q-decoder-and-ibm-quantum-hardware.html Quantum X Labs’ QEC decoder delivers 12–13% fewer logical errors on NVIDIA CUDA-Q using Google hardware data; LayerQake reduces maximum cumulative error 15- to 21-fold and measurement bias to below 6% across three IBM quantum processors ———————————————————————————————————————————————————————————— Resemble AI Ad Study Finds 1 in 11 Ads on Meta Platforms Contain AI-Generated Media, Many Featuring UGC-Style “Reviews” 2026-10-22 · EIN Presswire · AI, SaaS, Marketing & advertising, Internet & apps https://www.einpresswire.com/article/951278611/resemble-ai-ad-study-finds-1-in-11-ads-on-meta-platforms-contain-ai-generated-media-many-featuring-ugc-style-reviews Resemble AI Synthetic Ad Report Resemble AI logo Study of 37,768 ads from 509 brands: 57% have run AI-generated ads, 70% of fake images were built to pass as real, and only 0.06% disclosed AI use MOUNTAIN VIEW, CA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Resemble AI, the generative AI security platform, today released the 2026 Synthetic Advertising Report , the first large-scale, independent audit of ———————————————————————————————————————————————————————————— UAE leads landmark global operation with 30 countries and leading technology companies against AI-powered fraud networks 2026-10-22 · PR Newswire · AI, Payments & fintech, Government & policy, Internet & apps https://www.prnewswire.com/news-releases/uae-leads-landmark-global-operation-with-30-countries-and-leading-technology-companies-against-ai-powered-fraud-networks-302916914.html Operation Confrontation Ghost brings together INTERPOL, Meta, TikTok, Mastercard, Huawei, and other partners together in a united front against cross-border scam networks and sextortion. VIENNA, Oct. 22, 2026 -- Under the leadership of the United Arab Emirates Ministry of... ———————————————————————————————————————————————————————————— 85% of Marketers Measure ROI, but Only 32% Track It Across Traditional and Digital Mediav 2026-10-22 · EIN Presswire · Retail, Marketing & advertising, Internet & apps https://www.einpresswire.com/article/951440713/85-of-marketers-measure-roi-but-only-32-track-it-across-traditional-and-digital-mediav Trackier PR Banner 85% of marketers measure ROI, but only 32% track it across traditional and digital channels. Discover why e-commerce brands need better attribution. NEW DELHI, DELHI, INDIA, October 22, 2026 / EINPresswire.com / -- E-commerce marketing teams operate through paid search, social media, affiliate networks, display advertising, and e-mail channels. Each channel generates performance data, but consolida ———————————————————————————————————————————————————————————— How Africa can turn energy investment into lasting economic value (By Grant Villet) 2026-10-22 · APO Group · SaaS, Energy, Telecom, Industrial, Logistics, Sustainability, Government & policy, Jobs & workplace, Internet & apps, Construction & engineering, Mining & metals, Oil & gas https://www.africa-newsroom.com/press/how-africa-can-turn-energy-investment-into-lasting-economic-value-?lang=en By Grant Villet, Business Development and Integration Executive, Aurex Constructors (www.Aurex.com). Africa’s energy story is often around gas discoveries and investment potential. However, the real opportunity extends far beyond the resource itself. Mozambique and Namibia are emerging as important players in Africa’s oil and gas landscape, and what makes these markets particularly exciting is not simply the scale of their energy resources. It is the potential for major energy developments to become platforms for broader economic transformation. The question we should be asking is not only how we develop these resources, but what we build around them and what remains when the project itself is complete. The opportunity extends far beyond the oil and gas facility In Mozambique, the scale of gas discoveries has already attracted global investment and created momentum for infrastructure development. Namibia is generating similar interest through its offshore discoveries. These developments create demand for far more than the facilities required to produce or handle gas. They require ports, roads, logistics networks, power infrastructure, telecommunications and accommodation facilities. They also require a skilled workforce comprising artisans, supervisors, engineers and project managers, supported by the technical and operational expertise needed to deliver large-scale projects. Local suppliers capable of meeting international standards for safety, quality and delivery are equally important. This supporting ecosystem is critical because it is where much of the broader economic opportunity lies. If the ecosystem develops alongside the project, local businesses can participate meaningfully and the benefits can extend throughout the economy. Energy investment can then build demand and capability across multiple sectors rather than remaining concentrated within the project itself. For Southern Africa, this creates an even greater opportunity. Developments in Mozambique and Namibia could strengthen regional supply chains and create opportunities through improved energy security for businesses across multiple countries. The real value lies in recognising these projects as platforms for broader economic growth rather than simply as energy-producing assets. A successful project leaves a legacy For me, success in a major infrastructure project cannot be measured only by whether a facility is completed on time and on budget. Those things are obviously important, but they are only part of the story. The projects that leave the biggest impact are those that develop people and strengthen local businesses creating lasting economic benefits long after construction has finished. That requires something that is sometimes harder to quantify, namely trust. Major energy developments bring together governments, international operators, contractors, local suppliers and communities. These relationships can become complicated, particularly in complex operating environments, but our experience has shown that projects perform better when relationships are built on transparency and shared goals. Problems are solved faster. Decisions can be made more effectively. Stakeholders remain focused on the bigger picture rather than becoming trapped in competing interests. Ultimately, the most successful projects create enduring economic and social value alongside the infrastructure they deliver. Local capability cannot be an afterthought There is often significant attention on the investment and jobs generated by major energy projects. Those benefits matter, but they should be viewed as part of a much longer-term process. If local participation and skills development are treated as box-ticking exercises, the benefits will inevitably be limited. For local economic participation to become transformational, it must be intentional. Governments, operators and contractors need to genuinely invest in building sustainable local capacity. That means creating opportunities for local companies to grow, investing in training programmes and providing pathways for people to develop technical expertise that remains with them long after a project has been completed. The measure of success should extend well beyond the construction phase. Five or ten years down the line, are local businesses stronger? Are local professionals more experienced? Has technical expertise been developed that can be applied to future projects? Is the economy better positioned to take advantage of the next opportunity? If the answer to those questions is yes, then real value has been created. Lessons from complex operating environments Our experience in Mozambique and Namibia has reinforced another important lesson in that technical capability alone does not guarantee success. Every major project has its own challenges, whether they are logistical, regulatory or operational. Understanding the local environment, building strong relationships and remaining adaptable are therefore essential. We have also seen the value of engaging local businesses early and investing in local partnerships. Early investment in local partnerships and skills development generally delivers stronger long-term outcomes. This is particularly important when projects are being delivered in remote or developing regions, where resilient supply chains require careful planning and strong collaboration between stakeholders. These lessons extend well beyond Mozambique and Namibia. They are relevant to energy and infrastructure projects across the continent. Collaboration works best when it starts early The complexity of major energy developments means that no single organisation can deliver their full potential in isolation. Governments, international companies, engineering and construction firms, African contractors and local suppliers all have roles to play. Collaboration succeeds when there is early engagement, clear communication and mutual respect between stakeholders. Where challenges tend to arise is when stakeholders operate in silos or when local companies are brought into the conversation too late. Misaligned expectations can quickly create friction and undermine the potential of the wider project. The most successful projects recognise the complementary strengths that different participants bring. International companies can contribute technology, experience and investment. Local businesses bring valuable market knowledge, established relationships and an understanding of local operating conditions. When those strengths are combined effectively, everyone benefits. This is why local participation should be regarded as a strategic advantage rather than a compliance requirement. It should be understood as a source of capability, and knowledge  that can make the project itself stronger. Oil and gas and the wider question of energy security As industrial and economic demand grows, oil and gas also has an important role to play in Southern Africa’s energy future. Countries need reliable energy sources to support economic growth and industrial development and address energy security challenges while supporting sectors such as manufacturing, mining and heavy industry. Importantly, oil and gas does not have to be viewed in opposition to renewable energy. It can form part of a balanced energy mix as countries develop the reliable energy systems required to support growing economies. There is also a broader regional opportunity. Major energy developments can help connect infrastructure, supply chains and markets across national borders. In doing so, they can create stronger economic linkages and support greater regional integration. The opportunity extends beyond energy production to building more connected economies, stronger supply chains and greater regional growth. Africa’s biggest opportunity and risk Looking beyond individual oil and gas developments, I believe Africa has a unique opportunity to use its natural resources as a foundation for industrialisation, job creation and the development of globally competitive industries. However, that opportunity comes with a significant risk. We could focus too heavily on extracting resources without building the skills, infrastructure and industries needed to maximise their long-term value. Natural resources alone do not create prosperity. What matters is how effectively those resources are translated into economic development and sustainable business growth. That requires a different way of thinking about major energy projects. The oil and gas facility is not the end point. It is one component of a much larger economic system. Ports, roads, logistics, telecommunications, power infrastructure, accommodation, skills, local suppliers and resilient supply chains all form part of the picture. So do the relationships between governments, international companies, contractors, communities and local businesses. If these elements are developed deliberately and in parallel, the impact of an energy project can extend far beyond the project itself. Mozambique and Namibia demonstrate the scale of the opportunity. Their energy developments have the potential to strengthen regional supply chains, improve energy security, support industrial development and create opportunities that extend across borders. The challenge and the opportunity is to ensure that Africa captures that wider value. If we can balance resource development and capability development, support international investment while strengthening local participation, and connect individual projects to broader regional growth, energy investment can become much more than an export opportunity. It can become a foundation for lasting economic transformation. And that is when Africa’s natural resources can truly become an engine for the continent’s future. Distributed by APO Group on behalf of Aurex Constructors. Aurex Constructors Contact: lauryn.joseph@aurex.com Media Contact: thobile@ngage.co.za Connect with Aurex Constructors on Social Media to receive the company’s latest news: https://apo-opa.co/4z5jnw3 https://apo-opa.co/4iaL4Mr About Aurex Constructors: As a 100% South African owned and managed company with 51% black ownership, Aurex takes pride in its highly skilled workforce, which has a proven track record of delivering innovative and customised project management solutions tailored to the specific requirements of customers. Aurex Constructors is dedicated to fostering growth and sustainability in the regions it serves. We strive for excellence. Web: www.Aurex.com ———————————————————————————————————————————————————————————— NigerianSMM Panel Streamlines Multiple Client Order Management for Social Media Agencies in Nigeria 2026-10-22 · MarketersMEDIA · SaaS, Internet & apps https://news.marketersmedia.com/nigeriansmm-panel-streamlines-multiple-client-order-management-for-social-media-agencies-in-nigeria/89206977 -- As social media agencies in Nigeria manage increasingly diverse client portfolios, coordinating service purchases, campaign budgets, and delivery schedules has become an important part of daily operations. NigerianSMMPanel provides a centralised platform for agencies to browse social media services, place orders, and monitor their progress across multiple client accounts. Agencies frequently handle different servi ———————————————————————————————————————————————————————————— Virtual Kidnapping Enters the AI Era: When a Familiar Voice Becomes a Ransom Demand 2026-10-22 · Business Wire · AI, Internet & apps https://finance.yahoo.com/technology/ai/articles/virtual-kidnapping-enters-ai-era-100100614.html A simple family verification plan can help people spot AI-powered impersonation scams before sending money LOS ANGELES & ROAD TOWN, British Virgin Islands, October 22, 2026--A familiar voice pleading for help can make a fabricated emergency feel real. The FBI's 2025 Internet Crime Report records more t ———————————————————————————————————————————————————————————— Nexconn Launches Free Chat Plan for Up to 10,000 MAU With Full Pro Features and Additional Cloud Discounts 2026-10-22 · ACCESS Newswire · SaaS, Payments & fintech, Cloud & data centers, Internet & apps https://finance.yahoo.com/technology/articles/nexconn-launches-free-chat-plan-094500640.html Production-grade in-app messaging with no credit card required to start, plus an optional Cloud Bonus offering your choice of either 15% off AWS or 30% off Alibaba Cloud SINGAPORE, SG / October 22, 2026 / Nexconn , a global cloud communications platform, announced the launch of its production-ready Free Chat Plan. Under the new initiative, developers and startups can deploy enterprise-grade chat inf ———————————————————————————————————————————————————————————— Zhipu, Jiangmen, QuantGroup and Other Investors Join Forces to Back RMB 1 Billion Cognitive Intelligence Venture Capital Fund for Physical AI Ecosystem Development 2026-10-22 · ACN Newswire · Finance, AI, Energy, Retail, Automotive, Food & drink, Industrial, Investing & markets, Government & policy, Internet & apps, Oil & gas https://www.acnnewswire.com/press-release/english/110993/ Hong Kong, Oct 22, 2026 - Competition in AI has evolved from contests over individual technologies into a new phase defined by coordination across foundational ecosystems and industry value chains. Zhipu, a leading large-model developer, has again expanded its footprint as a limited partner (LP) in the primary market by teaming up with Jiangmen Ventures to establish a cognitive intelligence venture capital fund. QuantGroup (02685.HK), a provider of world foundation models for Physical AI, is among the fund's LPs. Corporate registration records show that Zhejiang Zhipu Jiangmen Cognitive Intelligence Venture Capital Partnership (Limited Partnership) was incorporated in Shangcheng District, Hangzhou, on 24 September with total subscribed capital of RMB 1 billion. Its business scope covers venture capital, limited to investments in unlisted companies. The fund combines local state-owned capital, industrial investors and specialist investment firms. Two local government-backed limited partners, Hangzhou Shangcheng Linghang Venture Capital Co., Ltd. and Hangzhou Urban Investment Industry Development Investment Partnership (Limited Partnership), hold a combined 60% interest. The other partners are Zhejiang Zhipu Xinpian Technology Co., Ltd., an affiliate of Zhipu; Hainan QuantGroup Technology Co., Ltd., an affiliate of Hong Kong-listed QuantGroup (02685.HK); Hainan Hezun Investment Co., Ltd.; and Hangzhou Jizhi Enterprise Management Consulting Co., Ltd. The latter also serves as the fund's executive partner, and its appointed representative is Du Feng, a founding partner of Jiangmen Ventures. The deadline for partners to pay in their subscribed capital is September 2031. Industry observers generally expect that collaboration among leading companies raises the success rate of ecosystem-building, reinforcing a Matthew effect in which the strong become stronger. Companies that are first to form ecosystem alliances can secure early access to downstream use cases and early-stage projects. Zhipu has pursued precisely this approach. In 2025, it partnered with Unilumin Group (300232.SZ), a leader in optoelectronic smart display technology, and MetaView to establish Shenzhen Zhixian Robot Technology Co., Ltd., building an innovation ecosystem for AI-powered smart terminals. In the energy sector, iFlytek worked with PetroChina, China Mobile and Huawei to develop the Kunlun large model,  helping PetroChina set a new benchmark for AI in energy. QuantGroup's presence among the LPs has attracted considerable attention. As Hong Kong's first listed "intelligent species" company, QuantGroup positions itself as a provider of world foundation models for Physical AI. It has pursued a two-pillar strategy combining AI-enabled e-commerce solutions with Physical AI, using cash flow from its established consumer business to fund frontier R&D. For infrastructure providers, ecosystem building is a core capability: connecting upstream model developers, midstream embodied-robotics developers, downstream use cases and capital providers to secure a central position in the Physical AI ecosystem during its early development. At the ecosystem level, QuantGroup works with partners including ByteDance's Volcengine, Beijing Ruihong Embodied Intelligence Robot Technology Co., Ltd., an affiliate of Tungkong Inc. (002117.SZ), and Chewujie to build an embodied AI ecosystem. This has extended its commercial reach from restaurant kitchens to brick-and-mortar venues such as car showrooms. Its role as an LP in the cognitive intelligence fund established by Zhipu and Jiangmen Ventures marks another step toward moving upstream in the Physical AI value chain and gaining earlier access to large-model capabilities and early-stage projects. Building an ecosystem with the first publicly listed large-model company naturally improves the odds of success, as the two sides can combine their strengths, complement one another and develop benchmark industry solutions quickly. Zhipu (02513.HK) listed on the Hong Kong Stock Exchange on 8 January, becoming the world's first publicly listed large-model company. In May, Beijing Zhipu Future Technology Co., Ltd., a wholly owned subsidiary of Zhipu, and Guotai Junan Innovation Investment Co., Ltd., a wholly owned subsidiary of Guotai Haitong, jointly established an RMB 540 million AI industry fund in Zhangjiang, Shanghai. Earlier, in 2024, Zhipu led the establishment of the Z Fund (LinkX Capital), an AGI ecosystem fund with RMB 1.5 billion of assets under management at its first close. According to Zhipu's 2025 financial report, LinkX Capital (Z Fund) had an aggregate value of RMB 1.3027 billion at the end of 2025 and had invested in more than 30 AI companies. Jiangmen Ventures, which is partnering with Zhipu on the new fund, is an early-stage venture capital firm focused on discovering technology-driven start-ups. It primarily invests in foundational AI technologies and their industrial applications, and was one of Zhipu's Series A investors. The two organizations have a long-standing relationship. The "cognitive intelligence" in the fund's name aligns with Zhipu's large-model technology roadmap. The fund's location in Hangzhou also builds on Zhipu's ties with the city. In March 2025, Zhipu raised more than RMB 1 billion in strategic financing, with participation from Hangzhou municipal state-owned investors including Hangzhou City Investment Industrial Fund and Shangcheng Capital. Venture capital professionals note that, for companies expanding into Physical AI, investing as an LP in an industry fund led by a leading large-model company can generate financial returns and provide early access to upstream model capabilities and early-stage projects. As large-model competition shifts from pure performance to ecosystem strength, more industrial companies are entering the primary market as investors. ———————————————————————————————————————————————————————————— AgeReverse RESURGE Now Available on OneLavi.com 2026-10-22 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Food & drink, Sports, Biotech & pharma, Marketing & advertising, Internet & apps, Consumer goods https://newsworthy.ai/news/202610223065/agereverse-resurge-now-available-on-onelavicom Boca Raton, Florida Thursday Oct 22, 2026 @ 5:00 AM Eastern — AgeReverse, a Canadian longevity company focused on healthy aging and cellular vitality, today announced that its flagship RESURGE formulation is now available to U.S. consumers through OneLavi.com, marking another milestone in the company's expanding U.S. retail presence. The One Lavi launch follows the recent availability of RESURGE on Amazon and reflects AgeReverse's strategy to build a broader U.S. distribution network through multiple retail and e-commerce channels. "Expanding our availability through OneLavi is another important step in introducing AgeReverse to more consumers across the United States," said Kubi Turkmen, Founder and CEO of AgeReverse. "Our goal is to make RESURGE accessible through established retail destinations while continuing to build awareness of our comprehensive approach to healthy aging." AgeReverse developed RESURGE around the scientific framework of the 12 Hallmarks of Aging, which describes interconnected biological processes associated with aging. Rather than emphasizing a single ingredient or isolated wellness benefit, the company designed its flagship formulation to bring together multiple ingredients in a simplified daily regimen. The 90-capsule RESURGE formulation includes NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract and Noni Berry. Key features of RESURGE include: Developed around the scientific concept of the 12 Hallmarks of Aging Combines multiple ingredients associated with antioxidant support and everyday wellness Supports nutrient metabolism, cardiovascular health and immune function Helps support collagen formation, connective tissue development and joint health Simplifies what the company describes as 12 or more individual products and 15 or more capsules per day into a three-capsule daily regimen Manufactured in GMP-certified facilities in Ontario, Canada using vegan capsules Registered as a Natural Health Product with Health Canada under NPN 80130202 The expansion onto OneLavi comes as AgeReverse continues developing its presence in the U.S. longevity and healthy aging market. The company recently participated in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where it introduced RESURGE and its broader product strategy during scheduled meetings with retail buyers across health, specialty, food, drug and mass retail channels. Beyond RESURGE, AgeReverse is developing a range of products focused on both internal wellness and external skin aging. Its broader plans include biological age testing, daily skincare, professional aesthetic formulations and non-invasive mesotherapy technology. "Our long-term strategy is about more than a single product or sales channel," Turkmen added. "We are building a complete range of healthy aging solutions while expanding the ways consumers can access the AgeReverse brand." The OneLavi availability represents another step in that strategy, complementing the company's existing Amazon presence and its ongoing efforts to develop additional U.S. retail relationships. RESURGE is now available on OneLavi.com and Amazon. Visit the AgeReverse Website and follow the company on Instagram and LinkedIn. About AgeReverse AgeReverse is a Canada-based longevity wellness company focused on developing science-driven products designed to support healthy aging and cellular vitality. Founded by Kubi Turkmen, who has more than 30 years of experience in anti-aging innovation, the company’s approach combines longevity research, telomere science, and wellness innovation to create comprehensive healthy aging solutions. The company’s expanding AgeReverse platform includes longevity supplements and other wellness technologies designed to support multiple biological pathways associated with aging and long-term vitality. Products are manufactured in GMP-certified facilities in Ontario, Canada. Learn more at the company’s website.  FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— Curiosity Is Her Niche: Alex Cabni Builds a Brand 2026-10-22 · MarketersMEDIA · Media, Travel, Marketing & advertising, Internet & apps https://news.marketersmedia.com/curiosity-is-her-niche-alex-cabni-builds-a-brand/89206934 Content creator Alex Cabni announces a personal brand built around curiosity rather than a single content niche, spanning travel and adventure. -- Alex Cabni, a Mexican content creator and marketing professional based in Guadalajara, has announced the continued expansion of a personal brand built on a single guiding principle: curiosity. Rather than following the long-standing advice that creators must select one sub ———————————————————————————————————————————————————————————— Upscayl Expands Image Upscaling Workflow for Product Photos and Digital Content 2026-10-22 · 24-7 Press Release · Retail, Media, Internet & apps https://www.24-7pressrelease.com/press-release/539805/upscayl-expands-image-upscaling-workflow-for-product-photos-and-digital-content The online tool helps ecommerce teams, designers and content creators prepare clearer product photos, campaign assets and social visuals from low-resolution source images. ———————————————————————————————————————————————————————————— Live Audio Streaming Market Growth Opportunities and Forecast by 2031 2026-10-22 · PR News Releaser · Media, Internet & apps, Entertainment https://www.prnewsreleaser.com/news/475838 The global live audio streaming market is experiencing significant growth as consumers, businesses, and content creators increasingly adopt digital platforms for real-time audio communication and entertainment. Live audio streaming enables users to broadcast and listen to audio content over the ... Read more ———————————————————————————————————————————————————————————— Proxibid Named Exclusive Third-Party Marketplace Partner for Jeff Martin Auctioneers 2026-10-22 · EIN Presswire · Internet & apps https://www.einpresswire.com/article/951323813/proxibid-named-exclusive-third-party-marketplace-partner-for-jeff-martin-auctioneers The agreement reflects JMA’s confidence in Proxibid’s buyer network, auction technology, and longstanding experience supporting equipment auctions. Auction Technology Group (LSE:ATG) NEW YORK, NY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Proxibid, a leading online marketplace for live and timed auctions and part of Auction Technology Group (ATG), today announced an expanded strategic partnership with J ———————————————————————————————————————————————————————————— GoUp Social Team Issues Guidance on Content Strategy Amid Changes to Social Media Recommendations 2026-10-22 · MarketersMEDIA · Media, Internet & apps https://news.marketersmedia.com/goup-social-team-issues-guidance-on-content-strategy-amid-changes-to-social-media-recommendations/89206841 Following changes to Instagram's originality recommendations and Facebook's audience controls, GoUp Social Team urges businesses to review their social content creation and distribution practices. -- TURKEY – October 19, 2026 – GoUp Social Team has issued guidance encouraging businesses and creators to reconsider social media content strategies following changes to recommendation systems at Instagram and Facebook. Th ———————————————————————————————————————————————————————————— PHP2Shell: GitLab helps find and remediate critical PHP flaws 2026-10-22 · GitLab · AI, SaaS, Cybersecurity, Jobs & workplace, Marketing & advertising, Software & IT, Cloud & data centers, Internet & apps https://about.gitlab.com/blog/gitlab-helps-remediate-critical-php-flaws/ GitLab is not affected by PHP2Shell (CVE-2026-109618 and CVE-2026-109619). The GitLab application is not written in PHP and does not run it to serve web requests, and our Security team has found no evidence of impact to GitLab-managed infrastructure. GitLab.com, GitLab Self-Managed, and GitLab Dedicated are not impacted. PHP is a widely used programming language that runs on web servers and powers popular platforms like WordPress, Drupal, and Magento, so a flaw in PHP itself can affect many websites and applications. On October 21, 2026, the PHP project fixed two critical remote code execution flaws in PHP, together known as PHP2Shell (CVE-2026-109618 and CVE-2026-109619). PHP rates both 9.2 on CVSS v4.0. The flaws are in the PHP engine, not in any framework, library, or application code, so there is no application-level fix. Any web server that runs PHP is affected, including NGINX and Apache. The PHP project confirmed the vulnerability on Apache with mod_php, where an unauthenticated request can achieve remote code execution before any application code runs. Upgrade every server and container that runs PHP to serve web requests to PHP 8.5.12, 8.4.27, 8.3.36, or 8.2.35, or to your distribution’s patched package now. This guide is for security and platform teams with PHP projects on GitLab. It covers the fixed version for each PHP branch and distribution, how to use GitLab features to locate PHP projects across your groups, how to track remediation, and how to check for signs of compromise. Upgrade PHP to a fixed version now Upgrade the PHP runtime on every host and in every container image to a fixed version. Framework updates, Composer updates, input validation, and authentication don’t help, because PHP handles the request before application code runs. BranchFixed in PHP 8.5.x8.5.12 PHP 8.4.x8.4.27 PHP 8.3.x8.3.36 PHP 8.2.x8.2.35 (end of life December 31, 2026) PHP 8.6 release candidates8.6.0RC4. The official php:8.6-rc image was still on RC3 on October 21, and RC3 does not have the fix. PHP 8.1 and olderNo official release. PHP published minimal source backports for 7.4, 8.0, and 8.1, and some distributions ship patched packages. If your PHP comes from a distribution package, upgrade that package. Fixed package versions as of October 22: DistributionFixed package Ubuntu 26.04php8.5 8.5.4-0ubuntu1.5 Ubuntu 24.04php8.3 8.3.6-0ubuntu0.24.04.13 Ubuntu 22.04php8.1 8.1.2-1ubuntu2.28 Debian 13php8.4 8.4.27-1~deb13u1 Debian 12php8.2 8.2.35-1~deb12u1 Alpine 3.24php83 8.3.36, php84 8.4.27, php85 8.5.12 RHEL 10php 8.3.36-1.el10_2 (RHSA-2026:87070), php8.4 8.4.27-1.el10_2 (RHSA-2026:87071) RHEL 9php 8.0.30-8.el9_8.1 (RHSA-2026:87151), php:8.2 8.2.35-1 (RHSA-2026:87072), php:8.3 8.3.36-1 (RHSA-2026:87079); php:8.4 had no fix yet on October 22 RHEL 8php:7.4 7.4.33-8 (RHSA-2026:87080); check Red Hat’s CVE pages for php:8.2. Retired streams (7.2, 7.3, 8.0) get no fix Sources: Ubuntu, Debian, Alpine, and Red Hat security trackers, as of October 22, 2026. Ubuntu, and Red Hat for its 7.4 and 8.0 packages, keep the old upstream version number and backport the fix. Compare the package versions rather than php -v. Restart every process that runs PHP after upgrading. Rebuild your container images. If your image uses a floating tag of the official php image, such as php:8, php:8.3, php:8.3-apache or php:latest, rebuild it with docker build --pull and redeploy it. Images that pin a patch version, such as php:8.3.35-apache, need the tag changed to the fixed version first. Images built on derivatives such as wordpress or drupal get the fix only after their maintainers publish an updated image, so check the upstream image before you rebuild. Locate PHP projects across your GitLab groups Any project that runs PHP to serve web requests needs a fixed version, including the ones that are easy to forget, such as an internal dashboard, a marketing site, or a CI job image. Finding them takes two views: a static search of what your repositories declare and your images contain, and a runtime inventory of what actually runs. GitLab covers the static view with two features. Use both, in this order. 1. Container scanning Container scanning reports vulnerabilities in operating system packages, so it finds PHP installed with apt, apk, or dnf, and it reports the two CVEs once they reach the scanner’s vulnerability database. To turn it on for a project, add the template to .gitlab-ci.yml: include: - template: Security/Container-Scanning.gitlab-ci.yml You can also use a group-level scan execution policy to turn container scanning on for every project in a group at once. When a policy is enabled, the next time a pipeline is run, it will be run with container scanning. Container scanning results for the default branch can be reviewed in the Vulnerability Report after the scanner completes. Additionally, you can set up Merge Request Approval policies with container scanning. With merge request approvals in play, if a code change contains PHP2Shell, the policy will block a merge without approval from the selected parties. Container scanning detects only PHP installed as a package. PHP compiled from source, including the official php images, has no package record, so a project can pass container scanning and still run a vulnerable PHP. Code search covers that gap. 2. Code search Exact code search can find the two types of files that indicate a PHP project. Run these at the top-level group with regular expression mode enabled (the .* toggle at the right of the search box): Container base images: This query searches for every file GitLab detects as a Dockerfile. The pattern matches any image whose name or tag contains php, so it also finds derivatives such as wordpress, frankenphp, or bitnami/php-fpm. Expect a few false positives that you can rule out by reading the result: lang:Dockerfile ^FROM.*php Composer projects: This query finds projects that use PHP even when they have no Dockerfile, or when the Dockerfile takes its image from a build argument such as FROM $BASE_IMAGE: file:composer\.json$ Exact code search covers the default branch only. On GitLab.com it is on by default for paid plans. On GitLab Self-Managed instances an administrator must install Zoekt first. GitLab Dedicated doesn’t support exact code search. For each result, confirm the version. You can check the FROM php: line, or run php -v in the running container, and compare it with the table above. The group dependency list shows Composer packages and framework versions but not the PHP runtime version. 3. Compare with your runtime inventory Container scanning and code search show what your projects declare and build, not what runs. PHP can run outside your GitLab projects, for example on web servers with mod_php or PHP-FPM enabled only in their configuration, on hosts configured by hand, or in containers that still run in clusters without an active pipeline. Compare the static results with an inventory of your running workloads from your configuration management (Ansible, Puppet, Chef, etc.), cloud, or VM inventory tools. For Kubernetes, operational container scanning scans the images that run in your clusters, with the same package-only detection as container scanning. Treat every PHP runtime that appears in only one of the two views as a gap to investigate. Remediate at scale with GitLab Duo Agent Platform Start with asking GitLab Duo Agentic Chat to: collect every container scanning finding for CVE-2026-109618 and CVE-2026-109619 across the group from the vulnerability report (requires an Ultimate subscription) run the code search queries above across the group, review each hit and read the PHP version from the Dockerfile or the Composer files open a merge request per affected project that bumps the base image tag or the package to the fixed version, and assign it to the right maintainer track the whole effort in an epic with one issue per project, and is closed when the fixed version is deployed and confirmed From each issue, the Developer Flow can open a merge request that updates the base image tag or package to a fixed version. Turn on automatic reviews with the Code Review Flow to get a first review that follows your custom review instructions. Review and merge each merge request, then close the issue once the fixed version is deployed. Searches find candidates, but a security or platform engineer still has to review each match, resolve CI includes, and tell what the code declares apart from what actually runs. An example agent skill from the GitLab Developer Advocacy team handles this work. It runs on GitLab Duo Agent Platform and with agents that use GitLab MCP server or the glab CLI, such as Claude Code, Codex, and Cursor. The skill checks container images, CI jobs, OS packages, configuration management variables, Composer pins, and environments. It returns a cited findings table with deployment evidence, and open gaps. The skill is read-only: It makes no changes, and remediation merge requests remain a separate, reviewed step. It cannot confirm what is running on hosts it cannot access, so verify those directly. Adapt the skill to your own environment before you use it. Check for compromise Reports of exploitation differ. Security researchers reported an exploit attempt on October 17, 2026, before public disclosure, and further reports of exploitation followed the release. The PHP project identified no functional exploits at the time of release. If an internet-facing server ran a vulnerable PHP version, review its logs from October 17, 2026, onward for: Multipart requests followed by memory-limit errors or repeated HTTP 500 responses Unusually large or malformed PHPSESSID response cookies Unexplained PHP worker restarts, or shell processes started by PHP workers Unexpected files on the PHP web server, outbound connections from PHP workers, or unexpected cron entries A successful exploit can return HTTP 200 and leave the worker running, so an absence of errors doesn’t rule out compromise. If you find signs of exploitation, isolate the server and start an incident investigation. Where possible, capture memory, disk, and logs before patching and restarting. Restarting PHP workers may erase evidence. CVE-2026-109619 can also expose process memory, even when an attacker doesn’t achieve code execution. Rotate any credentials, tokens, or keys the PHP process could read. Note: Scanners may flag the Gemnasium dependency scanning image (gemnasium:6), deprecated since GitLab 17.9, for its bundled PHP. It is used only as a command-line tool and never handles HTTP requests, so it is not exploitable, and a fixed version has already shipped under the same tag. Timeline DateWhat happened August 1Calif discovers the first flaw during an AI-assisted PHP audit and reports it to PHP on August 11; Wiz Research independently finds and reports the flaws on August 24. October 17Amazon’s honeypots record the first known exploit attempt, while the flaws are still under embargo. October 20PHP announces that a security release fixing two critical vulnerabilities will ship on October 21. October 20Vulnerability details leak before coordinated disclosure. (Huntress) October 21, 14:00 UTCPHP releases 8.5.12, 8.4.27, 8.3.36 and 8.2.35 and publishes the advisories. html .default .shiki span {color: var(--shiki-default);background: var(--shiki-default-bg);font-style: var(--shiki-default-font-style);font-weight: var(--shiki-default-font-weight);text-decoration: var(--shiki-default-text-decoration);}html .shiki span {color: var(--shiki-default);background: var(--shiki-default-bg);font-style: var(--shiki-default-font-style);font-weight: var(--shiki-default-font-weight);text-decoration: var(--shiki-default-text-decoration);} ———————————————————————————————————————————————————————————— Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027 2026-10-22 · ACN Newswire · Finance, Healthcare, Food & drink, Industrial, Biotech & pharma, Legal, Nonprofits, Internet & apps https://www.acnnewswire.com/press-release/english/110981/ Mountain View, CA, 21 Oct, 2026 - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/unicycive-therapeutics. "We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor's facility was last inspected by the FDA in March 2024 and received 'No Action Indicated' status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia." The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline. The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review. The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA. The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC's preclinical or clinical data, including safety data, included in the original NDA submission. About Oxylanthanum Carbonate OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035. About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.[1] Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream. [1] Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com. Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive's clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive's dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Contacts: Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com Media Contact: Unicycive Therapeutics, media@unicycive.com Additional Contact: David Shapiro, B2i Digital, Inc., +1 212-579-4844, david@b2idigital.com B2i Digital Social Media: LinkedIn X Facebook Instagram YouTube TikTok Stocktwits Reddit Pinterest Threads To learn more about the B2i Digital Media Network, visit:  https://b2idigital.com/media-network SOURCE: Unicycive Therapeutics, Inc. ———————————————————————————————————————————————————————————— TikTok Shop Announces Black Friday and Cyber Monday Campaign Running November 11–30 2026-10-20 · MarketersMEDIA · Internet & apps https://news.marketersmedia.com/tiktok-shop-announces-black-friday-and-cyber-monday-campaign-running-november-11-30/89206780 New trends, brands and shopping experiences happening only on TikTok Shop will define this holiday season -- TikTok Shop will bring back its Black Friday and Cyber Monday campaign from November 11 to November 30, bringing together brands, creators and shoppers for one of the biggest shopping moments of the year. This holiday season, shoppers can discover a wider selection of products from emerging sellers and major b ———————————————————————————————————————————————————————————— FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer 2026-10-09 · Roche · Healthcare, Automotive, Food & drink, Biotech & pharma, Jobs & workplace, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-09 FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone1 First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years2,3 Approval marks the twelfth indication for Tecentriq in the US Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. This approval marks the twelfth indication for Tecentriq in the US. “This approval provides a new adjuvant treatment option for people with stage III dMMR colon cancer who face a high risk of disease recurrence,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Tecentriq combined with chemotherapy has the potential to become the new standard of care as the first approved immunotherapy-based regimen for this setting.” “Until now, the adjuvant standard of care for stage III colon cancer has not differed based on mismatch repair status,” said Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator for the Alliance ATOMIC trial. “This milestone represents an important therapeutic advance that leverages immunotherapy to target the specific biology of dMMR stage III colon cancer after surgical resection. By reducing the risk of disease recurrence or death by 50%, atezolizumab plus chemotherapy is a practice-changing regimen that can improve clinical outcomes of this group of patients living with colon cancer, one of the most common cancers and a leading cause of cancer-related death.” The FDA approval is based on the landmark phase III ATOMIC study, recently published in The New England Journal of Medicine. ATOMIC demonstrated that adding Tecentriq to modified (m)FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50%, compared to chemotherapy alone for people with stage III dMMR colon cancer, as determined by an immunohistochemistry test, such as the VENTANA® MMR RxDx Panel.1 The 36-month disease-free survival was 86% for Tecentriq combined with mFOLFOX6 compared with 76% in the mFOLFOX6 alone group. The safety profile was consistent with previous studies of Tecentriq and mFOLFOX6.1 Colon cancer remains one of the world's most common and deadliest tumours.4 Over one million people are diagnosed globally each year, and nearly 25% of all colon cancers are diagnosed at stage III.2-4 Despite surgery and chemotherapy, nearly 30% of stage III patients experience disease recurrence within five years.2,3 Approximately 15% of colon cancer patients present with dMMR or microsatellite instability-high (MSI-H) tumours, which indicate a higher mutation rate and thus have the potential to respond to immunotherapy.5 Roche is pursuing further regulatory filings for Tecentriq, including with the European Medicines Agency, to bring this immunotherapy-based adjuvant option to patients with dMMR colon cancer worldwide as soon as possible. About the ATOMIC study ATOMIC (A021502, NCT02912559) is a phase III, randomised, open-label, multicentre study investigating the addition of Tecentriq® (atezolizumab) to modified (m)FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair (dMMR). The trial enrolled 712 patients. Participants were randomised 1:1 to receive either mFOLFOX6 plus Tecentriq for 12 cycles (six months) followed by Tecentriq monotherapy for 13 cycles (an additional six months), or mFOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS). The global study in the US was sponsored by the US National Cancer Institute (NCI), part of the National Institutes of Health, and led by the Alliance for Clinical Trials in Oncology (Alliance) with participation from other NCI-funded National Clinical Trials Network (NCTN) groups. Genentech, a member of the Roche Group, provided support for the study through a Cooperative Research and Development Agreement between NCI and Genentech. The trial was led globally by Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator within the Alliance. German participation in this major international academic collaboration was enabled through close cooperation between the Alliance and the AIO-Studien-gGmbH, in partnership with the AIO (Arbeitsgemeinschaft Internistische Onkologie) of the German Cancer Society (Deutsche Krebsgesellschaft, DKG), under the national leadership of Prof. Dr. Anke Reinacher-Schick (Ruhr-Universität Bochum). AIO-affiliated study sites enrolled patients during the later recruitment phase, ensuring access for eligible patients in Germany. About Tecentriq® (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer, and is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations. About Roche in oncology For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Sinicrope F, et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer. N Engl J Med. 2026;394:1155-1166. [2] Gonzalez B, et al. Analyzing recurrence in colorectal cancer: Is a five years follow-up enough? Annals of Oncology. 2024;35(1);11. [3] Nors J et al. Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncology. 2024;10(1):54–62. [4] World Health Organization. Cancer [Internet; cited 2026 October]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer. [5] Boland CR, et al. Microsatellite Instability in Colorectal Cancer. Gastroenterology. 2010;138:2073–2087. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media&Investor Release FDA approval for Tecentriq Tecentriq Hybreza English ———————————————————————————————————————————————————————————— Every artifact your teams ship, assembled right the first time 2026-10-06 · GitLab · Crypto, AI, SaaS, Cybersecurity, Software & IT, Internet & apps https://about.gitlab.com/blog/transcend-artifact-central/ Every software build is assembled from open source packages, base images, and libraries, with your code on top. When one of those components is missing or has drifted, the build fails. At agent speed, those failures multiply, and no team can clear them as manual exceptions. Project-by-project registry sprawl makes it worse because retention rules, storage limits, and publish access all live separately inside each project. Project-level design works when a person sets up each registry by hand, but breaks down when agents are running continuously across hundreds of projects. At GitLab Transcend today, we announced GitLab Artifact Central: one organization-level registry that replaces hundreds of project-level ones, so every pull or publish by a human or an agent runs through the same governed door, enabling platform teams to assemble the right software the first time. Here is more on why we developed Artifact Central, and how it can help your team. Set policy once, enforce everywhere In GitLab, retention rules, storage limits, and who can publish all live inside each project’s free package and container registry, configured on its own. GitLab Artifact Central moves that job up one level. Teams assign retention rules, quota settings, and access policies once at the organization level, instead of recreating them in every project underneath it. Every repository is closed by default: Being a member of the organization is the gate, not the grant. Organization membership alone doesn't unlock a single repository until a role grants it. We’ve built four roles specifically for artifacts: Admin, Manager, Contributor, and Viewer. These roles are kept separate from GitLab's existing project roles, so granting someone access to a repository never touches their privileges anywhere else. One URL for publishing, proxying, or both Instead of navigating an internal wiki page explaining what is where, developers point to one URL for everything. GitLab Artifact Central does this through three repository types: Hosted — The private packages and images your teams build and publish. Remote — A proxy in front of an external source, like Docker Hub or Maven Central, with the connection tested before anything depends on it. Virtual — A single endpoint that brings hosted and remote repositories together. GitLab checks the hosted repository first, then falls back to the remote source. The first external pull is cached, so subsequent pulls come directly from GitLab without another trip to the internet. Virtual repositories matter most for teams comparing GitLab with other artifact management solutions. They give developers the familiar single-endpoint experience without requiring them to think about where an artifact lives. Whether it was built internally or pulled from an external registry, developers request it the same way. During the beta period, Artifact Central supports Maven, npm, Docker, and OCI, with more formats to follow. Trace anything back, automatically Here's the part that's hard to replicate outside GitLab. Every artifact that publishes through GitLab Artifact Central carries its build provenance automatically: which pipeline built it, which branch and commit it came from, who triggered the job. Since it is the same platform that ran the build, the registry already knows. Authentication works the same way. Publishing and pulling use CI_JOB_TOKEN, the identity your pipelines already have, for people and agents alike. An agent publishing or pulling through CI pipelines uses that exact same job token, not a bolted-on service account with separate permissions to maintain. With a standalone registry, tracing an artifact back to its source means separately correlating IDs across your CI system and your registry – using a script someone owns and maintains. With Artifact Central, the pipeline, branch, commit, and job are already attached to the artifact itself. Answer 'what did we publish?' in seconds Artifact Central lives in the same platform as your code, merge requests, and pipelines, so artifacts published from CI carry their build provenance: the pipeline that built them, the commit, and who published them. Next, we plan to connect that across your organization through GitLab Orbit, so "which of my running services are affected by this vulnerability?" becomes one question with one answer, instead of a manual search across four or five tools. Pair Artifact Central with Dependency Firewall GitLab Dependency Firewall, a separate GitLab product now in early access for Premium and Ultimate customers, works out of the box with Artifact Central. With Dependency Firewall, you can stop risky packages before they ever reach a build. You add its check to each pipeline using the glab CLI, so coverage is pipeline by pipeline, no matter which package manager your teams use. Next, we plan to enable tighter integration between the two capabilities, so that one policy for your whole organization blocks risky packages by vulnerability, license, or package age the moment they're pulled. Two benefits of the same registry Here's what that looks like from two different desks: a developer shipping code, and the platform team making sure the whole thing holds together. A developer publishing from CI. Your pipeline publishes a Maven artifact using the job token it already has without any new secrets to manage. If that same developer needs an internal package alongside something from Maven Central, they point at one virtual repo URL and let GitLab Artifact Central sort out where each one actually lives. A platform team setting policy once. Instead of configuring rules across 100s of separate projects, an admin sets storage quotas and repository access rules at the organization level, one time — and every repository underneath inherits it. When someone asks how much the company is storing, and where, there's one dashboard with the answer. Migrating your artifacts Most companies aren't starting from zero, and switching cold from an existing registry isn't realistic. With GitLab Artifact Central, you can add your existing repos as remotes behind a virtual repo, so developers point at one URL and artifacts move over only when a build actually asks for one. There is no need for bulk copies, weekend migration windows, or moving petabytes of data across your network. Your old registry remains the system of record. When you're ready, you convert that remote to a hosted repo on Artifact Central. Your migration is safer and gradual. Try Artifact Central, free in beta GitLab Artifact Central is available today in beta for GitLab.com, with availability on GitLab Self-Managed planned for later this month. There's no billing during the beta, and nothing to purchase. We're tracking usage to shape pricing ahead of general availability, and we'll share details then. Help us continue to build GitLab Artifact Central None of this would be where it is without our design partners, who've been running Artifact Central with real workflows for weeks. Their feedback already shaped what's shipping today, and your feedback will shape what comes next. No invitation is required to participate in the beta of Artifact Central, just sign up on our website and a member of our team will be in touch to help enable it for your account. If you don’t have a GitLab account yet, you can also sign up for the beta, and a member of our team will reach out. We can't wait to see what you build. Watch the replay of our Transcend event to see demos of new platform capabilities and explore what it takes to carry the speed of agentic AI across the full software lifecycle. ———————————————————————————————————————————————————————————— Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions 2026-10-01 · Roche · AI, Healthcare, Education, Food & drink, Biotech & pharma, Government & policy, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-01b New real-world results for Vabysmo in nAMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals1-3 Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care4,5 With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide1-3 Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust anatomical improvements in untreated eyes and stable or improved vision with improved anatomical outcomes in previously treated eyes.1-3 In the nAMD and DME cohorts of the study, vision and central subfield thickness (CST) improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after 12 months of Vabysmo treatment.1,2 In RVO, both subtypes of the disease showed improvements in efficacy in people treated with Vabysmo.3 In the central/hemi-RVO cohort, vision and CST improved in both previously untreated and treated eyes after six months of Vabysmo therapy.3 In the branch RVO cohort, vision and CST improved in previously untreated eyes, while vision remained stable and CST improved in previously treated eyes, after six months of Vabysmo treatment.3 The data are being presented at the EURETINA 2026 Annual Meeting in Vienna, Austria. “These real-world results underscore how the efficacy and safety observed in our pivotal Vabysmo studies translate directly into routine clinical practice globally,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The sustained visual improvements and meaningful anatomical drying seen in the VOYAGER study reinforce the role of Vabysmo in helping to address important unmet needs for patients with retinal conditions.” “In daily clinical practice, we manage diverse patient populations with complex treatment histories who don’t always mirror the strict entry criteria of controlled Phase III trials.” said Professor Robyn Guymer, Chair of the VOYAGER Steering Committee and Deputy Director of the Centre for Eye Research Australia. “The latest VOYAGER data give physicians from across the world the confidence that Vabysmo delivers sustained visual gains, meaningful anatomical drying, and an established safety profile in everyday practice – whether a patient is starting treatment for the first time or transitioning from another therapy.” The new VOYAGER real-world data in nAMD, DME and RVO are consistent with previous Phase III study results and demonstrate the effectiveness, durability and safety of Vabysmo across diverse global practices.1-3 Across all cohorts of the study, the presence of subretinal fluid (SRF) or intraretinal fluid (IRF) was consistently reduced in previously untreated and treated eyes.1-3 In the nAMD and DME groups, fewer Vabysmo injections were received during months 7-12 compared with months 1-6, suggesting extension of treatment intervals.1,2  Mean change in visual acuity (VA) Early Treatment Diabetic Retinopathy Study (ETDRS) lettersMean change in central subfield thickness (CST) µmPresence of subretinal fluid (SRF) % of eyesPresence of intraretinal fluid (IRF) % of eyes nAMD (after 12 months of Vabysmo treatment)1 No prior treatment+4.6–110.572.1→25.348.5→20.6 Previously treated-0.1-26.161.6→37.935.4→25.0 DME (after 12 months of Vabysmo treatment)2 No prior treatment+8.2-127.826.5→6.887.3→58.1 Previously treated+2.7-71.322.1→9.380.5→68.1 Branch RVO (after 6 months of Vabysmo treatment)3 No prior treatment+10.0-171.336.3→11.883.8→50.0 Previously treated+2.0-59.015.9→6.682.6→80.3 Central/hemi-RVO (after 6 months of Vabysmo treatment)3 No prior treatment+16.6-287.450.7→9.885.7→29.4 Previously treated+3.9-63.414.9→10.389.4→74.4 In VOYAGER, the Vabysmo safety profile was generally consistent with that established in the Phase III studies in nAMD, DME and RVO.1-3 About VOYAGER VOYAGER is the largest global, prospective, non-interventional real-world study of Vabysmo (faricimab).1-3 It captures real-world data from 28 countries/regions across six continents representing more than 5,000 patients treated for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) or retinal vein occlusion (RVO).1-3 The study leverages state-of-the-art AI and deep learning algorithms to evaluate SD-OCT images captured during routine clinical practice.4-6 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye.7-9 It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilising blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking pathways involving Ang-2 and VEGF-A, Vabysmo is designed to stabilise blood vessels.9,10 Vabysmo is approved in more than 100 countries around the world, including the United States (US), Japan, the United Kingdom and the European Union (EU) for people with neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema, and in more than 60 countries, including the US, EU and Japan, for people with macular edema following retinal vein occlusion (RVO).7,8,11-14 Review by other health authorities is ongoing. About Roche in Ophthalmology At Roche, we are on a mission to save and restore eyesight. Over 330 million people around the world are blind, or living with vision loss, creating a profound personal and socioeconomic burden. With the broadest pipeline in Ophthalmology, we continue to invest at scale to redefine what is medically possible in eye care. Our comprehensive ophthalmology pipeline integrates diverse targets, advanced delivery systems, cell and gene therapies, and AI-augmented imaging capabilities, targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Guymer R, et al. One-year Clinical and Anatomical Outcomes of Faricimab Treatment in Eyes With nAMD From the Global, Prospective Observational VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [2] Sheth V, et al. One–Year Clinical and Anatomical Outcomes of Faricimab Treatment in Eyes With DME From the Global, Prospective Observational VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [3] Hattenbach L-O, et al. Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Retinal Vein Occlusion From a Global, Prospective Observational Study: The VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [4] Bailey C, et al. Anatomical Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration: 12-Month Real-World Imaging from the VOYAGER Study. Presented at:26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [5] Koh A, et al. Anatomical Outcomes of Faricimab in Patients with Diabetic Macular Edema: 12-Month Real-World Imaging from the VOYAGER Study. Presented at: 26th EURETINA Congress; 1–4 October 2026; Vienna, Austria. [6] Guymer R, Bailey C, Chaikitmongkol V, et al. Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice. Ophthalmol Sci. 2024;4(3):100442. doi:10.1016/j.xops.2023.100442. [7] United States (US) Food and Drug Administration (FDA). Highlights of Prescribing Information, Vabysmo. April 2026. [Internet; cited September 2026]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761235s008lbl.pdf [8] Medicines and Healthcare products Regulatory Agency approves faricimab through international work-sharing initiative. May 17, 2022. [Internet; cited September 2026]. Available from: https://www.gov.uk/government/news/mhra-approves-faricimab-through-international-work-sharing-initiative [9] Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1. [10] Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741-755. doi:10.1016/S0140-6736(22)00018-6. [11] European Medicines Agency. Summary of Product Characteristics, Vabysmo. August 2026. [Internet; cited September 2026]. Available from: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_en.pdf. [12] Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with RVO. [Internet; cited September 2026]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20240326160000_1054.html. [13] Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, for nAMD and DME. [Internet; cited September 2026]. Available from: https://www.chugai-pharm.co.jp/english/news/detail/20220328160002_909.html. [14] Roche data on file. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Attachment Media Release Vabysmo EURETINA 2026 English ———————————————————————————————————————————————————————————— Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine 2026-10-01 · Roche · Healthcare, Food & drink, Biotech & pharma, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-01 Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus1 By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes1 The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026 Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine (NEJM). The evERA trial is evaluating giredestrant, an investigational oral selective oestrogen receptor degrader (SERD), in combination with everolimus in people with oestrogen receptor (ER)-positive locally advanced or metastatic breast cancer who had disease progression or recurrence following treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy.1 “Despite advancements with CDK4/6 inhibitor treatment in the first-line setting, many people with advanced breast cancer will eventually experience disease progression as their tumours become resistant to endocrine therapy,” said Dr Erica L. Mayer, Medical Oncologist at Dana-Farber Cancer Institute. “The evERA trial demonstrated that the giredestrant combination significantly delayed disease progression, potentially offering a promising all-oral treatment option in a setting where there remains a need for additional treatments to improve patient outcomes.” In the ESR1-mutated population, the median PFS was 10.0 months with giredestrant plus everolimus compared with 5.5 months in the comparator arm (stratified hazard ratio [HR]=0.38, 95% CI: 0.27-0.54, p<0.001).1 In the intent-to-treat (ITT) population, the median PFS was 8.8 months compared with 5.5 months in the giredestrant and comparator arms, respectively (HR=0.56, 95% CI: 0.44-0.71, p<0.001).1 Overall survival (OS) data were immature at the time of analysis, but a clear positive trend has been observed in the ITT (HR=0.69, 95% CI: 0.47-1.00) and ESR1-mutated populations (HR=0.62, 95% CI: 0.38-1.02).1 Follow-up for OS will continue to the next analysis. Adverse events for the giredestrant combination were manageable and consistent with the known safety profiles of the individual medicines.1 No unexpected safety findings were observed, including no photopsia and low rates of bradycardia.1 “The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the positive phase III lidERA results in early breast cancer, these findings reinforce the potential of giredestrant to redefine care in both metastatic and early disease settings.” Additional evERA analyses were presented at the 2026 American Society of Clinical Oncology Annual Meeting, showing that giredestrant plus everolimus prolongs PFS2 (time from randomisation to disease progression following second-line therapy) and chemotherapy-free survival compared with standard endocrine therapy, suggesting that the clinical benefit may be sustained beyond initial progression.2 Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of breast cancer cases.3 Resistance to endocrine therapies, particularly in the post-CDK inhibitor setting, increases the risk of disease progression and is associated with poor outcomes.3,4 evERA was the first positive phase III readout for giredestrant, followed by the lidERA Breast Cancer study in the early-stage setting.1,5 Based on these evERA data, the US Food and Drug Administration (FDA) accepted Roche’s New Drug Application (NDA) for giredestrant in combination with everolimus for the treatment of people with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after completing endocrine-based adjuvant therapy, or who have progressed on at least one endocrine-based regimen in the metastatic setting. The FDA is expected to decide on the application by 18 December 2026. The FDA also accepted an NDA under Priority Review for giredestrant as an adjuvant treatment for adults with ER-positive, HER2-negative, stage I, II, and III breast cancer based on the lidERA results. The FDA has set a Prescription Drug User Fee Act goal date of 30 November 2026. Roche’s expanding giredestrant clinical development programme spans distinct treatment settings and lines of therapy, reflecting our commitment to deliver innovative medicines to as many people with HR-positive breast cancer as possible. About the evERA Breast Cancer study evERA Breast Cancer [NCT05306340] is a phase III, randomised, open-label, multicentre study evaluating the efficacy and safety of giredestrant in combination with everolimus versus standard endocrine therapy in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase (CDK)4/6 inhibitor and endocrine therapy, either in the adjuvant or locally advanced/metastatic setting.6 The co-primary endpoints are investigator-assessed progression-free survival in the intention-to-treat and ESR1-mutated populations, defined as the time from randomisation to the time when the disease progresses or a patient dies from any cause.6 In the post-CDK inhibitor setting, up to 40% of people with ER-positive disease have ESR1 mutations.7,8 Key secondary endpoints include overall survival, objective response rate, duration of response, clinical benefit rate and safety.6 About giredestrant Giredestrant is an investigational, oral, potent next-generation selective oestrogen receptor degrader and full antagonist.9 Giredestrant is designed to block oestrogen from binding to the oestrogen receptor (ER), triggering its breakdown (known as degradation) and stopping or slowing down the growth of cancer cells.10 Giredestrant has an extensive clinical development programme including five company-sponsored phase III clinical trials to address the needs of patients acrossmultiple treatment settings and lines of therapy: Giredestrant versus standard endocrine therapy as adjuvant treatment in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (lidERA Breast Cancer; NCT04961996)11 Giredestrant plus everolimus versus standard endocrine therapy plus everolimus in ER-positive, HER2-negative, locally advanced or metastatic breast cancer (evERA Breast Cancer; NCT05306340)6 Giredestrant plus palbociclib versus letrozole plus palbociclib in ER-positive, HER2-negative, endocrine-sensitive, recurrent locally advanced or metastatic breast cancer (persevERA Breast Cancer; NCT04546009)12 Giredestrant plus investigator’s choice of a cyclin-dependent kinase (CDK)4/6 inhibitor versus fulvestrant plus a CDK4/6 inhibitor in ER-positive, HER2-negative advanced breast cancer resistant to adjuvant endocrine therapy (pionERA Breast Cancer; NCT06065748)13 Giredestrant plus Phesgo® (pertuzumab, trastuzumab, and hyaluronidase subcutaneous) versus Phesgo in ER-positive, HER2-positive locally advanced or metastatic breast cancer (heredERA Breast Cancer; NCT05296798)14 About hormone receptor (HR)-positive breast cancer Globally, the burden of breast cancer continues to grow, with 2.3 million women diagnosed and 670,000 dying from the disease every year.15 Breast cancer remains the number one cause of cancer-related deaths amongst women, and the second most common cancer type.16 HR-positive, human epidermal growth factor receptor 2-negative breast cancer accounts for approximately 70% of breast cancer cases and the majority are diagnosed in the early-stage.3 A defining feature of HR-positive breast cancer is that its tumour cells have receptors that attach to hormones like oestrogen, which can contribute to tumour growth.17 Despite treatment advances, HR-positive breast cancer remains particularly challenging to treat due to its biological complexity.18 Patients often face the risk of disease progression, treatment side effects and resistance to endocrine therapy.18,19 There is an urgent need for more effective treatments that can delay clinical progression and reduce the burden of treatment on people’s lives.18,19 About Roche in breast cancer Roche has been advancing breast cancer research for more than 30 years, and it continues to be a major focus of research and development. Our legacy began with the development of the first targeted therapy for human epidermal growth factor receptor 2-positive breast cancer, and we continue to push the boundaries of science to address the complexities of all breast cancer subtypes. By leveraging our dual expertise in pharmaceuticals and diagnostics, we are dedicated to providing tailored treatment approaches and improving outcomes for every patient, from early to advanced stages of the disease. Together with our partners, we are relentlessly pursuing a cure, as we strive for a future where no one dies from breast cancer. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Mayer E, et al. Giredestrant plus Everolimus in Advanced Breast Cancer. NEJM; 2026 October. DOI:10.1056/NEJMoa2602457. [2] Jhaveri K, et al. Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor–positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 29 – June 02; Chicago, Illinois, US. #1016. [3] Lim E, et al. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696. [4] Sahin T, et al. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Treatment Reviews. 2025 April;135:102924. [5] Bardia A, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Presented at: San Antonio Breast Cancer Symposium (SABCS); 2025 December 9-12; San Antonio, Texas, United States. #GS1-10. [6] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT05306340. [7] Meisel J L, et al. Real-world estrogen receptor 1 (ESR1) testing patterns and results in U.S. patients with metastatic breast cancer, 2018-2024. JCO Oncol Pract. 2025;21:579. [8] Chaudhary N, et al. CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. npj Breast Cancer. 2024;10,15. [9] Martin M, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study. Presented at: The ESMO Annual Meeting; 2022 September 9-13; Paris, France. Abstract #211MO. [10] Metcalfe C, et al. GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes. Presented at: SABCS; 2018 December 4-8; San Antonio, Texas, USA. Abstract #P5-04-07. [11] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT04961996. [12] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT04546009. [13] ClinicalTrials.gov. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT06065748. [14] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) [Internet; cited 2026 September]. Available from: https://clinicaltrials.gov/study/NCT05296798. [15] World Health Organization. Breast Cancer [Internet; cited 2026 September]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. [16] World Health Organization. Cancer Today [Internet; cited 2026 September]. Available from: https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&types=1&group_populations=1&sexes=2&key=asr&age_end=14. [17] National Cancer Institute. Hormone Therapy for Breast Cancer [Internet; cited 2026 September]. Available from: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. [18] Hanker A, et al. Overcoming Endocrine Resistance in Breast Cancer. Canc Cell. 2020 Apr 13;37(4):496–513. [19] Başaran G, et al. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treat Rev. 2018 Feb;63:144-55. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan  Phone: +41 79 377 83 75 Albert Thottiyil  Phone: +41 79 775 66 12 Attachment 20261001 evERA phase III NEJM ———————————————————————————————————————————————————————————— Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis 2026-09-30 · Roche · Healthcare, Food & drink, Biotech & pharma, Internet & apps, Medical devices, Chemicals & materials https://www.roche.com/media/releases/med-cor-2026-09-30 Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in delaying disability1 Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a Phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus2 Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression1,2 If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million Americans living with MS3 Basel, 30 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The filing acceptance is based on data from the comprehensive clinical programme, including the Phase III FENhance 1 and 2 RMS studies and the Phase III FENtrepid PPMS study.1,2 "People living with multiple sclerosis need treatments that go beyond controlling relapses to help preserve function and independence as the disease progresses," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. "Three Phase III studies have demonstrated the potential for fenebrutinib to address both relapsing and progressive disease, thereby bringing us closer to an oral treatment that could make a meaningful difference across the MS spectrum." “Ocrevus transformed how we treat MS, helping more than 525,000 people live a life less defined by their disease. Yet, over a third of all people with MS still receive lower-efficacy treatment,” said Teresa Graham, Roche’s Chief Executive Officer, Pharma. “If approved, fenebrutinib could open a new chapter as the first high-efficacy oral therapy for both relapsing and primary progressive MS, helping to control disease activity while giving people more flexibility and choice.” Concurrently addressing the life-disrupting relapses and long-term disease progression – the slow, steady loss of physical and mental abilities over time – remains one of the greatest challenges in MS.4 Fenebrutinib is designed to act throughout the body and to cross the blood-brain barrier into the central nervous system to target both the acute inflammation that causes relapses and the chronic inflammation that is thought to drive disability progression.1,2 The NDA for fenebrutinib is supported by three positive Phase III studies: The FENhance 1 and 2 RMS studies showed that fenebrutinib significantly reduced relapses and both active and chronic brain lesions compared with standard of care, teriflunomide. Fenebrutinib reduced the annualised relapse rate (ARR) by 51.1% (p<0.001) in FENhance 1 and 58.5% (p<0.00001) in FENhance 2 compared with teriflunomide over 96 weeks. This equates to patients having approximately one relapse every 17 years, which is the lowest relapse rate seen in Phase III MS studies. In addition, measures of disability progression, including 12-week composite confirmed disability progression (cCDP12), showed consistent positive trends favouring fenebrutinib over teriflunomide.1 The FENtrepid PPMS study showed fenebrutinib met its primary endpoint of non-inferiority compared with Ocrevus® (ocrelizumab), the current standard of care and only approved medicine for PPMS, in reducing disability progression. Fenebrutinib numerically reduced the risk of progression by 12% compared to Ocrevus, as measured by the time to onset of cCDP12 (hazard ratio [HR] 0.88; 95% confidence interval [CI]: 0.75, 1.03), with curves separating as early as 24 weeks. A consistent treatment effect on disability progression was observed across patient subgroups, including those without active inflammation, and for the entire treatment duration after 24 weeks.2 The overall rate of serious adverse events for fenebrutinib and teriflunomide, respectively, was 9% and 9% in FENhance 1 and 11% and 6% in FENhance 2. The overall rate of serious adverse events in FENtrepid was 19% for fenebrutinib and 19% for Ocrevus. Liver enzyme elevations were comparable between the fenebrutinib and teriflunomide arms in the RMS studies and observed more often with fenebrutinib compared to Ocrevus in the PPMS study. While an imbalance in reported fatalities was observed across the three pivotal studies, the deaths occurred at different timepoints and had various causes.1,2 Overall, fenebrutinib has shown a manageable safety profile across the three Phase III trials and earlier studies, with a large safety database including more than 2,700 study participants.1,2,5 About fenebrutinib Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression. While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme. About multiple sclerosis Multiple sclerosis is a chronic disease that affects more than 3 million people worldwide. People with all forms of multiple sclerosis experience disease progression from the beginning of their disease. Therefore, an important goal of treating multiple sclerosis is to slow, stop and ideally prevent progression as early as possible. Approximately 85% of people with multiple sclerosis are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Relapsing forms of the disease (RMS) include RRMS and active secondary progressive MS, and people with RMS experience relapses and worsening disability over time. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form of the disease. Until the FDA approval of Ocrevus®, there had been no FDA-approved treatments for PPMS, and Ocrevus is still the only approved treatment for PPMS. About Roche in Neurology Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally. Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Oh J, et al. Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies. Presented at: 2026 American Academy of Neurology (AAN) Annual Meeting; April 21, 2026; Chicago, IL, USA, and virtual. [2] Bar-Or A, et al. Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study. Presented at: Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026; February 7, 2026; San Diego, CA, USA, and virtual. [3] MS International Federation. Atlas of MS. [Internet; cited September 2026]. Available from: https://atlasofms.org/map/global/epidemiology/number-of-people-with-ms  [4] Bittner S, Zipp F. Progression in multiple sclerosis - a long-term problem. Curr Opin Neurol. 2022;35(3):293-298. doi:10.1097/WCO.0000000000001044 [5] Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025;24(8):656-666. doi:10.1016/S1474-4422(25)00174-7 Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone:  +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media & Investor Release Fenebrutinib FDA Filing English ———————————————————————————————————————————————————————————— U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes 2026-09-17 · Bayer · Healthcare, Education, Food & drink, Biotech & pharma, Sustainability, Internet & apps, Oil & gas https://www.bayer.com/media/en-us/us-fda-approves-finerenone-for-new-indication-in-patients-with-chronic-kidney-disease-associated-with-type-1-diabetes/ Berlin, September 17, 2026 – Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Kerendia™ (finerenone), a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for the treatment of adult patients with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). Finerenone (10mg, 20mg) is now indicated to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease associated with type 1 diabetes. Approximately 30% of people with type 1 diabetes in the U.S. develop chronic kidney disease, increasing their risk of kidney failure and cardiovascular events. Even with recommended treatments for blood glucose and blood pressure management, many patients remain at risk of kidney disease progression and cardiovascular complications. “For more than three decades, people with chronic kidney disease and type 1 diabetes have had limited options to address the risk of kidney disease progression," said Dr. Janet McGill, Professor of Medicine in the Division of Endocrinology, Metabolism, and Lipid Research at Washington University School of Medicine in St. Louis, and Co-Chair of the study’s Executive Committee. "The approval of Kerendia to reduce UACR, which is expected to slow chronic kidney disease progression in adults with type 1 diabetes, provides an important new treatment option for a population that has continued to face substantial unmet need.” “Today’s approval in the U.S. marks an important advance for people living with chronic kidney disease associated with type 1 diabetes—a serious and often under-recognized condition. As the first new FDA-approved treatment option in more than 30 years for this patient population, Kerendia reflects Bayer’s commitment to addressing significant unmet needs and bringing meaningful new treatment options to patients,” said Christine Roth Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. In May 2026, the FDA granted Priority Review designation for Bayer’s supplemental New Drug Application for finerenone for the treatment of adult patients with CKD associated with T1D. The approval of finerenone by the FDA is based on the positive results of the Phase III FINE-ONE study, which were published in the New England Journal of Medicine in March 2026 and presented in November 2025 as “Featured High-Impact Clinical Trial” during the Opening Plenary session of the American Society of Nephrology’s (ASN) Kidney Week. These findings are supported by pooled analyses from the Phase III FIDELIO-DKD and FIGARO-DKD studies in CKD associated with type 2 diabetes (T2D), showing that more than 80% of finerenone's kidney benefit was explained by reductions in UACR. In the U.S., Kerendia has been approved since 2021 for the treatment of adult patients with CKD associated with type 2 diabetes (T2D), since 2025 for the treatment of adult patients with symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≥ 40%, and now for the treatment of adult patients with CKD associated with type 1 diabetes. About Kerendia™ / Firialta™ (finerenone) Kerendia™ and Firialta™ are globally protected trademarks for finerenone. Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone so far has been studied in more than 20,000 patients across multiple populations with chronic kidney disease and/or heart failure. Finerenone is the first drug targeting the MR pathway that in five pivotal Phase III studies has demonstrated clinically proven heart and/or kidney benefits across a broad range of patient populations, for patients with HF LVEF ≥40%, CKD associated with T2D, CKD associated with T1D, and CKD without diabetes. Since 2021, finerenone is marketed as Kerendia™ or, in selected countries, as Firialta™, and approved for the treatment of adult patients with CKD associated with type 2 diabetes (T2D) in more than 100 countries worldwide, including in China, Europe, Japan, and the U.S. Finerenone is also approved for the treatment of heart failure with LVEF ≥ 40% in the U.S., Europe, Japan, China, and several other markets. Applications for marketing authorization of finerenone in non-diabetic CKD have been filed in China and Japan; so far, finerenone is not approved in non-diabetic CKD in any country worldwide. With the new approval by the FDA, the U.S. are the only country where Kerendia is approved for the treatment of adult patients with CKD associated with type 1 diabetes. About FINE-ONE In FINE-ONE, 242 participants were randomized from more than 80 sites across 9 countries worldwide to receive either finerenone or placebo once daily. In addition, patients in the study received usual therapy to treat symptoms and comorbidities. FINE-ONE is a global, randomized, placebo-controlled, double-blind, multicenter Phase III study in people with CKD and T1D. In FINE-ONE, finerenone in addition to standard of care significantly reduced the primary endpoint of relative change in urine albumin-to-creatinine ratio, or UACR, by 25% over six months compared with placebo. At Month 3 and at Month 6, UACR reduction with finerenone was 22%, and 28%, respectively, compared to placebo. At any time following baseline, 68.1% of participants receiving finerenone achieved a reduction in UACR of at least 30%, compared with 46.6% receiving placebo. A reduction in UACR of 30% is a threshold established by the American Diabetes Association (ADA) as being associated with slower CKD progression in patients with CKD associated with type 2 diabetes. Reductions in UACR of this magnitude have been shown in prior Phase III studies in adults with CKD and T2D to be associated with a delay in kidney disease progression and a reduction in cardiovascular events. The safety profile of finerenone in FINE-ONE was largely consistent with the existing body of evidence in adults with chronic kidney disease associated with type 2 diabetes. About Chronic Kidney Disease associated with Type 1 Diabetes Type 1 Diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of pancreatic beta cells leading to insulin deficiency and requiring lifelong insulin treatment. Among the US population overall, crude estimates for 2018 indicated that 1.4 million adults aged 20 years or older (or 5.2% of all US adults with diagnosed diabetes), reported both having T1D and using insulin. CKD is a common and potentially deadly condition that is widely underrecognized. CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. CKD is one of the most frequent complications arising from diabetes and is also an independent risk factor of cardiovascular disease. CKD affects approximately 30% of people with T1D. The 2017 global prevalence of CKD due to T1D was an estimated 32.5 per 100,000 individuals. The clinical course of CKD in people with T1D is characterized by an increased urinary albumin excretion rate, which is a first sign of kidney damage and may progress to macroalbuminuria and decrease in kidney function as measured by estimated glomerular filtration rate (eGFR). The treatment of T1D consists of insulin treatment to control hyperglycemia. In people with T1D, blood glucose intervention targeting HbA1c levels ≤7% can slow onset and progression of kidney disease. Despite guideline-recommended treatment with ACEIs and ARBs, residual risk remains high in people with CKD and T1D, with up to a quarter progressing to end-stage-kidney-disease. CKD associated with T1D significantly increases the risk of kidney failure and cardiovascular events, contributing to CKD being a leading cause of death in T1D. About Bayer’s Commitment in Cardiovascular, Kidney and Cerebrovascular Diseases Bayer is a leader in the area of cardiology and is advancing a portfolio of innovative treatments for cardiovascular, kidney and cerebrovascular diseases with high unmet medical needs. The company has set a clear focus on developing therapies to treat such diseases (e.g., heart failure, cardiomyopathies, chronic kidney disease, and stroke), and it is its ambition to take a leading role in the care of patients with these diseases. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular, kidney, and cerebrovascular diseases are diagnosed and treated. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Hyundai Motor Group Accelerates Autonomous Driving Innovation with AI-Powered Data Flywheel 2026-09-13 · Hyundai Motor Company · AI, Government & policy, Internet & apps, Mining & metals https://www.hyundai.com/worldwide/en/newsroom/detail/0000001273 Hyundai Motor Group hosts “HMG Autonomous Driving Media Day”, outlining its roadmap for the next era of autonomous driving; first showcase of Level 2++ technology Dual-Track strategy accelerates Level 2+ production through NVIDIA collaboration while internalizing key autonomous driving technologies through proprietary Atria AI ⋯NVIDIA solutions-based Level 2+ production targeted for the H1 2028 and Level 2++ in H2 2028, followed by Atria AI-powered Level 2++ vehicles in H2 2029 ⋯Progressive sensor standardization across Hyundai Motor, Kia, 42dot and Motional brings together autonomous driving capabilities across the Group Data Flywheel strategy establishes a virtuous cycle of data collection, training, validation and deployment to continuously advance AI capabilities   ⋯Expands the Group’s data ecosystem by leveraging its annual sales of 7 million vehicles and Data Union framework, while implementing a data-centric development framework based on hard example mining, continuous training and SER ⋯Real-world Level 4 pilot to launch in Gwangju by year-end in partnership with Korea’s Ministry of Land, Infrastructure and Transport to secure large-scale validation data 42dot shares Vision-Language-Action (VLA)-based autonomous driving technology that integrates visual information and language-based reasoning to guide driving decisions ⋯VLA research focuses on addressing edge cases, while parallel development of end-to-end (E2E) autonomy and VLA models enhances technical stability and scalability ⋯VLA model validation currently underway, with on-road testing and the full development process scheduled to run through early next year New Atria AI urban driving videos — an executive ride-along, one-take footage, and edge-case handling — are live on the Group’s YouTube channel ———————————————————————————————————————————————————————————— U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer 2026-09-09 · Bayer · Healthcare, Automotive, Education, Food & drink, Biotech & pharma, Sustainability, Government & policy, Internet & apps https://www.bayer.com/media/en-us/us-fda-grants-accelerated-approval-to-bayers-targeted-therapy-sevabertinib-as-a-first-line-treatment-option-for-adults-with-her2-mutant-non-small-cell-lung-cancer/ Berlin, September 9, 2026 – Following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug Administration (FDA) has granted accelerated approval for sevabertinib as a first-line treatment option for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. Sevabertinib is an oral, reversible, small molecule, tyrosine kinase inhibitor (TKI). “The FDA’s accelerated approval of sevabertinib marks an important advance for treatment-naïve patients with HER2-mutated NSCLC who historically have a poor prognosis,” said SOHO-01 lead investigator, Xiuning Le, MD, PhD, associate professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. “This milestone also underscores the critical importance of comprehensive molecular testing at diagnosis, including for activating HER2 mutations, to ensure patients receive the most appropriate treatment as early as possible.” The FDA approved this indication for sevabertinib under accelerated approval based on objective response rate (ORR) and duration of response (DOR) demonstrated in a cohort of treatment-naïve patients (N=69) in the ongoing Phase I/II SOHO-01 trial (NCT05099172), evaluating the efficacy and safety of sevabertinib in patients with locally advanced or metastatic HER2-mutant NSCLC. In this cohort, the ORR was 75% including complete responses in 6% of patients and partial responses in 70% of patients, with 73% of responders maintaining response for at least six months. The safety profile of sevabertinib was consistent with previous findings. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the ongoing Phase III SOHO-02 confirmatory trial (NCT06452277), which is evaluating sevabertinib versus standard of care in treatment-naïve patients with advanced HER2-mutant NSCLC. “Today’s FDA approval of sevabertinib as an initial treatment option for locally advanced or metastatic non-squamous HER2-mutated NSCLC is an important milestone for patients and a powerful validation of Bayer’s commitment to advancing precision oncology in areas with the highest unmet needs,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. “Lung cancer remains the leading cause of cancer-related deaths worldwide and for patients with HER2-mutated NSCLC, a distinct subtype that often affects people who have never smoked, there remains a critical need for additional treatment options. This approval underscores the potential of precision medicine to transform outcomes by matching the right patients to the right therapy at the right time.” In November 2025, sevabertinib received FDA accelerated approval for patients with previously treated advanced HER2-mutant NSCLC based on objective response rate (ORR) and duration of response (DOR) data from the SOHO-01 trial (from cohort D - previously treated patients who had not received HER2-targeted therapy and cohort E - patients who had previously received HER2-directed antibody-drug conjugates). Earlier this year, sevabertinib was also approved by the National Medical Products Administration (NMPA) in China as monotherapy in adult patients with unresectable, locally advanced or metastatic NSCLC whose tumors have HER2 activating mutations, and who have received one prior systemic therapy. The approval follows the Center for Drug Evaluation (CDE) in China granting sevabertinib Breakthrough Therapy Designation for this patient population. The CDE has also granted sevabertinib Breakthrough Therapy Designation to expedite its development for first-line use in patients with advanced HER2-mutant NSCLC. Sevabertinib has also recently been approved as the first approved targeted therapy for this indication that can be used regardless of line of therapy, including as a first-line treatment, by the Ministry of Health, Labour, and Welfare in Japan. About sevabertinib Sevabertinib is a new, oral, reversible, small molecule, tyrosine kinase inhibitor (TKI) that potently inhibits mutant human HER2, including HER2 exon 20 insertions and HER2 point mutations. Sevabertinib works by blocking certain enzymes called tyrosine kinases, which are involved in the growth of cancer cells. Reversible TKIs can temporarily block their targets, allowing for more precise control over treatment and potentially reducing long-term side effects compared to irreversible TKIs. Sevabertinib is derived from Bayer’s strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA. As part of its clinical development program, alongside the SOHO-01 trial, sevabertinib is also being studied in the Phase III SOHO-02 trial (NCT 06452277) evaluating sevabertinib in treatment naïve patients with HER2-mutant NSCLC and in the panSOHO study (NCT06760819) in patients with metastatic or unresectable solid tumors with HER2-activating mutations, excluding advanced NSCLC. About Non-Small Cell Lung Cancer (NSCLC) Lung cancer is the leading cause of cancer-related deaths worldwide. NSCLC is the most common type of lung cancer, accounting for more than 85% of cases. Activating HER2 mutations are found in 2% to 4% of patients with advanced NSCLC. 80% of people diagnosed with NSCLC have already progressed to advanced stages, which makes it more difficult to treat. Patients with HER2-mutant NSCLC currently face limited treatment options, highlighting an urgent need for more effective therapies. About Oncology at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. The oncology franchise at Bayer includes several marketed products across diverse indications and multiple compounds in different stages of clinical development. We have a wealth of expertise in areas including: Tumor Intrinsic Pathways, Targeted Radionuclide Therapies, and Next-Generation Immuno-Oncology. We are advancing prostate cancer treatment from early to metastatic stage, with the goal of extending survival while limiting side effects. Part of Bayer’s focus on innovative precision oncology treatments, includes an approved TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion, the oncogenic driver of tumor growth and spread. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Etsy to Participate in Upcoming Investor Conference 2026-08-06 · Etsy · Finance, Internet & apps https://investors.etsy.com/news-events/press-releases/detail/226/etsy-to-participate-in-upcoming-investor-conference August 06, 2026 4:05pm EDT Etsy, Inc. (NYSE: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced that its executives will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston. There will be a webcast fireside chat on August 12, 2026 at 8:00 a.m. ET, which investors can listen ———————————————————————————————————————————————————————————— Bayer submits application for next indication of Kerendia in China 2026-07-30 · Bayer · Healthcare, Biotech & pharma, Sustainability, Government & policy, Internet & apps https://www.bayer.com/media/en-us/bayer-submits-application-for-next-indication-of-kerendia-in-china/ Berlin, July 30, 2026 – Bayer today announced the submission of a New Drug Application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), seeking approval to extend the indication of finerenone in China to include adult patients with non-diabetic chronic kidney disease. The regulatory submission is supported by the positive results from the Phase III FIND-CKD study, which were presented at ERA Congress 2026 and simultaneously published in the New England Journal of Medicine. Approximately 850 million people worldwide are living with chronic kidney disease (CKD) and more than half of them have non-diabetic CKD. Worldwide, more than 3.5 million people with kidney failure are treated with dialysis, which is associated with a 5-year survival rate of about 40% after treatment initiation. Non-diabetic CKD can have a range of etiologies, of which the most common include kidney disease linked to hypertension and glomerulonephritis (including IgAN and FSGS). Despite standard of care, patients with non-diabetic CKD remain at risk for kidney failure and cardiovascular events. Chronic kidney disease linked to hypertension is the second most common cause of kidney failure. In addition, patients with advanced non-diabetic CKD face a significantly increased risk for a fatal cardiovascular event, about 2.6 times higher than that of the general population without CKD, which increases further as kidney function declines. “People living with non-diabetic chronic kidney disease (CKD) face a substantial risk for progressive kidney function decline and cardiovascular events. The FIND-CKD study adds robust evidence supporting the potential of finerenone to address this risk across a diverse range of non-diabetic CKD etiologies, including CKD due to hypertension and glomerular diseases,” said Dr. Christian Rommel, Global Head of Research and Development at Bayer’s Pharmaceuticals Division. “Building on the evidence generated across the finerenone clinical development program, the submission of these data marks an important step in our efforts to bring finerenone to more patients who may benefit from its cardio-kidney protective effects and reflects our commitment to advancing innovation for people living with heart and kidney diseases worldwide.” Since 2021, finerenone has been marketed as Kerendia™ or, in selected countries, as Firialta™, and approved for the treatment of adult patients with CKD associated with type 2 diabetes (T2D) in more than 100 countries worldwide, including in China, Europe, Japan, and the U.S. Finerenone is also approved for the treatment of heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in the U.S., the EU, in Japan, and in China, with additional applications under regulatory review. About Kerendia™ / Firialta™ (finerenone) Kerendia™ and Firialta™ are globally protected trademarks for finerenone. Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway that in five pivotal Phase III studies has demonstrated cardiovascular and/or kidney benefits across a broad range of patient populations, including patients with HF with left ventricular ejection fraction (LVEF) ≥40%, patients with CKD associated with type 2 diabetes, patients with CKD associated with type 1 diabetes, and patients with non-diabetic CKD. Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. The clinical study program with finerenone, FINEOVATE, currently comprises twelve Phase III studies with dedicated programs in CKD and HF respectively. The THUNDERBALL CKD program consists of the completed Phase III studies FIDELIO-DKD, FIGARO-DKD, FIND-CKD, and FINE-ONE, and the Phase II study CONFIDENCE; as well as the ongoing Phase III studies in pediatric patient populations FIONA, and FIONA-OLE. The MOONRAKER program includes the completed pivotal Phase III study FINEARTS-HF, the ongoing investigator-sponsored, collaborative studies REDEFINE-HF, CONFIRMATION-HF, and FINALITY-HF, as well as the ongoing Phase III studies in pediatric patient populations, FIORE and FIORELLO. About FIND-CKD FIND-CKD is the largest Phase III study to date focused on non-diabetic CKD. The study investigated finerenone in a broad patient population spanning different etiologies of non-diabetic CKD, adding to the positive data and breadth of evidence of finerenone in CKD associated with diabetes. FIND-CKD (FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease) investigated the efficacy and safety of finerenone compared to placebo in addition to standard of care in more than 1,500 patients with non-diabetic chronic kidney disease etiologies, including kidney disease linked to hypertension and glomerular diseases. Patients were randomized to receive either finerenone 10mg or 20mg or placebo on top of maximum tolerated labeled doses of a renin-angiotensin system (RAS)-blocking therapy such as an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB). In the FIND-CKD study, finerenone showed a statistically significant and clinically meaningful improvement of kidney function compared with placebo: The mean annual decline in eGFR from baseline to 32 months (total slope) was −4.0 ml/minute/1.73 m2/year with placebo and −3.3 ml/minute/1.73 m2/year with finerenone, corresponding to a 0.7 ml/minute/1.73 m2/year slower decline with finerenone [95% CI, 0.3-1.1; p Finerenone was well-tolerated in the FIND-CKD study, which is consistent with the well-established safety profile of finerenone. About Chronic Kidney Disease Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. CKD progresses silently and unpredictably, with many symptoms not appearing until the disease is well-advanced. Chronic Kidney Disease (CKD) represents a major global health challenge, affecting 850 million people worldwide – in fact, as the ninth leading cause of death, it results in 1.5 million fatalities each year, translating to one death every 20 seconds. In the U.S., 1 in 3 adults is at risk for the disease. At advanced stages of CKD, patients may need dialysis or a kidney transplant to stay alive. Healthy kidneys act as the body’s filter, removing waste products from the blood. They also control how much water and electrolytes are in the body, regulating blood pressure. As kidney function goes down, patients may experience a range of symptoms including leg swelling, tiredness in the day, nausea, muscle cramps, joint pain and confusion, trouble focusing, memory problems. Major underlying causes of CKD include diabetes, hypertension, and glomerular diseases such as immunoglobulin A nephropathy, focal segmental glomerulosclerosis and membranous nephropathy. About Bayer’s Commitment in Cardiovascular and Kidney Diseases Bayer is a leader in the area of cardiology and is advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The strategy is to unlock the strong potential of the future cardiovascular market by transforming Bayer’s portfolio into precision cardiology, addressing the high disease burden, and driving long-term growth. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular and kidney diseases are treated. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Etsy to Announce Second Quarter 2026 Financial Results on August 5, 2026 2026-07-17 · Etsy · Finance, Internet & apps https://investors.etsy.com/news-events/press-releases/detail/223/etsy-to-announce-second-quarter-2026-financial-results-on-august-5-2026 July 17, 2026 8:30am EDT Etsy, Inc. (NYSE: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, plans to release its second quarter financial results after the close of the market on Wednesday, August 5, 2026 . At that time, our second quarter 2026 Shareholder Letter will be accessible on the Etsy Investor Relations ———————————————————————————————————————————————————————————— Bayer completes acquisition of Perfuse Therapeutics 2026-06-17 · Bayer · Finance, SaaS, Healthcare, Biotech & pharma, Sustainability, Legal, Internet & apps, Medical devices https://www.bayer.com/media/en-us/bayer-completes-acquisition-of-perfuse-therapeutics/ Berlin, Germany, June 17, 2026 – Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now holds the full rights pertaining to PER-001 intravitreal implant, a first in class, sustained release small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR). This acquisition strengthens Bayer’s pharmaceutical pipeline and strategically fits with Bayer’s strong footprint and expertise in ophthalmology. Under the terms of the agreement, Bayer paid an upfront payment of USD 300 million. The transaction carries a total potential value of up to USD 2.45 billion, comprising of the upfront payment and additional success-based milestone payments. For Bayer, BofA Securities acted as exclusive financial advisor and Baker McKenzie acted as legal counsel. For Perfuse, Centerview Partners LLC acted as exclusive financial advisor and Goodwin Procter LLP acted as legal counsel. About Perfuse Therapeutics Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. About Bayer' Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com/ Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. Contact for media inquiries: Lisa Varrelmann, phone: +49 1746466492 Email: lisa.varrelmann@bayer.com Contact for investor inquiries:' Bayer Investor Relations Team, phone +49 214 30-72704 Email: ir@bayer.com' www.bayer.com/de/investoren/ir-team ———————————————————————————————————————————————————————————— Bayer’s low-dose MRI contrast agent approved in U.S. 2026-06-15 · Bayer · Healthcare, Media, Food & drink, Biotech & pharma, Sustainability, Internet & apps, Medical devices https://www.bayer.com/media/en-us/bayers-low-dose-mri-contrast-agent-approved-in-us/ Not intended for U.S. and UK Media   Bayer’s low-dose MRI contrast agent gadoquatrane approved in U.S.   Gadoquatrane from Bayer receives FDA approval for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and non-CNS body regions / Gadoquatrane becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved in the U.S., with a recommended dose of 0.01 mmol/kg actual body weight, corresponding to 0.04 mmol Gd/kg body weight / Approval is supported by data from the Phase III QUANTI clinical studies, which demonstrated efficacy at a fraction of the dose compared to mGBCAs dosed at 0.1 mmol Gd/kg body weight / Gadoquatrane received its first approval in Japan in March 2026, further submissions to health authorities worldwide are ongoing to secure marketing authorization in additional markets Berlin, June 15, 2026 – Bayer today announced that the U.S. Food and Drug Administration (FDA) approved gadoquatrane, a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) under the brand name Ambelvist™. The product is indicated for contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (CNS) and non-CNS body regions in adult and pediatric patients, including term neonates. Gadoquatrane is a next-generation mGBCA with a novel tetrameric structure and high relaxivity (a measure of signal enhancement). With this approval, gadoquatrane becomes the lowest dose mGBCA in the U.S. It has a recommended dose of 0.01 mmol/kg actual body weight (which corresponds to 0.04 mmol Gd/kg body weight), representing 60% less Gd compared to mGBCAs with a Gd content of 0.1 mmol Gd/kg body weight and 20% less Gd compared to gadopiclenol dosed at 0.05 mmol Gd/kg body weight. There is a rising need for medical imaging, driven by the increasing incidence of chronic diseases such as cancer and cardiovascular diseases. Contrast-enhanced MRI is a medical imaging examination often used by clinicians to gain insight into what’s happening in the human body and can play an important role in detecting abnormalities, monitoring disease progression and informing treatment decisions. For some adults and children with chronic diseases or conditions that require close, long-term monitoring – such as multiple sclerosis, other neurological or spinal conditions as well as different types of cancer – regular, repeat administrations may be required. “I often rely on contrast-enhanced MRI exams to inform clinical decision making,” said Dr. Christopher Hancock, Director of Neuroradiology at HALO Diagnostics Desert Cities, USA, and an investigator for the QUANTI clinical studies. “With this approval, we now have an additional option that can help deliver contrast-enhanced images at the lowest macrocyclic GBCA dose, reducing gadolinium exposure while preserving the clinical information we often need.” “Bayer is a leader in radiology and has played a pioneering role in MRI contrast agent development, having launched the first gadolinium-based contrast agent in 1988,” said Dr. Konstanze Diefenbach, Head of Radiology R&D at Bayer’s Pharmaceuticals Division. “With gadoquatrane – a next generation high-relaxivity, low-dose MRI contrast agent demonstrating high stability – we continue driving advances for patients and their treating physicians. Reducing patients’ lifetime exposure to gadolinium is an important consideration and reflects the growing clinical guidance to use the lowest gadolinium dose necessary to adequately image patients.” Gadoquatrane received its first approval in Japan in March 2026, and Bayer has submitted applications for marketing authorization in additional markets around the world, including the EU and China, with more to follow. Key Clinical Trial Findings The FDA’s approval is based on the global pivotal Phase III QUANTI clinical studies, which evaluated the efficacy and safety of gadoquatrane in adult and pediatric patients, including term neonates, undergoing contrast-enhanced MRI. Key findings demonstrated: ·         Increased lesion visualization with the combined pre-contrast and post-contrast MRI sets with the decreased Gd dose in gadoquatrane compared with only pre-contrast MRI images. ·         Visualization scores and number of lesions identified per blinded independent reader for gadoquatrane dosed at 0.01 mmol/kg body weight (which corresponds to 0.04 mmol Gd/kg body weight) were similar to mGBCAs with a Gd content of 0.1 mmol Gd/kg body weight. ·         Use in children is supported by evidence from adequate and well-controlled studies of gadoquatrane in adults, with additional pharmacokinetic and safety data from the pediatric study, including 93 patients aged 28 days to less than 18 years who received one 0.01mmol/kg dose and underwent MRI of any body region. About gadoquatrane Gadoquatrane is Bayer’s extracellular macrocyclic contrast agent for contrast enhancement in MRI. This low-dose gadolinium-based contrast agent features a distinct tetrameric structure with high stability and high relaxivity. The compound has been approved under the brand name Ambelvist™ in Japan in March 2026 and in the U.S. in June 2026. It has not been approved in any other jurisdiction. Bayer has submitted applications for marketing authorization of gadoquatrane in additional markets around the world. About MRI MRI is a non-invasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues. This supports physicians in answering critical medical questions related to the detection and monitoring of diseases. MRI contrast agents commonly contain gadolinium. For 2024, it is estimated that over 60 million doses of gadolinium-based contrast agents were administered worldwide. Cumulatively, since 1988, more than 900 million GBCA doses have been delivered globally. About Radiology at Bayer Building on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer’s comprehensive offerings also include informatics solutions. In 2025, Bayer’s radiology products generated €2.2 billion in sales. Bayer continues to advance research and innovation in medical imaging, including in molecular imaging and other promising fields. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com/ Follow us on Facebook: http://www.facebook.com/bayer Follow us on Twitter: @BayerPharma Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. Global contact for media inquiries: Victoria Vigener, phone +49 151 23438911 Email: victoria.vigener@bayer.com US contact for media inquiries: Elaine Colon, phone +1-732-236-1587 Email: elaine.colon@bayer.com Contact for investor inquiries: Bayer Investor Relations Team, phone +49 214 30-72704 Email: ir@bayer.com www.bayer.com/de/investoren/ir-team ———————————————————————————————————————————————————————————— European Medicines Agency confirms Bayer’s FXIa inhibitor marketing authorization application for assessment in secondary prevention of ischemic stroke 2026-06-10 · Bayer · Healthcare, Food & drink, Biotech & pharma, Sustainability, Internet & apps https://www.bayer.com/media/en-us/european-medicines-agency-confirms-asundexian-marketing-authorization-application-for-assessment-in-secondary-prevention-of-ischemic-stroke/ Not intended for U.S. and UK Media   European Medicines Agency confirms asundexian marketing authorization application for assessment in secondary prevention of ischemic stroke   This application for asundexian is the first marketing authorization application submission of a Factor XIa (FXIa) inhibitor in Europe and is based on positive data from the pivotal, global Phase III OCEANIC-STROKE study / With increasing prevalence of ischemic stroke and stroke-related mortality, stroke is the second leading cause of death in Europe   Berlin, June 10, 2026 – Bayer today announced that the European Medicines Agency (EMA) has positively validated and begun assessing the company’s marketing authorization application for asundexian, an oral Factor XIa (FXIa) inhibitor, in the prevention of ischemic stroke in adults after a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). Validation of the application confirms the submission is complete and begins the EMA’s centralized review procedure. Stroke is a growing public health issue, affecting around 10 million people in Europe who are living with the consequences of stroke and more than one million people who are newly impacted each year. Globally, and in Europe, stroke is the second leading cause of death, resulting in a significant burden on healthcare systems with estimated global costs reaching 891 billion US-Dollar annually. “Between 2010 and 2019, the prevalence of ischemic stroke and stroke-related mortality increased by 4 percent and 7 percent, respectively, across EU member states underscoring the growing burden of this disease,” said Christian Rommel, Ph.D., Global Head of Research and Development at Bayer`s Pharmaceuticals Division. “The acceptance of our marketing authorization application by the EMA is a testament to our unwavering commitment to offering patients in need novel treatment options.” Bayer is continuing to submit applications for marketing authorization for asundexian to other health authorities globally. China’s Center of Drug Evaluation and the U.S. Food and Drug Administration (FDA) have recently granted asundexian Priority Review designation. About OCEANIC-STROKE The Phase III OCEANIC-STROKE study investigated the efficacy and safety of the oral Factor XIa inhibitor asundexian 50 mg once-daily compared to placebo, for prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy. It is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that randomized 12,327 participants worldwide. The primary efficacy endpoint was time to ischemic stroke; the primary safety endpoint was ISTH major bleeding. The full results from OCEANIC-STROKE have been published in The New England Journal of Medicine. The application to the European Medicines Agency is based on positive data from the Phase III OCEANIC-STROKE study. The study found that asundexian 50 mg, significantly reduced ischemic stroke by 26 percent in patients after a non-cardioembolic ischemic stroke or high-risk TIA compared to placebo, both in combination with antiplatelet therapy, with no increase in ISTH (International Society on Thrombosis and Hemostasis) major bleeding. About FXIa Inhibitors and Asundexian Factor XIa (FXIa) is a protein in the blood coagulation pathway with different roles in hemostasis and thrombosis. FXIa is thought to contribute to the formation of pathological thrombus growth and vessel blockage. However, FXIa has a minor role in the formation of a hemostatic plug that seals the leak at the site of vessel injury. Asundexian is an investigational compound and has not been approved by any health authority for use in any country for any indication. About Bayer’s Commitment in Cardiovascular and Cerebrovascular Medicine Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) and cerebrovascular diseases of high unmet medical need. The company has set a clear focus on developing therapies to treat such diseases (e.g., stroke, heart failure, cardiomyopathies, and chronic kidney disease) and it is our ambition to take a leading role in the care of patients with these diseases. Bayer is actively shaping the future of cardiology and neurology with a robust and diversified pipeline, strategically positioned to address critical unmet needs and drive significant long-term value. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Follow us on LinkedIn: Bayer | Pharmaceuticals Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— New drug applications for Bayer’s FXIa inhibitor accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare 2026-05-19 · Bayer · Healthcare, Food & drink, Biotech & pharma, Sustainability, Government & policy, Internet & apps https://www.bayer.com/media/en-us/new-drug-applications-for-asundexian-accepted-by-us-food-and-drug-administration-under-priority-review-and-by-japans-ministry-of-health-labour-and-welfare/ Berlin, May 19, 2026 – Bayer today announced that the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare have accepted the company’s New Drug Applications (NDA) for its investigational Factor XIa (FXIa) inhibitor, asundexian, for the prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). In addition, the U.S. FDA granted asundexian Priority Review designation. Approximately 12 million people experience a stroke every year.3 Of those who survive a stroke, approximately 1 in 10 will have another stroke within 1 year, even with available secondary stroke prevention strategies.1 “The acceptances of submissions in key markets represent another milestone in the development of asundexian and in our commitment to secondary stroke care. More than 90 million people worldwide are living with the consequences of a stroke, highlighting its significant impact on public health,” said Christian Rommel, Ph.D., Head of Research and Development at Bayer`s Pharmaceuticals Division. “We are collaborating with health authorities to advance the approval process.” Bayer is continuing to submit applications for marketing authorization for asundexian to other health authorities globally. China’s Center of Drug Evaluation has also recently accepted Bayer’s marketing authorization application for asundexian and granted it Priority Review designation. About OCEANIC-STROKE The Phase III OCEANIC-STROKE study investigated the efficacy and safety of the oral Factor XIa inhibitor asundexian 50 mg once-daily compared to placebo, for prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy. It is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that randomized 12,327 participants worldwide. The primary efficacy endpoint was time to ischemic stroke; the primary safety endpoint was ISTH major bleeding. The full results from OCEANIC-STROKE have recently been published in The New England Journal of Medicine. The applications to the U.S. FDA and to Japan’s Ministry of Health, Labour and Welfare are based on positive data from the Phase III OCEANIC-STROKE study. The study found that asundexian 50 mg, significantly reduced ischemic stroke by 26 percent in patients after a non-cardioembolic ischemic stroke or high-risk TIA compared to placebo, both in combination with antiplatelet therapy, with no increase in ISTH (International Society on Thrombosis and Hemostasis) major bleeding. About FXIa Inhibitors and Asundexian Factor XIa (FXIa) is a protein in the blood coagulation pathway with different roles in hemostasis and thrombosis. FXIa is thought to contribute to the formation of pathological thrombus growth and vessel blockage. However, FXIa has a minor role in the formation of a hemostatic plug that seals the leak at the site of vessel injury. Asundexian is an investigational compound and has not been approved by any health authority for use in any country for any indication. About Bayer’s Commitment in Cardiovascular and Cerebrovascular Medicine Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) and cerebrovascular diseases of high unmet medical need. The company has set a clear focus on developing therapies to treat such diseases (e.g., stroke, heart failure, cardiomyopathies, and chronic kidney disease) and it is our ambition to take a leading role in the care of patients with these diseases. Bayer is actively shaping the future of cardiology and neurology with a robust and diversified pipeline, strategically positioned to address critical unmet needs and drive significant long-term value. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Follow us on LinkedIn: Bayer | Pharmaceuticals Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. 1 Kolmos M, Christoffersen L, Kruuse C. Recurrent Ischemic Stroke – A Systematic Review and Meta-Analysis. J Stroke Cerebrovasc Dis. 2021;30(8):105935. 2 U.S. Food and Drug Administration. Priority Review. 2018. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review. Last accessed: May 2026. 3 Feigin VL, et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke. 2022;17(1):18-29. ———————————————————————————————————————————————————————————— Inside Hyundai Motor Group’s Renovated HQ Where Humans and Robots Work Together in Harmony 2026-05-15 · Hyundai Motor Company · Internet & apps https://www.hyundai.com/worldwide/en/newsroom/detail/0000001176 Hyundai Motor Group is spearheading the future of work within its revitalized Seoul headquarters. Discover how three specialized robots are working with employees to turn office life into a blueprint for human-robot collaboration. Videos of the new robots have also been posted on the Hyundai Motor Group official YouTube channel ———————————————————————————————————————————————————————————— Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline 2026-05-06 · Bayer · Finance, SaaS, Healthcare, Biotech & pharma, Sustainability, Legal, Internet & apps, Medical devices https://www.bayer.com/media/en-us/bayer-to-acquire-perfuse-therapeutics-to-complement-ophthalmology-pipeline/ Berlin, Germany and San Francisco, California USA, May 6, 2026 – Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR). This represents one of the first potential treatments for Glaucoma and DR being studied for its ability to improve the visual field for Glaucoma patients and to improve contrast sensitivity and reduce ischemia in DR patients. “We are excited by the work of the team at Perfuse Therapeutics and encouraged by the potential of PER-001,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. “With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients.”  “I’m incredibly proud of what the Perfuse team has accomplished and deeply thankful to all our investors and collaborators," said Sevgi Gurkan, MD, Founder and CEO of Perfuse Therapeutics, Inc. "Bayer’s vision aligns closely with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness. We are very excited to see our mission continue with even greater momentum.” Glaucoma is a progressive optic neuropathy that causes the loss of retinal ganglion cells, resulting in loss of visual fields. It is the leading cause of irreversible vision loss1 affecting ~76-80 million people worldwide (2020) and is projected to affect ~112 million people by 2040 due to population aging.2 Despite its prevalence, there are no approved treatments today, preventing disease progression and blindness independently from the saturated approach of lowering intraocular pressure. There is a high unmet medical need for neuroprotective treatments for patients with Glaucoma. Diabetic Retinopathy (DR) is a microvascular complication of diabetes that damages retinal capillaries, causing ischemia, leakage, and neovascularization affecting about 146 million people globally today. This includes about 25 percent of adults with diabetes and is projected to increase to 160 million people by 2045. Currently, 25 million people have vision‑threatening DR and 1.3 million people are blind.3 Under the terms of the agreement, the transaction carries a total potential value of up to USD 2.45 billion, comprising a USD 300 million upfront payment and additional development, regulatory, and commercial milestone payments based on success criteria. For Bayer, BofA Securities is acting as exclusive financial advisor and Baker McKenzie is acting as legal counsel. For Perfuse, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP is acting as legal counsel. The acquisition is subject to and will become effective after receiving the necessary antitrust clearances and Perfuse stockholder approvals. About PER-001 PER-001 is an investigational small molecule endothelin receptor antagonist being developed for the treatment of ophthalmic diseases. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma, diabetic retinopathy, age-related macular degeneration and retinal vein occlusion. Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells. The PER-001 intravitreal implant is a bio-erodible implant administered into the vitreous cavity of the eye using a single-use, 25-gauge applicator and designed to provide a sustained release of PER-001, allowing for a convenient dosing regimen. About Perfuse Therapeutics Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. For more information, visit www.perfusetherapeutics.com and LinkedIn. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. 1 Vision Loss Expert Group of the Global Burden of Disease, 2024, Eye ² Sarkis et al., 2025, Frontiers in Med ³ WHO, 2019, World report on vision Executive Summary Bayer Global Media Contact: Lisa Varrelmann, phone +49 1746466492 Email: lisa.varrelmann@bayer.com Contact for investor inquiries: Bayer Investor Relations Team,  phone +49 214 30-72704 Email: ir@bayer.com www.bayer.com/de/investoren/ir-team Perfuse Therapeutics Media Contact: Perfuse Therapeutics Team Email: info@perfusetherapeutics.com Perfuse Therapeutics investor inquiries: Perfuse Therapeutics Team Email: info@perfusetherapeutics.com ———————————————————————————————————————————————————————————— Etsy, Inc. Reports First Quarter 2026 Results 2026-04-29 · Etsy · Finance, Internet & apps https://investors.etsy.com/news-events/press-releases/detail/221/etsy-inc-reports-first-quarter-2026-results April 29, 2026 7:00am EDT Etsy, Inc. (NYSE: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced results for its first quarter ended March 31, 2026. These financial results are available within Etsy's first quarter 2026 Shareholder Letter, which can be found on the company's Investor Relations websit ———————————————————————————————————————————————————————————— China’s Center of Drug Evaluation accepts marketing authorization application for Bayer’s FXIa inhibitor in stroke prevention after a non-cardioembolic ischemic stroke or transient ischemic attack 2026-04-29 · Bayer · Healthcare, Biotech & pharma, Sustainability, Internet & apps https://www.bayer.com/media/en-us/chinas-center-of-drug-evaluation-accepts-marketing-authorization-application-for-asundexian-in-stroke-prevention-after-a-non-cardioembolic-ischemic-stroke-or-transient-ischemic-attack/ Berlin, April 29, 2026 – Bayer today announced that the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the company’s marketing authorization application for asundexian as a treatment for the prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). Stroke is the second-leading cause of death and the third-leading cause of disability globally. While in China it is the leading cause of death and disability.1,2 The prevalence of ischemic stroke in China increased by 10% between 2010 and 2021 to 20.80 million ischemic stroke cases.1 Recurrent ischemic strokes tend to be more disabling and carry a higher mortality risk than the first stroke.2,3,4 “The acceptance of our marketing authorization application marks a significant milestone in our efforts to advance secondary stroke prevention in China, where the burden of stroke is substantial and a need for additional options in secondary stroke prevention remains,” said Christian Rommel, Ph.D., Global Head of Research and Development, Bayer Pharmaceuticals.  The marketing authorization application to the CDE is based on positive data from the Phase III OCEANIC-STROKE study, which showed that asundexian significantly reduced ischemic stroke by 26 percent compared to placebo, both in combination with antiplatelet therapy, in patients after a non-cardioembolic ischemic stroke or high-risk TIA, with no increase in ISTH (International Society on Thrombosis and Hemostasis) major bleeding. These findings were consistent regardless of age or sex, index event (stroke or high-risk TIA), stroke subtype, NIHSS (National Institutes of Health Stroke Scale), and acute stroke therapy like thrombolysis or planned secondary prevention strategies (single or dual antiplatelet therapy). Bayer is continuing to submit applications for marketing authorizations of asundexian to health authorities globally. About OCEANIC-STROKE The Phase III OCEANIC-STROKE study investigated the efficacy and safety of the oral Factor XIa inhibitor asundexian 50 mg once-daily compared to placebo, for prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) in combination with antiplatelet therapy. It is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that randomized 12,327 participants worldwide. The primary efficacy endpoint was time to ischemic stroke; the primary safety endpoint was ISTH major bleeding. The full results from OCEANIC-STROKE recently been published in The New England Journal of Medicine, found that asundexian 50 mg significantly reduced ischemic stroke by 26 percent in patients after a non-cardioembolic ischemic stroke or high-risk TIA compared to placebo, both in combination with antiplatelet therapy, with no increase in ISTH (International Society on Thrombosis and Hemostasis) major bleeding. About FXIa inhibitors and Asundexian Factor XIa (FXIa) is a protein in the blood coagulation pathway with different roles in hemostasis and thrombosis. FXIa is thought to contribute to the formation of pathological thrombus growth and vessel blockage. However, FXIa has a minor role in the formation of a hemostatic plug that seals the leak at the site of vessel injury. Asundexian is an investigational compound and has not been approved by any health authority for use in any country for any indication. About Bayer’s Commitment in Cardiovascular and Cerebrovascular Medicine Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) and cerebrovascular diseases of high unmet medical need. The company has set a clear focus on developing innovative therapies to treat such diseases (e.g., stroke, heart failure, cardiomyopathies, and chronic kidney disease) and it is our ambition to take a leading role in the care of patients with these diseases. Bayer is actively shaping the future of cardiology and neurology with a robust and diversified pipeline, strategically positioned to address critical unmet needs and drive significant long-term value. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Follow us on LinkedIn: Bayer | Pharmaceuticals Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. 1 National Program for Stroke Prevention and Million Disability Reduction Initiative Expert Committee. China Stroke Prevention and Control Report 2024: An executive summary. Brain Circ. 2025;11(4):251-260. 2 Feigin VL, et al. Pragmatic Solutions to Reduce Global Burden of Stroke. Lancet Neurol. 2023;22:1160–1206. 3 Rochmah TN, et al. Economic Burden of Stroke Disease: A Systematic Review. Int J Environ Res Public Health. 2021;18(14):7552. 4 Skajaa N, et al. Risks of stroke recurrence and mortality after first and recurrent strokes in Denmark: a nationwide registry study. Neurology. 2022;98(4):e329-42.